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Abstract
Mono-ADP-ribosylation is a reversible, post-translational modification of cellular 
proteins that has been implicated in regulation of signal transduction, muscle cell 
differentiation, and protein trafficking and secretion. The reaction is catalysed by mono- 
ADP-ribosyltransferases that transfer a single ADP-ribose moiety from p-NAD+ to a 
specific amino-acid of acceptor proteins. An ADP-ribosylation reaction occurs in intact 
cells on the p subunit of heterotrimeric G proteins that is carried out by an arginine- 
specific, plasma-membrane-associated, mono-ADP-ribosyltransferase. This modification is 
reversed by a cytosolic ADP-ribosylhydrolase that regenerates native Py dimer by releasing 
the bound ADP-ribose. Once ADP-ribosylated, the py dimer is inactive towards its effector 
enzymes, such as adenylyl cyclase, phosphoinositide 3-kinase and phospholipase C. It thus 
appears that endogenous P subunit mono-ADP-ribosylation might represent a novel 
cellular mechanism for the modulation o f the G-protein-mediated signal transduction 
machinery through a direct regulation of the py dimer. In this study, the mechanisms that 
regulate endogenous mono-ADP-ribosylation of the p subunit have been investigated. The 
reaction appears to be under hormonal control both in vitro and in vivo, since the levels o f 
ADP-ribosylated p are increased upon activation of certain G-protein-coupled receptors 
(GPCRs), such as thrombin, serotonin and cholecystokinin receptors. Conversely, 
hormonal stimulation by additional GPCRs, such as the GnRH receptor, can lead to a 
decrease in p subunit mono-ADP-ribosylation. Thus, ADP-ribosylation o f the py dimer can 
be differentially regulated by different GPCRs in a receptor-type-dependent manner. In 
addition, the involvement of the ADP-ribosylating factor ARF6  in GnRH-mediated 
regulation o f p subunit mono-ADP-ribosylation is demonstrated. Indeed, removal o f ARF6  
from plasma membranes results in loss o f GnRH-mediated inhibition o f p subunit mono- 
ADP-ribosylation, which can be fully restored by re-addition of purified ARF6 . In
conclusion, the results reported in this thesis allow the definition o f the mechanisms that 
regulated endogenous ADP-ribosylation o f the p subunit, and demonstrate a novel role for 
ARF6  in hormonal regulation of p subunit mono-ADP-ribosylation.
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Chapter 1
Introduction
1.1 Heterotrimeric G-protein-mediated signalling
Heterotrimeric guanine-nucleotide-binding proteins (G proteins) mediate the ability 
o f eukaryotic cells to respond to a wide variety of extracellular signals and sensory stimuli. 
The G-protein-mediated signalling pathway is composed o f three major molecular entities 
(Morris and Malbon, 1999; Figure 1.1):
1) the G-protein-coupled receptor (GPCR): a seven-transmembrane-spanning protein 
that exposes a binding site for specific ligands and an interaction site for G proteins on its 
extracellular and intracellular faces, respectively.
2) the transducer: one or more frequently, two or three different families o f G proteins 
that are capable of translating the GPCR activation into the regulation of specific effectors, 
through its a  and Py subunits.
3) the effector: enzymes and ion channels that control the intracellular concentrations of 
the second messengers, which in turn amplify and propagate the stimulus within the cell, 
thus leading to physiological responses, including contraction, relaxation, cell division, cell 
differentiation and secretion.
Due to the central role of the heterotrimeric G proteins in the modulation o f almost 
all cell functions, both the G a and GPy subunits are strictly regulated by different 
mechanisms. In this study, the endogenous mono-ADP-ribosylation reaction o f the Gp 
subunit is discussed as a new mechanism controlling the GPy-dimer-mediated signalling 
(Section 1.2). In particular, the experimental work presented here is focused on an 
understanding o f the molecular mechanisms that regulate this reaction.
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Figure 1.1. General characteristics of the GPCRs. Model o f G protein mediated 
signalling pathways, showing: 1) the G-protein-coupled receptor, 2) the trimeric G protein 
composed o f an a  subunit and a py dimer, 3) effectors, which can be enzymes such as 
adenylyl cyclase and phosphodiesterases or ion channels.
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1.1.1 G-protein-couvled receptors
The GPCRs constitute the largest family o f membrane receptors involved in signal 
transduction. Members o f this family are able to recognize and bind molecules as different 
as neurotransmitters, hormones, chemokines, lipids, odorants and even photons o f light. 
Despite the remarkable structural diversity of their activating ligands, all o f the GPCRs 
share a common molecular architecture, predicted principally from the crystal structure of 
the mammalian visual pigment rhodopsin, the GPCR stimulated by light (Palczewski et al., 
2000). The typical GPCR protein sequence includes seven transmembrane helices (TM I- 
VII) joined by three intracellular (ii, i2, is) and three extracellular (ei, 92 , 63) loops 
(Baldwin, 1993). Two cysteine residues (one in ei and one in e2) that are conserved in most 
GPCRs form a disulfide bridge, which is probably important for the packing and 
stabilization the TMs. The extracellular surface o f the receptor, including the N-terminal 
domain, is critical for ligand binding, while the intracellular surface is involved in G 
protein recognition and activation (Schwartz, 1994; Strader et al., 1994). This region also 
comprises canonical sites for protein phosphorylation by protein kinase A (PKA), protein 
kinase C (PKC), G-protein receptor kinases (GRKs), receptor tyrosine kinases (RTK; e.g., 
insulin and IGF-I) and non-receptor tyrosine kinases (e.g., Src family kinases) (Lefkowitz, 
1998).
Both structural and physiological features were used by Kolakowski to classify 
GPCRs into several families, most o f which in turn contain subfamilies (Kolakowski, 
1994). According to this classification, family A comprises rhodopsin and a huge number 
of rhodopsin-related receptors, like the receptors for catecholamines, peptides, 
glycoproteins, and olfactory molecules; family B consists of secretin-like receptors, 
activated by large peptides, like calcitonin, parathyroid hormone, and glucagon; family C 
contains metabotropic glutamate receptors and related subfamilies. Frizzled and
19
smoothened receptors and a subgroup o f pheromone receptors form two additional classes 
o f GPCRs.
The entire known GPCRs shuttle between inactive and active conformations. While 
increasing evidence is emerging that some GPCRs exhibit constitutive activity (Leurs et 
al., 1998; Mitchell et al., 1998), it is generally assumed that in the absence o f activating 
ligands, the inactive conformation of the receptor is favoured. This implies that the 
receptor is functionally uncoupled from the G proteins. Upon activation by ligands, the 
GPCR shifts to the active conformation through a 30° clockwise rotation of TM VI 
(viewed from the cytoplasmic face), which moves apart from TM III. This conformational 
change in the core domain affects the conformation of the 12 and i3 loops that constitute key 
sites for G protein coupling and activation (Wong and Ross, 1994). In this state, the 
activated receptor is able to complex with and activate heterotrimeric G proteins, which in 
turn transmit the signal into the intracellular lumen of the cells, initiating the signalling 
cascade.
Several mechanisms exist to regulate the length and strength o f GPCR signals. In 
many cases, a time-dependent decrease in the cellular response to the external signal 
occurs despite the continued presence of the signalling ligand. This attenuation o f 
signalling is known as desensitization, and consists in the uncoupling o f a GPCR from its 
associated G proteins. Studies o f rhodopsin (Kuhn et al., 1984; Wilden et al., 1986) and the 
P2-adrenergic receptor (P2-AR) (Ferguson, 2001; Lefkowitz, 1998) have revealed that 
desensitization initiates with the recruitment of a GRK that phosphorylates the receptor. 
The “uncoupling” protein arrestin is then recruited from the cytosol to bind the 
phosphorylated receptor, causing the uncoupling o f the receptor and the G protein 
(Lefkowitz and Shenoy, 2005). The next event is the internalization (endocytosis) o f the 
receptor from the plasma membrane into the intracellular compartment (Figure 1.2).
Multiple pathways of receptor internalization have been described, which are 
mediated by clathrin-coated pits, caveolae or other uncoated vesicles (Claing et al., 2002;
20
Le Roy and Wrana, 2005). Once internalized, the receptors can be dephosphorylated, 
resensitized and recycled to the cell surface, or targeted to lysosomes for degradation, or 
engaged in additional intracellular signalling.
Monomeric GPCRs are believed to be the signalling unit; however, more recently, 
this view has been challenged, and largely supplanted by results consistent with the 
existence of GPCR receptors as dimers or higher-order oligomers (Filizola and Weinstein, 
2005; Maggio et al., 2005; Park et al., 2004). As an example, the functional GABAb is an 
obligatory heterodimer of GABAbRI and GABAbR2: the heterodimerization is crucial for 
its correct intracellular transport to the cell surface, for the binding of the ligand and for the 
activation of the G proteins (Jones et al., 1998; Kuner et al., 1999). Importantly, 
heterodimerization among different GPCRs may explain some aspects o f the cross-talk 
regulation that occurs between distinct signalling systems. The angiotensin ATi and the 
bradykinin B2 receptors form stable heterodimers that enhance the activation of the G aq 
and Goii proteins, the two major transducer proteins triggered by ATi (AbdAlla et al., 
2000). Such integration and communication between receptors can presumably tune the 
strength and duration of the signals, thereby leading to the fine regulation o f the ultimate 
physiological responses.
1.1.2 Heterotrimeric G proteins
The heterotrimeric G proteins are the signal transducers that switch the biological 
signal from the cell surface to the intracellular compartment (Preininger and Hamm, 2004). 
These proteins are composed of three different polypeptides: the a  subunit that binds and 
hydrolyses GTP, the p and the y subunits, which form the tightly associated Py dimer that 
dissociates only under denaturing conditions, and is, therefore, considered a functional 
monomer. Both the G a subunit and the Gpy dimer are involved in signal transduction 
pathways.
21
Agonist
COOH
G R K
Agonist
COOH
[3 arrest in
Receptor de-phosphorylation 
and recycling
Internalization 
NH2
clathrin
Lysosomal
degradation
X
r\
AP-2
(3-arrest in
Figure 1.2. General model of GPCR desensitization and internalization via clathrin- 
coated vesicles. The stimulation o f a GPCR by its agonist leads to activation o f the G 
protein. The active GPy dimer recruits G-protein-receptor kinases (such as GRK2 and 
GRIG) to the receptor, where they specifically phosphorylate the agonist-occupied 
receptor. The uncoupling protein arrestin is then recruited from the cytosol to bind the 
phosphorylated receptor, sterically uncoupling the receptor and the G protein. Arrestin, in 
turn, targets the receptor to internalization via clathrin-coated pits. Once internalized, the 
receptor can be de-phosphorylated and recycled to the cell surface, or targeted to 
lysosomes for degradation.
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Based on the amino acid similarities among the a  subunits, G proteins are divided 
into four major families, namely Gs, Gi/0, Gq/n and G12/13 (Table 1.1). The Gs family is 
mainly involved in the activation o f adenylyl cyclase (AC), whereas the Gj family inhibits 
AC, but also regulates ion channels, phospholipases and phosphodiesterases. Gq/i 1 activates 
phospholipase C (PLC), and G 12/13 is able to regulate the monomeric GTP-binding protein 
Rho, through the interaction with its exchange factor Rho-GEF (Freissmuth et al., 1999).
1.1.2.1 Gprotein subunits: classification and structure
According to current knowledge, there are 16 G a genes in the human genome that 
encode for 23 known G a proteins (McCudden et al., 2005), which range in size from 39 to 
45 kDa. The solution of crystal structures for Gaj and G at in both the active and inactive 
states has revealed two distinct domains: a nucleotide binding domain with high structural 
homology to the Ras-superfamily GTPases, and an a-helical domain that in combination 
with the Ras-like domain, helps to form a deep pocket that is involved in guanine 
nucleotide binding (Sprang, 1997). Three flexible regions, designated switch I, II and III, 
change conformation in response to GTP binding and hydrolysis.
The Gp subunit exists in five isoforms, known as pi, P2, P3, P4 and ps, with 
molecular weights ranging from 35 kDa and 39 kDa; and 12 Gy subunits have been cloned, 
with molecular weights ranging from 5 and 10 kDa (Clapham and Neer, 1997). The 12 Gy 
subunits are considerably different in their primary sequences (27-76% amino acid 
identity). In contrast, the Gp subunits are highly homologous (Gpi to GP4 share 78-88% 
amino acid identity), with the most divergent member of the family being GPs, which 
shares only 51-53% amino acid identity with the other Gp subunits. Moreover, while pi, 
p2, P3 and p4 are ubiquitously expressed, P5 appears to be tissue-specific, and has been 
detected only in the retina, neuronal tissue and platelets. Also, the Gy subunits show tissue 
expression profiles that indicate unique roles in specific signal transduction pathways.
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Class G a subunit Effectors
Gs Gets Adenylyl cyclase (+) 
Calcium channel (+) 
Sodium channel (+)
Gaoif Adenylyl cyclase (+)
Gi Gaii Adenylyl cyclase (-)
Gai2 Potassium channel (+)
Gai3 Calcium channel (-) 
Phospholipase C (?) (+) 
Phospholipase A2 (?) (+)
GaoA,B Potassium channel (+) 
Calcium channel (-) 
Phospholipase C (?) (+)
Gati,2 cGMP-phosphodiesterase (+)
Gag cGMP-phosphodiesterase (+) 
Phospholipase C-|3 (?)
Gaz Adenylyl cyclase (?)
Gq/11 Gaq
Gan
Gaie
Gai4
Gais
Phospholipase C-(3 (+)
G12 Gai2 GEFs, GDIs, GAPs (?)
Gai3 GEFs, GDIs, GAPs (?)
Table 1.1. Heterotrimeric G proteins: classification and effectors.
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Indeed, the expression of Gyi is restricted to retinal rod cells, and the G(3yi dimer interacts 
better with rhodopsin than with other receptors (Kisselev and Gautam, 1993).
The Gp subunit is a WD-40-containing protein, and is thus characterised by the 
presence o f tandem-repeating regions o f amino acids that contain two conserved dipeptide 
sequences, Gly-His (GH) and Trp-Asp (WD) (Garcia-Higuera et al., 1998). The WD 
repeats have been proposed to act as building modules for multimeric complexes. The 
crystal structure o f the G-protein heterotrimer reveals that the core WD-repeat portion of 
Gp is made up of seven four-twisted p sheets arranged in a ring, forming a propeller-like 
structure (Clapham and Neer, 1997; Neer and Smith, 1996). The circular structure is held 
closed by a molecular “velcro snap” in the seventh blade o f the propeller. Conserved 
residues establish a hydrophilic environment between the p-sheets, and the stabilisation of 
the propeller structure is achieved by inter- and intra-blade hydrogen bond triads (Neer and 
Smith, 1996). In addition to its WD-40 repeat regions, Gp has a unique N-terminal domain 
that adopts an a-helical structure. This region forms a coiled-coil interaction with the y 
subunit, which is critical for proper folding and function of the proteins, and which cannot 
be interrupted without strong denaturing conditions (Figure 1.3) (Clapham and Neer, 
1997).
The major interaction between G a and Gpy involves the G a N-terminus 
(Lambright et al., 1996; Wall et al., 1995). The G a subunit binds asymmetrically over the 
narrow end o f the GPy dimer, making contacts principally with residues in blades 1, 2 and 
3 (Figure 1.4). The G a switch-II region that changes its conformation in the GDP- and 
GTP-bound states is positioned over the central tunnel of Gp (Sondek et al., 1996). The 
association with the GPy dimer produces a significant change in conformation o f the G a 
switch I and II regions. By contrast, the structure of Gpy is not appreciably modified 
following its association with the G a (Cabrera-Vera et al., 2003). This interaction o f Gpy 
with G a increases the affinity o f G a for GDP, both by increasing the rate o f association
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Figure 1.3. G protein Py dimer. A: Model o f the (3y dimer. The WD repeats are 
represented by circles connected to the variable regions. Each WD repeat is predicted to be 
a structure made up of a p-strand-tum-p-strand. The putative a-helical region at the N- 
terminus is shown as a rectangle. The area of y that determines the specificity o f interaction 
with p is represented by violet box. The C-terminal prenyl group is indicated by the zigzag 
line. B: Structure of the WD40 propeller domain of the Gp subunit.
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(3 subunita subunit
y subunit
Figure 1.4. G protein structure. The G a subunit (green) interacts through its N-terminal 
region principally with residues in blades 1, 2 and 3 of the (3 subunit (orange). The G a 
region that changes its conformation in the GDP- and GTP-bound states is positioned over 
the central tunnel of Gp (indicated by the blue arrow). See text for more details.
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and by decreasing the rate of dissociation, probably due to the stabilisation of switch I and 
switch II. The overall effect is that Gpy facilitates the inactivation o f the stimulated G a 
subunit. Apparently in contrast with this view of Gpy as a negative regulator, Gpy needs to 
be present for efficient binding of G a to the receptor. A direct interaction of GPy with the 
receptor has been shown in the case o f the purified rhodopsin receptor (Phillips and 
Cerione, 1992): although the G a of transducin (the G protein involved in visual 
transduction, G at) can bind to rhodopsin without Gpy, GPy appears to increase the affinity 
of G at for rhodopsin. This effect is independent o f the ability o f GPy to enhance binding of 
G a to phospholipid vesicles, hence it appears to be independent of an increased binding of 
G a  to the membrane.
1.1,2.2 The heterotrimeric G-protein cycle
The G-protein activity is regulated by an activation/deactivation cycle that allows 
transmission of signals from receptor to effector (Gilman, 1987). In the inactive state, the 
G protein is an aPy-heterotrimer with GDP bound to the G a subunit. In this state, the rate 
of GDP release (Koff < 0.1 min'1) is much lower than the rate o f GTP hydrolysis (Kcat > 3 
m in'1); this kinetic feature clamps the system in the “o ff ’ position (Freissmuth et al., 1999). 
When a ligand activates a GPCR, the receptor becomes activated and changes its 
conformation, and now acts as a guanine nucleotide exchange factor for the G a. GDP is 
released from the G a, which then binds GTP present at a significant molar excess over 
GDP in cells. The binding of GTP results in conformational changes within the three 
flexible switch regions of the G a subunit (Morris and Malbon, 1999), leading to the 
dissociation of the GPy dimer. The cycle terminates when the intrinsic guanosine 
triphosphatase (GTPase) activity o f the G a  subunit catalyses the hydrolysis o f GTP to 
GDP. The inactive Ga-GDP then re-associates with Gpy, turning off the signalling (Figure 
1.5;. Interestingly, with the notable exception o f transducin, there is only weak evidence
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Figure 1.5. Receptor-mediated G-protein activation. In the inactive state (1) the G 
protein is a heterotrimer with GDP bound to the G a subunit. Upon activation by an 
appropriate signal (2), the receptor interacts with the G protein and catalyses the exchange 
of GDP for GTP on Ga. The GTP-bound G a and Gpy dimer dissociate from the receptor, 
as well as from each other, and initiate cellular responses through their interactions with 
effector molecules (3). The duration of the signal is determined by the intrinsic GTP 
hydrolysis rate o f G a (4) and the subsequent re-association of Ga-GDP with the GPy 
dimer (5).
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for the physical separation of the G a subunit from the GPy dimer (Fung, 1983). Recent 
data indicate that G a  and Gpy dissociation may not be required for downstream signalling: 
i.e. fusion of G a to its associated Py dimer does not impair G protein function (Levitzki 
and Klein, 2002). In addition, using a fluorescence resonance energy transfer (FRET)- 
based assay, it has been demonstrated in intact cells that fluorescent Ga* and a z subunits 
and Gpiy2 dimers do not dissociate, although conformational changes take place upon 
activation (Bunemann et al., 2003). According to this “clamshell” model of G protein 
activation, receptor-induced changes in G protein conformation lead to the exposure of 
previously buried interfaces between the G a and Gpy subunits that can thus interact with 
their respective effectors. However, a different study, using the same FRET-based 
approach to investigate G protein activation in Dictyostelium demonstrated the receptor- 
mediated dissociation o f G as (Janetopoulos et al., 2001). The most likely explanation for 
these contradictory results might reside in the difference between the two G protein 
families taken in consideration. Thus, Gj and G s, which are quite different in their primary 
structure, can differentially undergo either subunit dissociation (Gs) or an intersubunit 
rearrangement (Gj) upon activation.
1.1.2.3 The accessory proteins that regulate the G protein signalling
The GTPase activity of the G a subunit is regulated by accessory proteins, among 
which the RGS (Regulators of G protein Signalling) proteins have attracted attention due 
to their ability to act as GTPase-activating proteins (GAPs) for the G a  subunit (Siderovski 
et al., 1996). Each RGS protein contains a hallmark ~120 amino-acid “RGS-box” domain, 
which contacts the G a switch region, increasing their intrinsic GTPase activity (Berman et 
al., 1996; Watson et al., 1996). This provides an explanation for the paradox between the 
rapid physiological timing described for GPCR-mediated signal transduction in vivo and 
the slow rate of GTP hydrolysis (0.1 to 0.3 Pi/mol Goc/min for most Ga; Gilman, 1987) 
exhibited by purified G a subunits in vitro.
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A recent addition to the group of regulators o f the G-protein cycle is a family of 
Ga-interacting proteins characterised by one or more Go Loco motifs (otherwise known as 
GPR or “G-Protein Regulatory” motifs; Siderovski et al., 1999). These generally bind to 
GDP-bound G a subunits of the Gi class and act as guanine nucleotide dissociation 
inhibitors (GDIs), slowing the spontaneous exchange of GDP for GTP (Willard et al., 
2004). In this way, GPy-effector signalling can continue in the absence o f receptor- 
catalysed Ga-GTP formation.
A completely different family o f regulators of the G-protein cycle is constituted by 
the AGS (Activators o f G-protein Signalling) proteins, which have been characterised as 
putative GEFs for the G a subunit. To date, four AGS have been identified (AGS 1-4, 
Lanier, 2004) that interact with different subunits and/or conformations of the 
heterotrimeric G proteins, and that can selectively activate different G proteins, providing 
an as yet to be defined mechanism for receptor-independent regulation o f the G-protein 
cycle.
1.1.2.4 The G-protein signalling and diseases
Once activated, the G a and GPy subunits can interact with a variety o f target 
effectors. Because of this, abnormal G-protein signalling can lead to serious biological 
consequence. Gene mutations that alter the GTPase activities o f G a  subunits correlate with 
several human diseases, such as some human thyroid and pituitary tumours (reviewed in 
Dhanasekaran et al., 1995), and sporadic McCune-Albright syndrome, a disease 
characterised by the hyperactivity o f the endocrine tissues and hyper-proliferation 
(Weinstein et al., 1991). Recently, a critical role in pathogenesis has also been 
demonstrated for GPy (Bookout et al., 2003). In vitro, the expression o f GRK2ct, a peptide 
derived from the C-terminus of GRK2 that inhibits Gpy signalling, attenuates serum- 
induced prostate cancer cell growth. In vivo, the inhibition of GPy signalling induces a 
significant decrease in rate the of prostate tumour growth in mice. In parallel, altered levels
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of Gy subunit expression have been noted in different tumour tissues. Indeed levels o f Gy7 
are reduced in pancreatic and gastrointestinal tract cancers (Shibata, 1998; Shibata et al.,
1999).
Thus, G proteins are crucial elements that define a correct cellular response. The 
study o f the mechanisms that regulate signal transduction is an essential step towards being 
able to connect inappropriate responses from external signals with an abnormal cell 
function. Many current lines of research focus on how the G proteins transmit and integrate 
signals coming into the cell, and data that has accumulated over the last few years indicates 
that the Gpy dimer is a crucial modulator of a broad range of cellular activities, as is the 
G a  subunit. The role of Gpy dimers in signal transduction pathways is extensively 
discussed in the next Section.
1.1.3 The G-protein By dimer: role in signal transduction
For a long time, the prevalent hypothesis for the mechanism of G-protein-mediated 
signal transduction gave merit for the activation o f effector proteins to the Ga-GTP subunit 
exclusively. The GPy dimer was regarded only as a negative regulator o f G a  subunit 
activity. Release of free GPy from an abundant G protein, such as Gi, was thought to 
deactivate other G a subunits by forming inactive heterotrimers (Gilman, 1987). The first 
clear evidence that the Gpy dimer can itself regulate effectors emerged when Logothetis 
(Logothetis et al., 1987) showed that the Gpy dimer can activate a K+-selective ion- 
conducting channel in cardiac atrial cells. Now, we know that GPy dimers regulate Ca2+ 
homeostasis through the modulation of ACs and PLCPs, and can activate mitogen- 
activated protein kinase (MAPK) pathways through phosphoinositide 3-kinase (PI3K) and 
Ras activation, and are therefore involved in the regulation o f cell growth and 
differentiation (Table 1.2; Cabrera-Vera et al., 2003).
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EFFECTOR REGULATION
PLC-p Stimulation
ACI Inhibition
ACII, IV, and VII Stimulation
K+ channels (GIRK 1, 2,4) Stimulation
Ca2+ channels Inhibition
G protein receptor kinase Recruitment to membrane
PI3K Stimulation
Bruton’s tyrosine kinase Stimulation
Tsk tyrosine kinase Stimulation
Protein kinase D Stimulation
Calmodulin Inhibition of calmodulin kinase
Tubulin Increased GTPase activity
Dynamin I Increased GTPase activity
She phosphorylation Indirect activation of MAPK
Raf-1 protein kinase Sequestration of Gpy
Ras exchange factor Indirect activation of MAPK
KSR-1 Sequestration of Gpy
Table 1.2. Effectors regulated by GPy dimers. GIRK, G protein-activated inwardly 
rectifying potassium channel. Modified from Cabrera-Vera, 2003.
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L I .3.1 The GPydimer composition directs effector coupling
Current research indicates that the Gpy dimer composition determines the quality, 
the efficiency and the specificity o f effector activation. Since structural constraints 
preclude the formation of certain Gpy dimers, (most notably those involving the p2, p3 and 
yi subtypes; Yan et al., 1996) not all o f the potential Gpy pairs exist in nature. As an 
example, GPsy2 can activate in vitro PLCPi or P2, but not PLCP3, whereas Gpiy2 is 
effective with all o f these PLC isoforms (Maier et al., 2000). This observation is supported 
by the demonstration o f a greater level o f GPy specificity in vivo: while in neurons 
recombinant GPiy2, P3y2, and Psy2, but not Gp2-containing dimers, activate PLCp, in vitro 
both GPiy2 and Gp2y2 are equally effective at activating PLCp, although at a 30-fold higher 
concentration than in vivo (Diverse-Pierluissi et al., 2000). Moreover, Bayewitch and co­
workers (Bayewitch et al., 1998) have shown that different configurations of the Gpy 
subunit can modulate the ACs: Gp5y2 inhibits ACII, whereas Gpiy2 and a pool o f Py 
subunits purified from tissues stimulate ACII. More recently, the specificity o f coupling 
between GPi-sy2 dimers and ACI and ACII has been analysed in Sf9 insect cells. All of 
these dimer combinations activate ACII and inhibit ACI (with P3y2 having the weakest 
effect), with the sole exception of GPsy2 (Mclntire et al., 2001). Finally, the extent of 
inhibition of voltage-dependent N-type Ca2+ channels is related to the Gp subtype (GPi = 
GP2 > Gps »  GP3 = GP4; Ruiz-Velasco and Ikeda, 2000), and it depends on the abilities 
o f the different p subunits to interact physically with the Ca2+ channels.
Together, these data demonstrate that the primary sequence of the Gp subunit is a 
major determinant for effector coupling efficiency and specificity.
1.1.3.2 The Py binding sites fo r  effectors
The GPy proteins have so far not been crystallised in complexes with their effector
molecules. However, using the two-hybrid system, it has been demonstrated that the N-
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terminus of the Gp subunit (including the N-terminal coiled-coil, the outer p strand of
blade 7, and blade 1) interacts with three different effectors: ACII, the K+ channel and
PLCP2 (Yan and Gautam, 1996). In parallel, data from molecular modelling and the use of
peptides that are able to inhibit the Gpy-mediated activation o f the ACs have implicated
residues 85-143 o f the Gp subunit in effector interactions (Chen et al., 1997; Weng et al.,
1996). This region overlaps the domain that was identified with the two-hybrid system
(Yan and Gautam, 1997). Moreover, mutational analysis o f the Gp subunit N-terminal 100
residues demonstrates that the N-terminal helix within these 100 residues takes part in y-
subunit binding, but not in effector interactions, whereas different domains that are
downstream of this helix interact with AC and with the K+ channel and PLCP (Yan and
Gautam, 1997). These domains form the first and the second P sheets o f the Gp subunit.
The G a subunit N-terminus lies close to this region of the Gp subunit, providing an
explanation for the ability o f the G a subunit to turn off GPy signalling. (Lambright et al.,
1996; Wall et al., 1995). However, although the well-defined interacting domains o f the
Gp subunit are covered by the G a subunit in the resting heterotrimeric conformation, it
appears that different domains may be used by the Gpy dimer for activation of different
effectors. This conclusion was reached through testing various Gp mutated in the switch
interface between the G a and Gp subunits for their ability to interact with several GPy-
effectors, such as p-adrenergic receptor kinase (PARK), PLCp, ACII and ion channels
(Ford et al., 1998). In line with this, by mutating multiple amino acids in each o f seven
blades of the p propeller, Panchenko and colleagues (Panchenko et al., 1998) showed that
mutations in blades 2, 6  and 7 greatly inhibit the ability of Gpy to activate PLCP2, while
being completely unaffected for ACI and ACII. Moreover, Buck and co-workers (Buck et
al., 1999) have shown that a peptide mimicking the Gp amino acidic sequence 115-135
blocks GPy-dimer-dependent activation of PLCp2. This sequence is located on the outer
surface of the Gp blade 2, and overlaps one o f the domains identified by Panchenko
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(Panchenko et al., 1998) as being involved in PLCP2 activation. Another important region 
for interactions with effectors is the C-terminal region o f the Gp subunit: the sequence 
between Gly 306 and Gly 319 that is located at the top surface o f the p propeller o f p i is 
involved in the activation of PLCp2 and ACII (Myung and Garrison, 2000). Overall, these 
results indicate that the amino acids at the top surface and at the edges of the p torus are 
important for PLCp activation, whereas the activation o f ACII depends more on its 
interaction with the top surface of Gp, thus demonstrating that various regions o f GPy are 
involved in its interaction with its targets.
1.13.3 GPy dimers modulate the activity o f  ion channels
1 .133 .1  Potassium channels
The inward rectifier G-protein-gated K+ channel (GIRK) was the first identified 
effector of GPy. Early studies demonstrated that the channel is acutely gated by Gpy, with 
channel openings increasing up to 1 ,0 0 0 -fold upon activation o f the muscarinic receptor or 
application of Gpy to the intracellular face of an excised membrane patch (Logothetis et 
al., 1987). These results were confirmed upon cloning of the GIRK channel, with the 
demonstration of a functional interaction between the GPy dimer and the full-length GIRK 
protein (Krapivinsky et al., 1995) and with segments of the channel subunits (Huang et al., 
1995; Inanobe et al., 1995).
Mammalian GIRKs are homo- or heteromultimers o f GIRK monomers (Corey et 
al., 1998) that are found in brain, where they mediate the postsynaptic inhibitory effects o f 
various transmitters (dopamine, somatostatin, opioids and others), and in heart, where they 
underlie a large part of the negative chronotropic parasympathetic regulation (reviewed by 
Dascal, 1997). Gpy interacts directly with the N- and C-terminal intracellular domains of 
each GIRK subunit. The identification of amino acid residues within the pore that if  
mutated, render the channel constitutively active and GPy insensitive has contributed to the
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definition of the gating mechanism mediated by Gpy (Sadja et al., 2001; Yi et al., 2001). 
According to this model, the binding of GPy results in a conformational rearrangement of 
the channel structure that allosterically regulates the gating apparatus in the pore. More 
recently, studies with chimeras between Gy2 and yeast Gy have revealed that the C-terminal 
half o f the Gy2 subunit is required for channel activation by the GPy complex (Peng et al., 
2003). In addition, point mutations of Gy2 have identified several amino acids that 
significantly reduce the ability of GPy to stimulate channel activity, an effect that is not due 
to improper association with Gp. Most of the critical Gy residues that have been identified 
cluster together, forming an intricate network of interactions with the GP subunit, and 
defining an interaction surface of the Gpy complex with GIRK channels. These results 
reveal a functional role for Gy in GPy-mediated effector modulation.
Further studies indicated an additional level o f complexity in the regulation o f the 
GIRKs. Activation of the channel by GPy requires permissive levels o f membrane 
phosphatidylinositol4,5-bisphosphate (PI4 ,5 P2). In turn, binding o f PI4 ,5 P2 to GIRK 
channels is stabilized by GPy (Huang et al., 1998; Zhang et al., 1999). Probably the gating 
of the channel by GPy proceeds through the modulation of the channel-PI4 ,5 P2 interactions 
(Logothetis and Zhang, 1999).
1.1.3.3.2 Calcium channels
The Gpy subunit also has an important modulatory role in inhibition of some 
presynaptic Ca2+channels (Ikeda, 1996). Voltage-gated Ca2+ channels are transducers that 
couple cellular excitability to several cellular processes, including contraction, secretion 
and gene regulation. These channels are multimers that are composed o f a common a l  
subunit that forms the conducting pore, which is associated with the regulatory subunits
94-(a2, p, y, and 8 ). Inhibition of Ca channels by G proteins was first reported in the chick 
dorsal root ganglion (Marchetti and Robello, 1989), and subsequent studies using rat GH3
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pituitary cells have provided evidence for an involvement of Gpy subunits in the receptor- 
dependent inhibition of Ca2+ channel activity (Hescheler and Schultz, 1994). The over­
expression of GPy in rat sympathetic neurons and in cell lines expressing the reconstituted 
whole Ca2+ channel complex have contributed to the confirmation of these initial 
observations (Ikeda, 1996).
GPy inhibits the Ca current by forming contact with two regions on the channel 
a l  subunits: the intracellular I-II loop (De Waard et al., 1997; Page et al., 1997) and the C- 
terminus (Zhang et al., 1996), forcing the channel into a state of low open probability. 
Although direct binding studies between full-length a l  subunits and GPy have not been 
performed, indirect kinetic evidence suggests the presence of a single GPy binding site per 
channel (Zamponi and Snutch, 1998). The extent o f inhibition is dependent on the Gp 
subunit isoform and it is antagonized by PKC-dependent phosphorylation o f the channel 
(Zamponi et al., 1997). Finally, additional subunits and proteins can affect the binding of
04-GPy and its effects on Ca gating. First, the p subunit o f the channel appears to be 
indispensable for the Gpy activity (Meir et al., 2000) although the mechanism of this 
interaction is still unclear. Secondly, syntaxin.lA (a protein that is crucial for transmitter 
release) modulates the channels by binding to the a l  subunit and GPy, and it supports the 
GPy-induced inhibition (Jarvis et al., 2000). Finally, Gao and Ga* subunits form contacts 
with the Ca2+ channel and probably serve as donors of GPy (Furukawa et al., 1998; 
Kinoshita et al., 2001). These results suggest that an integrated crosstalk between G protein 
signalling and other cellular pathways takes place at the level o f the Ca2+ channel.
1.1.3.3.3 Other ion channels
Direct interactions of GPy with other ion channels have also been reported. Kir2.3, 
an inwardly rectifying K+ channel that does not belong to the GIRK family interacts
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directly with GPy and is inhibited by GPy co-expression in Xenopus oocytes (Cohen et al.,
1996). The physiological role o f this Gpy modulation is unclear.
GPy subunits also regulate ATP-sensitive K + (K a tp )  channels. These are normally 
inhibited by resting levels o f cytosolic ATP and they have a protective role during 
metabolic stress and cardiac excitability (Ashcroft, 1988). In COS cells, GPy interacts 
directly with the accessory proteins of the K a tp  channel leading to its activation by 
reducing the inhibition by ATP (Wada et al., 2000). Notably, the affinity o f GPy revealed 
by experiments in excised patches, is very high (5-10 pM caused substantial activation), 
suggesting a sensitivity to GPy at least two orders o f magnitude higher than that o f the 
GIRKs.
1.1.3.4 G py dimers and signal generating enzymes
1.1.3.4.1 PLCs
The PLC enzymes have key roles in signal transduction through their hydrolyzing 
of PI4 ,5 P2 with the release of the second messengers diacylglycerol (DAG) and inositol 
1,4,5-trisphosphate (IP3) (James and Downes, 1997). This leads to activation of protein 
kinase C (PKC) in the case of DAG and to the release o f Ca+ from intracellular stores in 
the case of IP3. A number of PLC isoforms have been purified and cloned. PLCp, y and 8  
were identified over a decade ago and two additional members of the family, PLCs and 
PLCS, have been cloned more recently.
The four PLCp isoenzymes (PLCp 1-4 ) that have been identified to date can be 
activated by both G aq/n and Gpy subunits, and these pathways are important in the 
regulation of cardiovascular function and neuronal plasticity (James and Downes, 1997). In 
reconstitution assays, it has been demonstrated that the GPy-dependent activation o f the 
PLCPs is due to a direct interaction, while by expression of single PLCp isoforms in cells 
or by using purified PLCp, it has been shown that GPy can activate all o f the PLCP
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isoenzymes. PLCP2 and PLCP3 appear more sensitive to stimulation by GPy than PLCpi 
and PLCP4 (Park et al., 1993; Rhee, 2001). In the case o f PLCp3, G aq and Py are about 
equally effective as activators (on a molar basis). For other members o f the PLCp family, 
the G aq subunits are considerably more potent (50- to 100-fold) than the Gpy dimer.
The activation o f the PLCp isoforms by G aq/i i and the Py subunit is independent, 
and not conditional upon the priming by either subunit (Smrcka and Stemweis, 1993). This 
reflects the different sites on the PLCp molecule to which they bind. Blank and colleagues 
(Park et al., 1993) isolated a shortened form of PLCp3 that is activated by py but not by 
G aq/n, and truncation of a sequence o f amino acids at the C-terminus eliminated activation 
by G aq, but not by GPy (Lee et al., 1993). From these observations, it has been postulated 
that Gpy binds to the N-terminus while G a binds to the C-terminal region (Wu et al., 
1993). The PLCp enzymes contain a pleckstrin homology (PH) domain at the N-terminus, 
but there are no direct investigations of the role for this domain in the binding o f the Gpy 
dimer.
Expression of Gpiy2, GPiy3 or GP2y2 in COS7 cells markedly stimulates the 
enzymatic activity of PLCs that is involved in the regulation o f cell morphology, 
development and proliferation (Wing et al., 2003). Whether this activation of PLCs by GPy 
occurs by a direct interaction is not known. Since PLCs is also modulated by the 
monomeric G proteins Ras and Rho, it can be considered as a nexus protein that senses and 
mediates crosstalk between heterotrimeric GTPase and small GTPase signalling pathways.
1.1.3.4.2 ACs "
The GPy subunit also regulates some form of the ACs (Patel et al., 2001; Sunahara 
et al., 1996). These catalyse the formation of cyclic AMP (cAMP), that in turn activates 
cAMP-dependent kinases (cAPK), such as PKA. Molecular cloning techniques have
40
identified nine mammalian AC isoforms, types I-IX, that encode membrane-bound ACs, 
and one gene encoding a soluble isoforms.
The GPy subunit is a strong modulator o f AC activity that can be either stimulated 
synergistically with G as (type II, IV and VII), or inhibited (ACI and ACVIII) (Tang et al., 
1991). The relationship between GPy and the other cyclase isoforms, such as type V and 
type VI, is however less understood. Transfection experiments suggest that GPy can inhibit 
ACV and ACVI activities, perhaps in an indirect manner (Bayewitch et al., 1998). A 
failure to detect inhibition of AC activity by isolated G a subunits has led to the proposal 
that sequestration o f Gas by GPy is the mechanism underpinning this inhibitory 
mechanism.
Interestingly, the GPy-inhibited and some GPy-independent isoforms of ACs (ACI, 
ACIII and ACVIII) are stimulated by Ca2+/calmodulin (Cali et al., 1994; Tang et al., 1991), 
while ACV and ACVI are inhibited in vitro by micromolar calcium concentrations (Cooper 
and Brooker, 1993; Cooper et al., 1994; Yoshimura and Cooper, 1992). Ca2+ levels are 
regulated by the phosphoinositide pathway through PLCp, and thus the GPy-mediated 
activation of PLCp that regulates calcium levels indirectly modulates the ACs, serving as a 
cross-link between these two pathways.
1.1.3.5 G py dimers and the M AP kinase cascade
In eukaryotic cells, the participation of the GPy subunit in the cell cycle was 
suggested when it emerged that Gpy dimers directly elicite signalling pathways leading to 
MAPK activation in response to Gao/Gaj-linked receptor activation (Crespo et al., 1994). 
Then, under a variety of experimental conditions, it was demonstrated that MAPK 
activation by Gpy is blocked by a dominant interfering mutant o f the monomeric G protein 
Ras, and that GPy can induce accumulation of the activated form of Ras (Crespo et al., 
1994; Koch et al., 1994). Taken together, these findings indicate that signalling from
41
GPCRs to MAPK involves a GPy-mediated Ras-dependent pathway and provides strong 
evidence that the GPCRs and RTK signalling use the same pathway to activate MAPK. 
First, the GPy- and RTK-dependent pathways converge on the activation o f Ras (Gutkind,
2000); secondly, the pathway by which GPy stimulates MAPK may include a non-receptor 
tyrosine kinase, such as Lck, Fyn or cSrc. Finally, in certain cells the activation of MAPK 
by Gpy may also require trans-activation of RTKs for the assembly of the Ras-activating 
complex (Della Rocca et al., 1999).
Several intracellular effectors have been proposed as the first step towards 
activation of MAPK by Gpy dimers (Figure 1.6). Since GPy can activate PLC, it has been
I
hypothesised that the IP3 derived from this PLC pathway can increase intracellular Ca ,
1
thus leading to Ca /calmodulin activation that, in turn, activates Pyk2 kinases. Pyk2 
phosphorylates She, recruiting Grb2 and Sos, and the protein complex Shc/Grb2/Sos 
initiates the sequential activation of Ras, Raf and MEK. In confirmation o f this proposal, 
the disruption of this complex blocks GPy-mediated MAPK activation (Della Rocca et al., 
1997). Gpy-mediated activation of PLC also leads to an increase in DAG and activation of 
PKC. Therefore, at least in some cell types, GPy should activate the MAPK pathway 
through a PKC-dependent, but Ras-independent, pathway, similar to the MAPK pathway 
activated by G aq.
In addition, PI3K type IB is considered to be an early intermediate in GPy- 
mediated MAPK activation (Hawes et al., 1996) since it is directly activated by Gpy 
dimers. The PI3Ks are a large family o f enzymes that phosphorylate the phosphoinositides 
(Pis) in the 3-phosphate position of the inositol rings (Fruman et al., 1998; Krugmann and 
Welch, 1998), forming lipids (PI3P, PI3 ,4 P2 and PI3,4,5Ps) that are crucial in various 
signalling pathways involved in cell proliferation, differentiation, apoptosis, cytoskeleton 
organization and membrane trafficking. The PI3Ks are subdivided into three main classes 
(I, II, III) based on sequence similarities, substrate specificities and physiological roles
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Figure 1.6. GPy dimer and MAP kinase cascade. Biochemical routes initiated by Gpy 
subunit activation can stimulate Ras by activation of non-receptor tyrosine kinases, such as 
Lck, Fyn and/or cSrc, or by activation of PLC and PI3K. IP3 derived from the PLC 
pathway can increase intracellular Ca2+, which in turn activates Pyk2. Pyk2 phosphorylates 
She, recruiting Grb2 and Sos, and the Shc/Grb2/Sos protein complex initiates sequential 
activation of Ras, Raf and MEK. GPy-mediated activation of PLC also leads to an increase 
in DAG and activation of PKC, causing activation of the MAPK pathway through a PKC- 
dependent, but Ras-independent, pathway. PI3Kp mediates MAPK stimulation through 
activation of the Gabl/SHP2 complex, while PI3Ky mediates MAPK stimulation through 
activation of the Shc/Grb2/Sos complex.
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(reviewed in Fruman et al., 1998). The class I PI3Ks are the best characterized, and they 
are composed o f a 110-kDa catalytic subunit (four isoforms, p i 10a, p, y and 5), that is 
associated with a regulatory subunit (p85 or p i 01) that defines two subclasses (A and B, 
respectively). Gpy dimers directly activate the sub-type IB PI3Ky that is formed by pi lOy 
and plOl (Stephens et al., 1997), both in vivo and in vitro (Krugmann et al., 1999). When 
expressed in Sf9 cells or COS7 cells, pllOy has a significant basal activity that is only 
slightly stimulated by the GPy dimer, but when p i lOy is co-expressed with its associated 
subunit, the p i lOy/plOl heterodimer is stimulated to a much greater extent (Stephens et al.,
1997). Thus, one of the functions of p i 01 is to increase the sensitivity to GPy-stimulation. 
Leopoldt and colleagues (Leopoldt et al., 1998) using co-purification of Gpy with a p i lOy- 
GST fusion protein provided evidence of the direct binding of GPy to multiple regions o f 
the pllOy subunit. In addition, since the Gpy-stimulated activity o f PI3Ky requires the N- 
terminus of p i01, the p i 01 subunit is also involved in binding the Gpy dimer (Krugmann 
et al., 1999). Thus, the mechanism by which Gpy activates PI3K involves direct binding o f 
GPy to both components of the pllOy/plOl heterodimer. Finally, the pllOy catalytic 
subunit in turn mediates MAPK stimulation through the activation of the Shc/Grb2/Sos 
complex (Bondeva et al., 1998). However, the molecular events underlying these 
observations remain to be clarified.
Also the activation of the IB PI3KP by Gpy dimers appears to be involved in MAPK 
activation. Early studies showed that PI3KP is greatly stimulated by Gpy and by peptides 
containing phosphotyrosyl residues (pY) (Kurosu et al., 1997), although the molecular 
determinants of this synergism have not been defined. In addition, a dominant-negative 
mutant o f p i 1 Op inhibits MAPK stimulation (Yart et al., 2002b), and activation o f p i 1 Op 
is essential for cell-cycle progression o f NIH-3T3 cells stimulated with lysophosphatidic 
acid (Yart et al., 2002a). The GPy/PI3Kp-mediated MAPK activation probably involves 
the pY-motif-containing adapter protein Gabl, and the tyrosine phosphatase SHP2 that is
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recruited through PI3K and Gabl. These findings indicate that the pll0p/G abl/SH P2 
pathway provides a novel link between Gpy and Ras in the activation o f the MAPKs.
Gpy also regulates the UV-induced activation o f p38 and JNK (Seo et al., 2002), 
suggesting that G proteins mediate the activation o f MAPK stimulated by stress, although 
this signalling cascade downstream of GPy is not well understood. The over-expression of 
GPy in COS-1 and human keratinocytes increases UV-induced activation of the small G 
protein Cdc42, and over-expression of a constitutively active Cdc42 increases UV-induced 
p38 activation (Seo et al., 2004). This activation of p38 enhances the resistance of normal 
human keratinocytes to apoptosis (Chouinard et al., 2002). In addition, GPy increases UV- 
induced phosphorylation of the epidermal growth factor receptor (EGFR), and UV-induced 
p38 activation is blocked by an EGFR kinase inhibitor. These results indicate that Gpy 
mediates UV-induced activation of p38 in a Cdc42-dependent way and that activation of 
EGFR is required (Seo et al., 2004).
The recruitment o f different signalling proteins, such as Src, Pyk2, monomeric G 
proteins and PI3Ks, by GPy subunits and the cross-talk between the G-protein and receptor 
tyrosine kinase signalling pathways allows cells to integrate the information from many 
different sources and this facilitates their delicate control over multiple regulatory systems.
1.1.3.6 Other Gf}y interactors
The GPy dimer has also been shown to interact directly with a variety o f regulatory
proteins, mainly through a region that contains sequences homologous to PH domains
(Touhara et al., 1994). An important group o f GPy interactors is represented by the ARF
family of monomeric G proteins. In its inactive GDP-bound form, recombinant ARF1 was
shown to bind the GPy subunit o f transducin on phospholipid vesicles, rather than the
entire GaPy protein heterotrimer. The physiological significance o f this interaction remains
uncertain due to its low affinity, although it may be involved in the dynamics o f Golgi
membranes (Franco et al., 1995). Concomitantly, using a different in vitro approach, it was
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demonstrated that both Gpy and G as interact with ARF1 and ARF4 (Colombo et al., 1995). 
In particular, GPy interacts directly with ARF-GDP, suggesting that the complex 
Gpy/ARF-GDP allows the interaction o f ARF proteins with nucleotide exchange factors, 
thus facilitating ARFs activation. Further demonstrations that ARFs and GPy can interact 
in vivo come from the work o f Galas and colleagues (Galas et al., 1997), who demonstrated 
that ARF6  is specifically associated with the membranes o f secretory chromaffin granules 
through its interaction with the Gpy subunit and, they proposed that the GPy dimer 
represents the membrane receptor that stabilises the interaction of ARF6  with secretory 
granules. In line with these observations, Le Stunff (Le Stunff et al., 2000) using an in vitro 
assay, provided evidence that in myometrial membranes, inactive ARF6  is bound to the 
Gpy subunit and that ammonium sulphate disrupts this association, enabling ARF6  to 
mediate PLD activation.
The interaction site between the ARFs and Gpy has not been defined. Although 
ARFs lack a PH domain, the ARF accessory proteins, such as GAPs or GEFs, do contain 
such a PH domain, and this may regulate ARF activation in conjunction with GPy.
Recently, Dell et al. (Dell et al., 2002) used a yeast two-hybrid screen to 
demonstrate that Gpy, through its own WD-40 domain can interact with several WD-40 
repeat proteins. These include RACK1, a partner of an activated PKC isozyme (PKCpiI), 
and dynein intermediate chain (DIC), a retrograde microtubule motor protein involved in 
cell division and intracellular transport. The possible functional roles o f the interactions 
between GPy and RACK1 and DIC remain to be determined. One possibility is that it 
regulates the binding o f RACK1 to the membrane. RACK1 lacks any post-translational 
modification that might promote its membrane association so its interaction with GPy may 
constitute the membrane receptor similar to that proposed for ARF6 .
Interactions between other WD-40 repeat proteins have also been reported in the 
literature (Tcherkasowa et al., 2002). These encompass diverse cellular processes, ranging
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from signal transduction to cell growth and vesicular trafficking. In general, interactions 
between Gpy and other WD-40-containing proteins might represent a new mechanism for 
the integration of signals across different pathways.
1.1.4 Resulation o f  By  dimer activities
The broad spectrum of action and the ability o f free Gpy dimers to activate so many 
effectors implies that its activity has to be tightly controlled. Based on present knowledge, 
the activation of GPy is mainly regulated by the same mechanisms that regulate the G a 
subunits: it depends on GPCR activation, as well as its deactivation which depends on the 
G a subunit GTPase activity. In addition, the activation state of Gpy can be modulated by 
regulators of the G a guanine nucleotide cycle, like the RGS, GoLoco and AGS proteins 
(as described in Section 1.1.2.3). Nevertheless, GPy functionality is also controlled by 
interactions with proteins other than the G a subunits, making the regulation of this subunit 
much more complex than would have been thought. In the following section, an overview 
o f the regulatory mechanisms active on the Gpy dimer in a Ga-subunit-independent 
manner is reported.
1.1.4.1 Proteins that directly regulate signalling o f  the Py dimer
1.1.4.1.1 G-Protein coupled receptor kinase
Important proteins involved in the regulation o f GPy dimers are the G-protein- 
coupled Receptor Kinases GRK2 and GRK3 (originally known as P-adrenergic receptor 
kinase, PARK). Interactions between GPy and GRK2 mediate the membrane association of 
the kinase, and enhance GRK2-mediated receptor phosphorylation. The phosphorylation of 
the receptor does not interfere with G protein activation itself; instead, it begins the 
receptor-desensitization processes (Penela et al., 2003).
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Free Gpy subunits bind GRK2 through basic residues on two distant sites of the C- 
terminal PH domain of GRK2. One o f these sites (R587) is in the N-terminal half of the 
PH domain, and the second is in the extended a-helix and involves three lysine residues: 
663, 665 and 667 (Carman et al., 2000). Modulation of GRK2 by Gpy could be more 
complex, since the occurrence of a regulatory GPy-binding site in its N-terminus (amino 
acids 1-53) has recently been Suggested (Eichmann et al., 2003). In addition, the PH 
domains o f GRK2 and GRK3 can interact directly with PI4,5P2, the production of which is 
regulated by GPy (DebBurman et al., 1996). This suggests that GPy contributes to GRK2 
localization and activation with multiple pathways.
1.1.4.1.1 Phosducin andphosducin-like protein
Another family of GPy-binding proteins is the phosducins, which have been shown 
to block the functions of the GPy dimers. This protein family consists o f phosducin, 
phosducin-like protein (PhLP), and several isoforms of each.
Phosducin is a 33-kDa, soluble phosphoprotein that is expressed at very high levels in 
retinal photoreceptor cells and in pinealocytes. In the retina, phosducin binds the 
photoreceptor-specific Gtpy with high affinity and inhibits its interaction with the G a 
subunit (Lee et al., 1992; Yoshida et al., 1994). When phosducin is phosphorylated at 
Ser73 by cAMP-dependent PKA, it no longer blocks the association with G at. The 
phosphorylation state of phosducin is determined by light, being phosphorylated in the 
dark and de-phosphorylated upon illumination (Lee et al., 1990). These data have led to the 
hypothesis that phosducin participates in light adaptation. In the light, the de- 
phosphorylated phosducin binds Gt(3y and this blocks the re-association with G at-GDP, 
thereby inhibiting further activation of the heterotrimeric Gt by light-activated rhodopsin.
PhLP also binds Gfy with high affinity (Schroder and Lohse, 1996; Thibault et al.,
1997) and prevents Gfy from binding Ga. However, PhLP is widely expressed in many
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tissues beyond the retina and pinealocytes. Because of this, it has been postulated that 
PhLP is a general regulator o f GPy signalling in non-retinal tissues.
Both phosducin and PhLP possess two distinct domains that interact with Gpy 
subunits. The N-terminal domains bind loops on the top of the Gp surface, overlapping the 
binding surface for G a  and other effectors, explaining why phosducin and PhLP block the 
functionality o f GPy (Ford et al., 1998; Hawes et al., 1994). Interactions with the N- 
terminal domain contribute to a conformational change in GPy that tucks its famesyl group 
into a protein pocket, thereby decreasing the affinity o f GPy for the membrane (Savage et 
al., 2000). The C-terminal domains of phosducin and PhLP appear to have no effects on 
the association of Gpy with its effectors but bind the blades 1 and 7 at the putative 
membrane-binding site o f GPy (Savage et al., 2000; Sondek et al., 1996).
Besides the ability to scavenge Gpy subunits, another previously unrecognized 
mechanism of inhibition o f GPy-mediated signalling was recently suggested. Humrich and 
colleagues (Humrich et al., 2005) reported that transfection o f PhLPs (a splice variant o f 
PhLP) is associated with down-regulation o f transfected and endogenously expressed GPy, 
and that this involves a proteasome-dependent pathway. Since, PhLP also interacts with 
and inhibits the function of the cytosolic chaperonin complex involved in the folding of 
several proteins, it was suggested that this interaction results in the misfolding o f the G- 
protein subunits and might thereby provide an indirect mechanism of inhibition.
1.1.4.2 Post-translational modifications
L I .4.2.1 Lipid modifications
Heterotrimeric G protein functions are also regulated by lipid modifications: 
depending on their identities, G a subunit are myristoylated or palmitoylated at the N- 
terminus, while Gy subunits are famesylated or geranylgeranylated at the C-terminus. G a- 
myristoylation is an irreversible, co-translational modification occurring only on the Ga*
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family and this anchors these G proteins to the plasma membrane (Casey, 1994) and is of 
importance for the interactions of Gaj with GPy and effectors (Linder et al., 1991; Taussig 
et al., 1993). The reversible, post-translational palmitoylation is also important for G- 
protein anchoring to the plasma membrane, and in addition, it increases the affinity of Got 
for GPy. It has the effect of inhibiting the interaction of GZGAP (an RGS protein) with G az 
(Tu et al., 1997).
The post-translational prenylation of Gy is not necessary for Gpy dimer formation; 
indeed, Gy subunits in which the cysteine (that is the target o f prenylation) is mutated to 
serine can form Gpy dimers as efficiently as wild-type Gy (Casey et al., 1994). However, 
lipid modifications o f Gy are necessary for membrane attachment o f the GPy dimer (Chen 
and Manning, 2001) and for the productive interactions o f Gpy with other proteins, 
including the G a subunit and effectors as well as the receptor.
1.1.4.2.2 Phosphorylation
In addition to lipid modifications, py subunits can be modified by phosphorylation. 
The first indication that Gp is phosphorylated was provided by Wieland (Wieland et al., 
1993; Wieland et al., 1991). Interestingly, the target of the phosphotransfer reaction is a 
histidine residue, which is phosphorylated by GTP. The phosphate can be re-transferred 
onto GDP so generating GTP, which can activate Gj and Gs heterotrimer. Recent evidence 
suggests that this unusual phosphotransfer reaction is catalysed by the ubiquitous 
membranous isoforms o f nucleoside diphosphate kinase (NDPK-B) (Cuello et al., 2003). 
Gpy and NDPK-B are able to interact directly, forming a complex that allows the 
phosphorylation o f Gp and then the transfer o f the phosphate on the GDP derived from the 
G a subunit. A physiological role of this reaction is suggested by the increase in cAMP 
formation that is dependent on the presence of NDPK-B complexes with GPy that occurs 
in rat heart myocytes (Hippe et al., 2003). These observations fit with a model where the
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phosphorylated NDPK-B/Gpy complex contributes to the receptor-independent activation 
of G proteins. Very recently, it has been reported that the phosphorylated Gp subunit is a 
substrate of a widely expressed protein histidine phosphatase (PHP), both in vitro and in 
vivo (Maurer et al., 2005). This finding delineates a cycle in which Gp is phosphorylated 
by NDPK and dephosphorylated by PHP. As Gp, NDPK and PHP are ubiquitously 
expressed, these data hint at a novel but widespread mechanism in eukaryotes for the 
regulation of the basal, receptor-independent activation of heterotrimeric G proteins.
Both the G a  and GPy subunits are subject to phosphorylation by Ser/Thr-protein 
kinases, such as PKC, and this results in altered functional properties. Indeed, 
phosphorylation of G a by PKC inhibits signal transduction through the Gaj, G az and G a i2 
family members. Interaction of phosphorylated G az subunit with free py is greatly 
impaired: it is likely that this prolongs Gpy-effector activation, while reducing G a  effector 
stimulation (Fields and Casey, 1995).
Similar to the G a subunit, GPy containing yi2 are substrates o f PKC 
phosphorylation (Asano et al., 1998). The free Gpyi2 is phosphorylated on an N-terminal 
Ser residue of the Gy subunit. Compared to the non-phosphorylated form, the 
phosphorylated protein is more resistant to digestion by calpain and appears to interact 
with the G a subunit more tightly. Interestingly, phosphorylation o f Pyi2 affects the 
interaction of GPy only with certain effectors. Indeed, phosphorylation inhibits Gpy- 
mediated AC activation while having no effect on activation o f PLCPy (Yasuda et al.,
1998). This demonstrates that several different mechanisms must cooperate to regulate 
signalling mediated by GPy subunit.
1.1.4.2.3 ADP-ribosylation
G proteins can also be regulated by the mono-ADP-ribosylation reaction. There are 
a number o f bacterial toxins that alter the action of specific heterotrimeric G proteins as
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part of their mechanisms of toxicity. Our laboratory provided the first demonstration that 
the G proteins can also be mono-ADP-ribosylated by an endogenous enzyme. Indeed, we 
showed that the Gp subunit is a substrate of a cycle of ADP-ribosylation/de-ribosylation 
that modulates its activity (Lupi et al., 2000; Lupi et al., 2002). This cycle represents the 
means to regulate the GPy dimers independently from the a  subunits. A deeper description 
of the endogenous mono-ADP-ribosylation reaction involving the Gp subunit is reported in 
Section 1.2.3.3.2.
1.1.4.2.4 Ubiquitylation
The ubiquitin proteasome pathway (UPP) provides yet another level of regulation 
(Obin et al., 1994). This is a conserved pathway o f selective protein modification and 
degradation that controls levels and activities o f highly regulated eukaryotic proteins 
(reviewed in Ciechanover et al., 2000). Substrates o f the UPP are covalently ligated to one 
or more monomers of the 8.5-kDa protein ubiquitin by the sequential activities o f three 
families o f enzymes: ubiquitin-activating enzymes (El), ubiquitin-conjugating enzymes 
(Ubc/E2) and ubiquitin-ligase (E3). Interestingly, the Gpy subunit o f transducin is one o f 
the targets o f UPP (Obin et al., 1994). Ubiquitylation of Gpy on Gy is catalysed by two 
different ubiquitin-conjugating enzymes (E2) and this coincides with the degradation of the 
entire Gpy dimer. The association of Gpy with phosducin blocks GPy ubiquitylation and its 
subsequent degradation (Obin et al., 2002), but phosphorylation o f phosducin, which 
inhibits the phosducin-GPy complex formation, completely restores ubiquitylation and 
degradation. Thus, ubiquitylation of GPy can be considered as a selective proteolytic 
mechanism that regulates transducin activities with phosducin probably serving as a 
protective factor for Gtpy following the light-dependent dissociation of Gtapy.
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1.2 The enzymatic ADP-ribosvlation reaction
Cells adapt rapidly to changes in their environment by regulating the functional 
status of signalling protein. This is achieved by various mechanisms, among which there 
are several post-translational modifications that are crucial for protein activation and/or 
inactivation. Whereas the best-described modifications involve phosphorylation of specific 
amino acids, evidence is also accumulating that endogenous ADP-ribosylation can have a 
similar role.
ADP-ribosylation consists o f the binding o f an ADP-ribose group, and it can occur 
by non-enzymatic or an enzymatic reaction. In the first case, ADP-ribose that is produced 
from NAD+ by glycohydrolase activity is attached non-enzymatically to reactive 
nucleophilic amino acids residues, primarily lysine and cysteine (Ziegler, 2000).
Alternatively, the ADP-ribose moiety is enzymatically transferred from NAD+ to 
specific amino acids of the acceptor proteins. ADP-ribosyltransferases, the enzymes that 
catalyse the enzymatic reactions, are capable of cleaving p-NAD+ at its p-N-glycosidic 
bond and covalently attaching either a single (mono-ADP-ribosylation) or multiple (poly- 
ADP-ribosylation) ADP-ribose moieties to the target proteins (Ame et al., 2004; Corda and 
Di Girolamo, 2003). These two classes of enzyme-catalysed ADP-ribosylation reaction 
differ not solely in the length o f the ADP-ribose chain, but also in the chemical nature of 
the ADP-ribosyl-bond (N-glycoside versus O-glycoside) and the site o f reaction (cytoplasm 
and cell membrane versus nucleus) (Shall, 1995).
1.2.1 The volv-ADP-ribosvlation reaction
Poly-ADP-ribosylation is a modification that occurs widely in nature and that has 
important roles in processes aimed at preserving the functional integrity o f the genome. It 
thus influences processes such as recombination, transcription, differentiation and 
apoptosis.
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The PARPs (poly-ADP-ribosylpolymerases) that catalyse this reaction are present in 
almost all eukaryotic cells, although they are apparently absent in yeast (Hassa and 
Hottiger, 2002). PARP1, the prototypical and most widely expressed member o f the PARP 
family, is a nuclear protein with highly conserved sequence, especially at amino acids 
comprising structural motifs and functional domains. These include: (1) an N-terminal 
double zinc-fmger domain (DBD) with a high affinity for DNA single strand breaks; (2) a 
C-terminal NAD+-binding catalytic domain, with a structure similar to that o f diphtheria 
toxin, indicating a phylogenetic relationship among the ADP-ribosyltransferases; and (3) a 
central auto-modification domain with several conserved glutamate residues (Ame et al., 
2004; Rolli et al., 1997). Auto-modification can inhibit PARP 1-DNA binding, protein- 
protein interactions and ADP-ribosyltransferase activity, which ultimately inactivates the 
protein (DAmours et al., 1999).
The product of the reaction catalysed by PARP1 is represented schematically in 
Figure 1.7. Initially, PARP1 catalyses NAD+ hydrolysis with concomitant release of free 
ADP-ribose that is attached to the acceptor amino acid (initiation phase). Then, this ADP- 
ribose serves as an acceptor for the successive attachment of ADP-ribose to the 2 ’ position 
(elongation phase). Branching occurs at approximately every 20-25th ADP-ribose units 
(branching phase) (Alvarez-Gonzalez et al., 1999). The resulting tree-like structure 
comprises many negative charges and profoundly alters the function o f the modified 
protein. The main target of poly-ADP-ribosylpolymerase is PARP-1 itself, but the polymer 
is also attached to other proteins, including histones, topoisomerases, and high mobility 
group (HMG) proteins.
An important feature o f PARP1 is the requirement for DNA strand breaks to 
activate its catalytic functions in DNA repair processes. In addition, to direct binding to 
DNA, PARP1 activity can also be stimulated by interactions with protein binding partners. 
In particular, PARP1 recruits repairing enzymes at sites of DNA damage and participates 
in the ligation step (Creissen and Shall, 1982). Indeed, 3-aminobenzamide, a specific
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Figure 1.7. PoIy-ADP-ribosylation. Poly-ADP-ribose polymers (PARs) are synthesised 
by the distinct enzymatic activities of PARP 1, including (A) initiation, (B) elongation, and 
(C) branching. PARs are attached to glutamate residues in target proteins via covalent 
linkages at the position labelled 1 in the expanded view of an ADP-ribose unit. The ADP- 
ribose units in the PAR polymers are linked via glycosidic ribose-ribose bonds at the 
positions labelled 1 and 2 in the expanded view. The blue arrows indicate the sites o f 
action o f poly-ADP-ribose glycohydrolase (PARG) and ADP-ribosyl protein lyase.
55
PARP inhibitor, prevents the ligation of lOkb-DNA-replication-intermediates to the high- 
molecular-weight DNA-replication forks in a human melanoma cell line (Lonn and Lonn, 
1985). In striking contrast to this cytoprotective function, in case of serious DNA damage, 
PARP1 becomes over-activated and cells undergo apoptosis due the depletion of the 
NAD+ pool. Excessive NAD+ consumption is prevented by the cleavage of PARP1 by 
caspases that generate two inactive fragments o f 24 and 89 kDa (reviewed in Soldani and 
Scovassi, 2002). The N-terminal fragment (p24) remains in the nucleus, retaining its 
DNA-binding activity, and inhibits the catalytic activity of uncleaved PARP1 and impairs 
DNA repair. The p89 fragment migrates from the nucleus to the cytoplasm in late 
apoptotic cells with advanced nuclear fragmentation and becomes a potential target of 
autoimmunity (Rodenburg et al., 2000; Figure 1.8).
In the absence of DNA damage, PARP1 regulates normal cellular functions, such as 
transcription and maintenance of chromatin structure. The available data suggest that 
PARP1 regulates transcription by modifying histones, the structural proteins that constitute 
chromatin, with severe effects on both the packaging of nucleosomes into high-ordered 
structures and on the stability o f single nucleosomes (D Amours et al., 1999). Indeed, poly- 
ADP-ribosylation of HI and H2 histones in vitro by purified PARP1 leads to nucleosome 
decondensation (Poirier et al., 1982).
The negatively charged ADP-ribose polymers can be recognised by histones, that 
dissociate from DNA, destabilizing the nucleosome structure (Realini and Althaus, 1992). 
These effects might allow access o f the enzymes involved in transcription to regions 
normally ocluded. In addition, PARP1 regulates transcription by functional interactions 
with various non-histone proteins, many of which are DNA-binding transcription factors 
(DAmours et al., 1999).
Telomeres represent another important cellular target for poly-ADP-ribosylation. 
Tankyrases (TNKS1 and TNKS2, also termed PARP5), PARP1 and PARP2 ADP- 
ribosylate the telomere-binding protein TRF1, a negative regulator o f telomere-length
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Figure 1.8. The involvement of PARP1 in DNA repair and apoptosis. PARP1, a 113- 
kDa protein, has three functional domains: the N-terminal DNA-binding domain (DBD); 
the central auto-modification domain (AD); and the C-terminal catalytic domain (CD). 
PARP1 is a DNA nick-sensor that is recruited to DNA damage sites where it poly-ADP- 
ribosylates itself. During DNA repair, auto-ADP-ribosylated PARP1 is detached from the 
DNA, thus allowing DNA damage to be accessible to DNA repair factors. During 
apoptosis, to avoid excessive NAD consumption, auto-ADP-ribosylated PARP1 is cleaved 
by caspases into its p24 and p89 inactive fragments .
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maintenance (Kaminker et al., 2001; Smith et al., 1998). In vitro, poly-ADP-ribosylated 
TRF1 moves from telomeric DNA, suggesting that poly-ADP-ribosylation is a positive 
regulator o f telomere length in telomerase-expressing cells.
Like other covalent protein modifications, poly-ADP-ribosylation is reversible. A 
poly-ADP-ribose glycohydrolase (PARG) catalyses the hydrolysis o f ADP-ribose units 
(Ame et al., 1999), and in vivo the steady-state cellular levels o f poly-ADP-ribosylation are 
determined by the opposing actions o f PARP and PARG.
1.2.2 The mono-ADP-ribosvlation reaction
The mono-ADP-ribosylation reaction consists o f the transfer o f a single ADP-ribose 
moiety from NAD+ to target proteins (Figure 1.9). The physiological and most efficient 
acceptor is usually a specific amino acid residue, although some o f the mono-ADP- 
ribosyltransferase can use water as an acceptor, leading to the glycohydrolysis o f NAD+ 
(NADase activity).
The mono-ADP-ribosylation was identified originally as the pathogenic mechanism 
of action of diphtheria, cholera, and other bacterial toxins (Ueda and Hayaishi, 1985). Only 
later were the enzymes related to the toxins identified in cells, and their potential 
physiological roles explored (Corda and Di Girolamo, 2003). In mammalian cells, enzymes 
that reverse the reaction and regulate the mono-ADP-ribosylation include the cytosolic 
ADP-ribosylhydrolases and the cytosolic and extracellular pyrophosphatases (Moss et al., 
1992; Zolkiewska and Moss, 1995). The former hydrolyse the protein-ADP-ribose linkage 
with the release o f the ADP-ribose moiety, while the pyrophosphatases hydrolyse the 
pyrophosphate linkage releasing AMP and a ribosylphosphoryl-protein. The presence o f 
these activities in the cell strongly suggests that the mono-ADP-ribosylation reaction 
represents a normal regulatory mechanism.
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Figure 1.9. The mono-ADP-ribosylation reaction. A schematic representation o f the 
reversible mono-ADP-ribosylation reaction that is catalysed by an arginine-specific mono- 
ADP-ribosyltransferase and an ADP-ribosylhydrolase (see text for details). The other 
amino acid residues that can be modified by this reaction are cysteine, diphthamide and 
asparagine (From Corda and Di Girolamo, 2003).
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1.2.2.1 Mono-ADP-Ribosylation in viruses and prokaryotes as a mechanism o f  
pathogenesis
Mono-ADP-ribosyltransferase enzymes were historically characterised as virulence 
factors of several bacterial pathogens that pose significant human health threats 
(Domenighini et al., 1994; Ueda and Hayaishi, 1985). Indeed, upon translocation into 
mammalian cells, bacterial toxins ADP-ribosylate crucial host cell proteins, such as the G a 
subunits of the heterotrimeric G proteins, the small G proteins Rho and Ras, monomeric 
actin and elongation factor 2 (EF-2), resulting in permanent activation or inactivation o f 
the cellular functions modulated by these proteins (reviewed by Krueger and Barbieri, 
1995; Table 1.3).
Diphtheria toxin (DTX) produced by Corynebacterium diphteriae was the first 
bacterial toxin to be identified as an ADP-ribosyltransferase. Using radiolabeled 
preparations o f NAD+, Honjo et al. (Honjo et al., 1968) demonstrated that DTX catalyzes 
the transfer of ADP-ribose to EF2, a 100-kDa protein that functions in polypeptide chain 
elongation on ribosomes. Subsequent studies demonstrated that DTX specifically ADP- 
ribosylates diphthamide, a modified histidine present uniquely in eEF2, with drastic 
consequences for the host cells due to the inhibition of protein synthesis (Collier and Cole, 
1969).
Since then, a wide variety of other toxins have been shown to use the mono-ADP- 
ribosylation reaction to disrupt metabolic processes within host cells.
Cholera toxin (CTX) and the closely related heat-labile enterotoxins LT-1 and LT-2 
from Escherichia coli are the etiological agents of cholera and traveller’s diarrhoea, 
respectively. They are arginine-specific ADP-ribosyltransferases that are able to modify 
the a  subunit of the heterotrimeric Gs proteins. The modified arginines are localized close 
to the domain responsible for the interaction with the y-phosphate o f GTP, locking the G 
protein in its active conformation through the reduction of its intrinsic GTPase activity
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: Enzymes Source Substrate/ amino acid
Effect o f the 
reaction
Viruses:
ALT Bacteriophage T4 RNA polymerase/ enhances viral
Arg265 transcription
Mod A Bacteriophage T4 RNA polymerase/ enhances viral
Arg265 transcription
ModB Bacteriophage T4 RNA polymerase/ enhances viral
Arg265; transcription
SI ribosomal protein/ 
________________________________________ Arg______________________
Prokaryotes:
Toxins:
Diphtheria C. diphtheriae EF2/diphtamide715 inhibits protein 
synthesis
Exotoxin A P. aeruginosa EF2/diphtamide715 inhibits protein 
synthesis
Exotoxin S P. aeruginosa Ras family/Arg41 disrupts actin 
microfilaments
Cholera V. cholerae Gas, Gat/Argl87 inhibits GTPase 
activity
LT1, LT2 E. coli Gas, Gat/Argl87 inhibits GTPase 
activity
Pertussis B. pertussis Gai/0, Gat/Cys351 uncuples receptor 
and G proteins
C3 C. botulinum Rho, Rac/Asn41 disrupts actin 
cytoskeleton
EDIN S. aunts Rho/Asn41 disrupts Golgi 
apparatus
SpvB
Intracellular:
S. enterica actin prevents actin 
polymerisation
DRAT R. rubrum dinitrogenase
reductase/
ArglOl
inhibits
dinitrogenase
reductase
Table 1.3. Mono-ADP-ribosylation in viruses and prokaryotes. Modified from Corda 
and Di Girolamo, 2003.
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(Figure 1.10). The prolonged activation and the consequent increase in cAMP in the 
intestinal epithelium causes net intestinal salt and water secretion, resulting in massive 
diarrhoea, and changes in cell morphology presumably due to activation of cAMP- 
dependent PKA (Barbieri et al., 2002; Donta et al., 1976; Peterson and Ochoa, 1989; Scott 
et al., 2003; Spangler, 1992). Structurally, CTX and the LTs are oligomeric proteins, 
consisting o f a monomeric A subunit, with ADP-ribosyltransferase activity (CTA), 
coupled to a homopentamer B subuhit that binds to the extracellular surface o f mammalian 
cells via specific interactions with the GMl-ganglioside receptors (Zhang et al., 1995). To 
cause disease, both CTX and LT co-opt molecular machineries o f the host cell: the toxin 
enters by endocytosis o f the toxin-receptor complexes, moves to the Golgi cistemae or to 
the endoplasmic reticulum (ER) via retrograde transport, and finally translocates to its site 
of action on the inner surface o f the plasma membrane (Lencer et al., 1999). The A subunit 
then requires proteolytic cleavage that allows the release of the 22-kDa catalytically active 
fragment (CTA1). The enzymatic activity of CTA1 is stimulated by the host protein 
family of ADP-ribosylation factors (ARFs) (Moss and Vaughan, 1995; see Section 1.3). 
Another well-characterised bacterial ADP-ribosyltransferase is pertussis toxin (PTX), 
which is produced by Bordetella pertussis as the etiologic agent o f whooping cough. It 
catalyses the ADP-ribosylation of the Gaj, G a 0 and G at subunits on a cysteine residue. 
Unlike CTX, PTX-catalyzed mono-ADP-ribosylation occurs when G a  is associated with 
the Py dimer, thus generating a modified G protein that is unable to transduce signals 
(Figure 1.11; Hepler and Gilman, 1992). PTX is a heterohexameric protein that is divided 
functionally into an A-B architecture similar to CTX (Tamura et al., 1982). The A protomer 
consists of a single subunit (SI) with ADP-ribosyltrasferase activity. The B oligomer is a 
pentameric complex of five polypeptides, which confers binding specificity to the target 
cell membrane, thus initiating toxin internalization by receptor-mediated endocytosis (Xu 
and Barbieri, 1995; Xu and Barbieri, 1996).
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Figure 1.10. Effects of cholera toxin on the cycling of Gsa  between its active and 
inactive forms. Normally, GTP in active Gsa-GTP is rapidly hydrolyzed (blue arrow), so 
that the activation o f adenylyl cyclase and rise in cAMP persist only as long as does 
hormone stimulation. In the presence o f cholera toxin (CTX), Gsa  is irreversibly modified 
by mono-ADP-ribosylation; the modified Gsa  can bind GTP but cannot hydrolyze it (green 
arrows). As a result, there is an excessive, non-regulated rise in the intracellular cAMP 
levels.
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Figure 1.11. Effects of pertussis toxin on the cycling of GiOt between its active and 
inactive forms. Normally, Gi inhibits eukaryotic adenylyl cyclase. In the presence of 
pertussis toxin (PTX), GiCt is irreversibly modified by mono-ADP-ribosylation. The 
modified GiCt cannot bind GTP (green arrows), and is unable to perform its normal 
function of inhibition of adenylyl cyclase. The conversion o f ATP to cyclic AMP cannot 
be stopped and the intracellular levels o f cAMP increase.
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Unlike cholera toxin, there is no evidence that the ADP-ribosyltransferase activity of the SI 
subunit requires cofactors, such as the ARFs.
In recent years, the bacterial-mediated ADP-ribosylation of the monomeric G 
proteins Rho and Ras has been studied in detail due to their pivotal role in the regulation of 
the actin cytoskeleton. The Rho proteins are modified by a variety of toxins that have been 
collected into the C3-like family. This group includes Clostridium botulinum exoenzyme 
C3, and the C. limosum exotoxin and transferases produced by Bacillus cereus and 
Staphylococcus aureus (Aktories and Just, 2005). All of these transferases are single­
chained 23-kDa exoenzymes that enter the host cells mostly via fluid phase endocytosis and 
pinocytosis. C3 toxin causes disorganization of actin filaments due to ADP-ribosylation of 
RhoA, B and C (Sekine et al., 1989). ADP-ribosylation of Rho does not impair the binding 
of GTP or effectors; rather, the recruitment of Rho to the membrane is affected. In line with 
this concept, there is the finding that activation of ADP-ribosylated Rho by GEFs is 
inhibited (Sehr et al., 1998), and downstream Rho signalling is blocked (Fujihara et al., 
1997). The ADP-ribosylation of Rho catalysed by the S. aureus toxin ED IN (Epidermal cell 
Differentiation INhibitor) also disrupts the Golgi complex by a process that is similar to 
that used by brefeldin A (Sugai et al., 1992). The other Rho subfamily members, Rac and 
Cdc42, are poor substrates for ADP-ribosylation under artificial conditions and do not seem 
to be the relevant in vivo targets.
Diverse members o f the Ras family are targets o f arginine-specific ADP- 
ribosylation by exotoxin S (ExoS) from Pseudomonas aeruginosa (Fraylick et al., 2002; 
McGuffie et al., 1998). Once modified, Ras and its related protein Rap, are unable to 
interact with their respective guanine nucleotide exchange factors; this results in their 
inactivation. This causes changes in cytoskeleton architecture induced by the consequent 
actin rearrangements (Riese et al., 2001). In parallel, ExoS can affect the cellular 
cytoskeleton structure with a mechanism that is unrelated to ADP-ribosylation o f the Ras 
family but involving the protein moesin (Maresso et al., 2004). Ezrin and radixin, two
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moesin homologues, are also ADP-ribosylated, indicating that the ezrin/radixin/moesin 
family (ERMs) collectively represent specific substrates o f ExoS. Since the ERM protein 
complex contributes to cytoskeleton dynamics, the ability o f ExoS to modify ERM links 
ADP-ribosylation to the actin cytoskeleton changes associated with ExoS intoxication.
The actin network is also affected by the activity o f bacterial toxins that directly 
ADP-ribosylate actin monomers. This is the case for C. botulinum type C and type D, 
which produce the C2 toxin that causes ADP-ribosylation o f monomeric actin on argl77, 
thereby inhibiting polymerization (Figure 1.12; Aktories et al., 1986) and actin ATPase 
activity (Geipel et al., 1989). In addition, actin polymerisation is affected by the activity of 
the Salmonella enterica virulence-associated protein SpvB. The spvB gene codes for a 
transferase that modifies actin monomers to prevent polymerization; thus, infected cells 
lose all o f their F-actin filaments (Lesnick et al., 2001). SpvB is expressed by Salmonella 
strains after invasion of epithelial cells and after phagocytosis by macrophages, and its 
activity causes local and global actin depolymerisation that affects either vesicular 
trafficking or cellular physiology, or both, to promote Salmonella proliferation.
There is an alternative means by which bacterial toxins interfere with signal 
transduction (Quan et al., 1999). In this case, a mycobacterial transferase causes ADP- 
ribosylation and inactivation of the antibiotic rifampicin. This constitutes a new mechanism 
used by pathogens to induce sickness in a host organism through resistance to antibiotic 
treatment.
Interestingly, some bacterial toxins are encoded by lysogenic phages that incorporate into 
the DNA of their host bacteria (Uchida et al., 1971). So far, three different ADP- 
ribosyltransferases have been discovered that are encoded by the bacteriophage T4: Alt, 
ModA and ModB. Alt, a structural component of the phage head, ADP-ribosylates Arg265 
of the host RNA polymerase (Goff, 1984), with the consequent enhancement o f viral 
transcription (Sommer et al., 2000). ModA and ModB both ADP-ribosylate the a-subunit 
o f the bacterial RNA polymerase and the SI ribosomal protein o f E. coli
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Figure 1.12. M echanism of F-actin disruption by bacterial toxins. In the host, there is a 
dynamic equilibrium between G-actin monomers and polymerized F-actin filaments. The 
SpvB protein and other actin-modifying toxins catalyse the covalent attachment o f ADP- 
ribose to G-actin monomers, preventing their incorporation into polymers. Since F-actin is 
continuously depolymerised by cytoskeletal regulatory proteins, the monomers are 
eventually trapped in an inactive form, and no more G-actin is available for 
polymerisation. The cell thus becomes completely depleted of F-actin filaments.
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(Tiemann et al., 1999), both o f which support the programme for the phage to gain control 
over the infected host cell. Computer analysis reveals that both the Mod and Alt protein 
sequences exhibit structural similarities to the catalytic domains o f prokaryotic ADP-mono- 
ribosyltransferases.
1.2.2.2 Endogenous mono-ADP-ribosylation in the prokaryotic world: the D RAT/DRAG  
cycle
Bacterial mono-ADP-ribosylation reactions occur not only through the secreted 
toxins, but also within the bacteria themselves, to control their metabolic enzymes. The 
best studied endogenous ADP-ribosylation reaction in bacteria is the modification of 
dinitrogenase reductase in Rhodospirillum rubrum (Figure 1.13; Ludden, 1994; Ludden et 
al., 1989). This modification regulates nitrogen fixation only in certain nitrogen-fixing 
bacteria (Halbleib et al., 2000), and it was the first clear demonstration o f the physiological 
role of this reaction. The dinitrogenase reductase (an enzyme that reduces nitrogen to 
ammonium) is inactivated rapidly and reversibly by mono-ADP-ribosylation on arginine, 
thus preventing non-productive nitrogen fixation during energy-limiting or nitrogen- 
sufficient conditions. This reaction is catalysed by dinitrogenase reductase/mono-ADP- 
ribosyltransferase (DRAT), a 30-kDa monomer having high specificity for ArglOl o f 
oxidised dinitrogenase reductase (Lowery and Ludden, 1988). DRAT is activated by 
environmental stimuli such as darkness or a source of fixed nitrogen. The reaction 
catalysed by DRAT is very similar to that o f CT although there is no obvious amino acid 
sequence homology between these enzymes, even though some residues are conserved 
between the two families (Bazan and Koch-Nolte, 1997).
Dinitrogenase reductase is fully reactivated by a specific ADP-ribosylarginine- 
hydrolase, called dinitrogenase reductase-activating glycohydrolase (DRAG), a 32-kDa 
monomeric, manganese-dependent enzyme that hydrolyses the N-glycosidic bond o f the 
ADP-ribosylated protein (Fitzmaurice et al., 1989). DRAG is activated after exposure o f
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Figure 1.13. A model of in vivo nitrogenase regulation in R. rubrum  by reversible 
ADP-ribosylation. Nitrogenase activity is regulated by reversible ADP-ribosylation of 
dinitrogenase reductase. Dinitrogenase reductase ADP-ribosyltransferase (DRAT) 
catalyzes the transfer of the ADP-ribose moiety from NAD to an arginine, rendering the 
dinitrogenase reductase inactive. The enzyme is reactivated upon the removal o f the ADP- 
ribose by dinitrogenase reductase-activating glycohydrolase (DRAG). The redox- 
dependent conformational change in the protein is shown by a shift in protein subunit 
position.
69
the bacteria to light or depletion of the nitrogen source and acts to regenerate free arginine 
and activating dinitrogenase reductase, thus completing the ADP-ribosylation cycle 
(Ludden, 1994). The DRAT/DRAG regulatory approach has also been found in other 
nitrogen-fixing bacteria such as the phototroph Rhodobacter capsulatus (Masepohl et al., 
1993; Willison et al., 1993) and the non-photosynthetic Azospirillum brasilense and 
Azospirillum lipoferum (Fu et al., 1989; Zhang et al., 1992). This DRAT/DRAG-induced 
modification represents the best-characterised endogenous ADP-ribosylation cycle and 
demonstrates that ADP-ribosylation represents a physiological mechanism to regulate the 
activities of cellular proteins.
1.2,3 Mono-ADP-Ribosvlation in eukaryotes: enzymes and substrates
After the discovery o f the bacterial ADP-ribosyltransferases, similar enzymatic 
activities were sought in eukaryotic cells. However, the enzyme responsible eluded 
molecular cloning until the groups o f Moss and Shimoyama succeeded in purifying and 
sequencing proteins with ADP-ribosylating activities from rabbit skeletal muscle and 
chicken bone marrow cells (Tsuchiya and Shimoyama, 1994; Zolkiewska et al., 1992). 
Then, using oligonucleotides derived from known mono-ADP-ribosyltransferases 
(mADPRTs), additional family members were cloned from chicken, mouse, human and 
other species (Davis and Shall, 1995; Koch-Nolte and Haag, 1997; Koch-Nolte et al.,
1996). Cloning of the mADPRTs gave new impetus to the study o f the ADP-ribosylation 
reaction; indeed, mADPRTs represent an exciting possibility for the characterisation o f the 
physiological role o f this modification. The growing number of mADPRTs identified has 
prompted the need to introduce a systematic nomenclature for the corresponding genes and 
proteins (Haag and Koch-Nolte, 1997). The mammalian mADPRTs are thus designated as 
ARTs and numbered from 1 to 5 (ART 1-5). In Table 1.4, the main features o f the cloned 
ARTs are summarised.
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Gene name Species Preferred site Predicted cellular 
o f expression localisation
ART1 human, mouse, 
rat, rabbit
skeletal and 
cardiac muscle
cell surface
ART2A, ART2B human (pseudogne), 
mouse, rat
peripheral T cells, 
intraepithelial 
lymphocytes NK cells
cell surface
ART3 human, mouse, 
rat, rabbit
testis cell surface
ART4 human, mouse, 
rat, rabbit
lymphatic tissue cell surface
ART5 human, mouse, 
rat, rabbit
testis secreted
ART6A, ART6B chicken bone marrow, 
heterophils
secreted (granules)
ART7 chicken erythroblasts secreted
Table 1.4. The ART family. Cloned vertebrate members o f the mono-ADP- 
ribosyltransferase gene family (modified from Haag and Koch-Nolte, 1998).
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1.2.3.1 The ARTfamily
Ecto-ADP-ribosyltransferases (ARTs) constitute a relatively small group of 
structurally related proteins that modify extracellular substrates. There are six mammalian 
ARTs: ART1 (the rabbit skeletal muscle ART), ART2.1 and ART2.2 (identified in rat and 
mouse), ART3, ART4 and ART5. Three further forms have been described in birds: 
ART6 A, ART6 B (Tsuchiya et al., 1991) and ART7 (Davis and Shall, 1995). There are 
only four functional ART genes in the human genome (ART1, ART3, ART4 and ART5; 
ART2 is present as a pseudogene; Glowacki et al., 2002). All the ARTs have a 
hydrophobic N-terminal signal sequence, which indicates that they are extracellular 
proteins; ART1-ART4 also have hydrophobic carboxyl-terminal signal sequences 
characteristic of glycosylphosphatidylinositol (GPI)-anchored membrane proteins, with an 
extracellular catalytic domain (Koch-Nolte and Haag, 1997; Koch et al., 1990; Zolkiewska 
et al., 1992). Mammalian ART5 and avian ART6  and ART7 possess hydrophobic N- 
terminal signal sequences and they are secreted proteins (reviewed in Bazan and Koch- 
Nolte, 1997; Moss et al., 1999; Okazaki and Moss, 1999). Ecto-ARTs ADP-ribosylate 
proteins on the cell surface of the same cells (cis-ADP-ribosylation), and/or of 
neighbouring cells in vivo during cell-cell contact (trans-ADP-ribosylation).
Members of this enzyme family share very limited amino acid sequence identity, 
with 20-30% identity among the ART paralogue members within any species; the 
exception is mouse ART2.1 and ART2.2, with 85% sequence identity indicating a recent 
evolutionary duplication o f the mouse art2 gene (Braren et al., 1998). As the human and 
mouse genome sequences have been completely determined, all o f the recognizable 
members of these toxin-related ARTs have now been identified for these two species, with 
the identity among orthologues ranging between 75% and 85%.
Despite the limited primary sequence homology among the different ADP- 
ribosyltransferases, a central cleft bearing the NAD-binding pocket has been remarkably
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conserved between bacterial toxins and eukaryotic mono- and poly-ADP- 
ribosyltransferases. This core comprises six p-strands, two a-helices and a single helical 
turn. The six P-strands fold in the form of two p sheets (in complex strand order 6-3-1 and 
2-5-4) that are perpendicular to each other, and the two a-helices in turn principally form 
the “walls” of a bi-lobed crevice formed by the curled sheets (Figure 1.14). Moreover, 
there are common structural features that characterize this family o f mammalian ARTs. 
Rappuoli and colleagues (Domenighini and Rappuoli, 1996) have proposed a structural 
model that applies to prokaryotic and eukaryotic ARTs. According to this, three common 
domains have been identified in the ART catalytic core. Region 1, near the N-terminus of 
the protein, is characterised either by a conserved arginine or by a conserved histidine 
(DTX, Pseudomonas exotoxin A, and eukaryotic PARP). Region 2 is characterized either 
by hydrophobic amino acids that are involved in NAD+ binding or by the serine-x-serine 
motif (where x represents threonine, serine or alanine), and region 3 is highly acidic and 
characterised by a conserved glutamate residue that is crucial for catalysis (Domenighini et 
al., 1994). In ART1 from rabbit, the conservative glutamate 240 to aspartate (E240D) 
substitution abolishes the transfer of ADP-ribose to arginine; the neighbouring glutamate 
238 has also been shown to be important for ADP-ribose transfer (Hara et al., 1996; 
Takada et al., 1995). In several of the ARTs, the replacement o f this second glutamate 
abolishes the ability of these transferases to use arginine as acceptors, thus further 
supporting the hypothesis that this region is involved in substrate recognition (Han and 
Tainer, 2002). Indeed, through a comparative analysis o f crystallographic structures, Han 
and Tainer have extended the significance of region 3 sequences by identifying an ARTT 
motif (ADP-ribosylating tum-tum motif) that they have implicated in substrate recognition 
(Han and Tainer, 2002). In line with the relevance o f the ARTT motif, it has been shown 
that the auto-ADP-ribosylation o f ART2.b is abolished by mutation o f its arginine 204, 
which is part of the ARTT motif. Similarly, if  tyrosine 204 o f ART2.a is mutated to an 
arginine (Y204R), it is possible to promote ART2.a auto-ADP-ribosylation
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Figure 1.14. The ART family. A, Core features of the ADP-ribosyltransferase fold as a 
schematic topology diagram. The location o f the catalytic Glu is marked by a pink circle. 
B, Gene structures of the ART1, ART2 and ART5 proteins. Exons (boxes) encode domains 
common to the ARTs. The transferase catalytic core contains the conserved amino acids 
that are critical for the formation of the active site. In ART1 and ART5, an arginine- and 
lysine-rich region is encoded by separate exons, whereas in ART2, this region is included 
in the exon that contains the catalytic core. The lines between the exon boxes represent the 
introns of the gene.
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(Stevens et al., 2003). Finally, four cysteines that are conserved among all of the ART 
isoforms form disulfide bridges at the C-terminus of the molecule, which are important for 
protein stabilization (Mueller-Dieckmann et al., 2002).
The possibility that the N- and C-terminal domains of the ARTs are involved in the 
regulation of ART activity has been investigated recently by measuring both the 
transferase and NAD glycohydrolase (NADase) activities o f truncated mutants of ART1 
(Bourgeois et al., 2003). In mouse ART1, the amino acids at 24-38 (an ARTl-specific 
extension) modulate both the transferase and NADase activities, and amino acids 39-45 (a 
common ART coil) are essential for both activities. The removal o f the C-terminal basic 
domain decreases the transferase, but enhances the NADase activity. The N- and C- 
terminal regions of ART1 are therefore required for its transferase activity, while the 
enhanced NADase activities of the shorter mutants indicate that there are sequences 
outside of the catalytic site that exert structural constraints, and that modulate the substrate 
specificity and catalytic activity (Bourgeois et al., 2003).
1.2.3.2 The ecto-ARTs: expression, distribution and biological significance in mammals
Although substantial progress has been made with regard to the molecular 
characterisation of ARTs, identification of their physiological target proteins has been 
difficult. This may be related to their high turnover or their low net modification in vivo, 
and to the low abundance of acceptor proteins. It is also difficult to recognise a common 
denominator for the target proteins described so far. They are highly diverse with respect 
to structure, function and cellular localization. In contrast, a common feature o f the ecto- 
ART-encoding genes is that their expression is restricted to one or few tissues (Seman et 
al., 2004; see Table 1.4). Northern blotting and RT-PCR with human and animal tissues 
have revealed a relatively broad distribution of ART3 and ART4, and a rather specific 
expression o f ART1 in heart and skeletal muscle in both species. ART5 is mainly 
expressed in testis, while ART2, which is absent in man, has been detected in mouse
75
peripheral and rat lymphoid tissues (Adriouch et al., 2001). The pattern o f ART expression 
in some cases is related to cell differentiation and/or activation state. In human 
polymorphonuclear neutrophils, translocation of ART1 to the cell surface depends on the 
presence o f activating ligands such as formyl-Met-Leu-Phe (fMLP), IL-8  or platelet 
activating factor (PAF) (Kefalas et al., 1999). Similarly, the rate of ART3-transcription is 
increased upon exposure of human monocytes to lipopolysaccharide, which also induces 
expression o f ART4 mRNA (Grahnert et al., 2002). Another typical example is ART2 
expression on murine T cells. ART2 is expressed only on a small subpopulation of mature 
thymocytes, and thus appears to be developmentally regulated (Koch-Nolte et al., 1999). 
Moreover, whereas ecto-ART expression increases with human PMN or monocyte 
activation, ART2 is shed from the membrane upon T-cell activation (Kahl et al., 2000; 
Nemoto et al., 1996).
Expression of ecto-ARTs on the cell membrane also appears to depend on genetic 
factors. Analysis o f ART2.2 levels on T lymphocytes has revealed a considerable variation 
from one mouse strain to another (Koch-Nolte et al., 1999), which might result from cis- 
acting regulatory elements in the promoters and their distribution in alternative splice 
variants (Sardinha et al., 1999).
1.2.3.2.1 ART1
ART1 is expressed predominantly in leukocytes and in skeletal muscle, where its 
substrates include integrin a l.  Although the functional consequences o f integrin a l  ADP- 
ribosylation remains to be determined, it has been postulated that this modification affects 
both cell adhesion and outside-inside cell signalling. In murine T-cell lymphoma EL-4 
cells, over-expressed ART1 ADP-ribosylates distinct cell surface molecules, including 
lymphocyte-function-associated antigen-1 (LFA-1), CD45, CD43 and CD44, causing 
inhibition o f T-cell receptor signalling (Liu et al., 1999).
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Another important and recently identified ART1 substrate is the human defensin 
HNP-1 (Paone et al., 2002). Defensin belongs to a large family o f cationic arginine-rich 
peptides of 2 to 6  kDa that are released from the granules of activated neutrophils. These 
peptides have a broad spectrum of antimicrobial and cytotoxic activities, and play an 
important role in the innate immune response. Moreover, it has recently been shown that 
defensins might also be a component of adaptive immunity: human natural killer cells and 
T and B lymphocytes produce HNP1-3 when stimulated with cytokines. The mechanisms 
o f defensin action are not completely understood, but they are generally believed to 
involve disruption of microbial membranes (Yang et al., 2002). Paone and colleagues 
(Paone et al., 2002) have demonstrated in vitro that A rgl4 of synthetic HNP-1 is a specific 
substrate for ART1. The ADP-ribosylation of the peptide reduces both its antimicrobial 
and cytotoxic activities, but enhances its ability to release IL- 8  from epithelial cells. 
Conversely, modified and unmodified HNP-1 show similar chemotactic activities when 
evaluated for their ability to recruit T lymphocytes. These data are in line with the concept 
that once modified, HNP-1 acquires properties that can result in the recruitment of 
neutrophils (by the release of IL-8 ) and in the modulation of its own antimicrobial and 
cytotoxic activities. Evidence that ADP-ribosylation of HNP-1 occurs in vivo is obtained in 
broncho-alveolar wash-fluid from habitual smokers (and not from non-smokers). Cigarette 
smoking results in pulmonary inflammation with increased numbers of neutrophils in the 
lungs. Here, HNP-1 reaches concentrations that are cytotoxic for airway epithelial cells in 
vitro. By inhibiting its antimicrobial and cytotoxic properties while promoting neutrophil 
recruitment, the ADP-ribosylation o f HNP-1 may thus have an important role in the 
regulation o f the inflammatory response. This observation has two interesting implications: 
it indicates that ADP-ribosylated HNP-1 participates in the inflammatory response, and it 
demonstrates that endogenous ADP-ribosylation occurs in humans.
Additional substrates o f ART1 including growth factors and membrane receptors 
have been identified in various cell lines over-expressing this enzyme. ART 1-transfected
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rat adenocarcinoma cells have been used to demonstrate ADP-ribosylation of basic 
fibroblast growth factor (FGF-2), which had been initially detected on the surface of adult 
bovine aortic endothelial and human hepatoma cells (Boulle et al., 1995; Jones and Baird,
1997). FGF-2 has a specific extracellular receptor (FGFR), but also a relatively high 
affinity for heparin. It can thus be sequestered by the heparan sulphates on the cell surface 
and in the extracellular matrix. Heparin inhibits the ADP-ribosylation reaction, which 
would imply that the heparin binding of FGF-2 and its ADP-ribosylation are mutually 
exclusive reactions. Furthermore, the ADP-ribosylated site o f FGF-2 is in its receptor- 
binding domain and so it is possible that ADP-ribosylation modulates the binding of FGF- 
2 to its receptor and to heparin, thus regulating its availability to the cell (Boulle et al., 
1995; Jones and Baird, 1997).
In ART 1-transfected V79 Chinese hamster lung fibroblasts, platelet-derived growth 
factor-BB (PDGF-BB) is a substrate for ART1 whereas its structural homologue PDGF- 
AA is not (Saxty et al., 2001). The ADP-ribosylated PDGF-BB loses its ability to stimulate 
mitogenic and chemotactic responses in human pulmonary smooth muscle cells, and it 
shows a reduced capacity for binding to PDGF receptors in competition-binding assay, as 
compared to unmodified PDGF-BB (Saxty et al., 2001). This indicates that PDGF-BB- 
dependent signalling can be regulated by ART1 activity at the cell surface.
1.2.3.2.2 ART2
ART2 is expressed in resting T cells and in natural killer cells, and it appears to be 
specific to the immune system. The presence o f ART2 on the surface o f immune cells thus 
suggests an immunomodulatory activity. Indeed, in different animal models, autoimmune 
disorders such as juvenile diabetes and systemic lupus have been found to coincide with 
defects in the structure and function of ART2 (Greiner et al., 1986; Koch-Nolte et al., 
1995). In the rat, susceptibility and resistance to diabetes correlate with the absence and 
presence o f ART2-expressing T cells, respectively (Fowell and Mason, 1993). Moreover,
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treatment of the animals with ART2 specific antibodies can induce an autoimmune 
reaction, up to diabetes (Greiner et al., 1987).
Nolte and co-workers (Seman et al., 2003) recently uncovered an intriguing 
function o f ART2: ADP-ribosylation activates the P2X7 purinoceptor. This is a member of 
the P2X family o f ATP-gated ion channels, and it is widely expressed in several type of 
blood cells (Di Virgilio et al., 2001). The interest in this purinoceptor rose because o f its 
peculiar ability to induce the formation o f large membrane pores (Di Virgilio et al., 2001). 
Thus, the activation o f P2X7 with millimolar concentrations of ATP triggers calcium 
fluxes, phosphatidylserine exposure and apoptosis (Di Virgilio et al., 2001). These same 
effects are triggered by NAD+ at micromolar concentrations via the ADP-ribosylation of 
P2X7. However, these effects are not seen in ART2-deficient T-cells, demonstrating that 
the activation o f P2X7 by NAD+ is ART2 dependent (Seman et al., 2003). These data 
provide an explanation for the rapid apoptosis induced by extracellular NAD (NAD- 
induced cell death or NICD) in naive T cells (Scheuplein et al., 2003). How does ADP- 
ribosylation activate P2X7? Covalently immobilized ADP-ribose could function as a ligand 
for the adenosine-binding site on P2X7. Alternatively, ADP-ribosylation could activate 
P2X7 by an allosteric conformational change independent o f the ligand-binding site. 
Identification of the ADP-ribosylated arginine residues will help to solve this question. 
Altogether, these data show that not only is ART2 expressed in the immune system, akin to 
ART1, but also that both of these two arginine-specific ARTs have clear roles in the 
regulation of the immune response.
1.2.3.2.3 ART3, ART4 andART5
The biological functions of ART3, ART4 and ART5 remain poorly defined. ADP- 
ribosyltransferase activity on the surface of human monocytes correlates with the presence 
of ART3 in unstimulated cells, while ART4 is expressed only in response to 
lipopolysaccharide stimulation (as, for example, in bacterial infection) in lymphatic tissue
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(Grahnert et al., 2002). Cell-surface ADP-ribosylated proteins on human monocytes are 
modified on cysteine residues, suggesting that ART3 and ART4 may be cysteine-specific 
enzymes (Grahnert et al., 2002). This is in line with the observation that when these two 
enzymes were assayed in vitro, neither displayed an arginine-specific enzymatic activity 
(Glowacki et al., 2002).
1.2.3.2.4 Extracellular J3-NAD+ availability
A point that remains to be clarified is the occurrence o f extracellular NAD+ that is 
required to sustain the extracellular ADP-ribosylation reaction. The steady-state 
concentration of NAD+ in the serum of healthy individuals is around 0.1 pM, and it can be 
kept low by the extracellular NAD-glycohydrolase CD38 (Berthelier et al., 1998). 
However, to be used by ecto-ARTs, extracellular NAD+ should reach the concentrations of 
1-10 pM that are required for ADP-ribosylation of P2X7 (Seman et al., 2003), or higher if  
the Km of the ARTs (from in vitro assay) is considered (Okazaki et al., 1996). The probable 
mechanism is that NAD+ is released from the cells, where its concentration is in the range 
of 0.5-1.0 mM, as a consequence either of cell lysis during inflammatory immune reactions 
and apoptosis, or o f non-lytic release, for example through the connexin 43 channels 
(Bruzzone et al., 2001).
1.2.3.3 Intracellular ADP-ribosyltransferases and endogenous substrates
All of the human and mouse ecto-mono-ADP-ribosyltransferases have now been
identified (Glowacki et al., 2002) and classified as either GPI-anchored or secretory
proteins, implying that the targets of these enzymes are extracellular proteins. However,
mono-ADP-ribosylation has also been demonstrated for intracellular proteins involved in
cell signalling and metabolism (Table 1.5). The enzymatic activities involved here have
been shown to be both cytosolic and membrane associated, although there is very little
further information available concerning their identities. Indeed, the intracellular ADP-
ribosyltransferases probably constitute a different family o f proteins having no obvious
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sequence similarities or structural relationships to the well-known ARTs described above. 
An example in line with this hypothesis is given by the sirtuin family. Thus, it has recently 
been shown that yeast Sir2p (silent information regulator 2 protein) has ADP- 
ribosyltransferase activity. Frye and colleagues (Frye, 1999) showed that a human Sir2p 
homologue (SIRT2) can transfer the label from NAD+ to BSA, providing evidence in 
support of the idea that human sirtuins might also act as mono-ADP-ribosyltransferases.
More recently, the in vitro characterization of mouse SIRT6  confirms that this 
enzyme is a nuclear protein with a robust auto-ADP-ribosylation activity (Liszt et al., 
2005). All of the seven human sirtuins so far cloned possess a conserved histidine that is 
important for the ADP-ribosyltransferase activity, although they lack any obvious 
sequence homology with the ARTs (Frye, 2000).
Sirtuins are not the only examples of unusual ADP-ribosyltransferases; indeed, the 
intracellular enzymes pierisin-1  and pierisin- 2  were discovered recently in the cabbage 
butterfly, Pieris rapae, as mono-ADP-ribosyltransferases (Matsushima-Hibiya et al., 2000; 
Watanabe et al., 1999). Pierisin-1 is a 98-kDa protein having a role in the development of 
the insect, and it induces apoptosis in a variety of human cancer cell lines (Kono et al., 
1999). Only after the characterisation o f its enzymatic activity did a very remote similarity 
to the ADP-ribosylating subunit of CT emerge (Watanabe et al., 1999). The use of known 
inhibitors for ADP-ribosylating enzymes greatly reduces pierisin-induced apoptosis, thus 
linking pierisin ADP-ribosylating activity to apoptosis (Watanabe et al., 1999). Once inside 
the target cell, intracellular proteases cleave pierisin, releasing a fragment that contains the 
ADP-ribosyltransferase activity (Kanazawa et al., 2001). The targets o f pierisin-1 were 
recently described as the 2’-deoxyguanosine residues in DNA so that the reaction yields 
N(2)-ADP-ribosyl-2’-deoxyguanosine, as determined by NMR and mass spectrometry 
(Takamura-Enya et al., 2001). Pierisin-1 induces apoptosis o f HeLa cells by activating a 
mitochondrial pathway involving Bcl2 and caspase (Kanazawa et al., 2002). Whether this 
process is due to the ADP-ribosylation o f deoxyguanosine in a specific DNA region or to a
Enzymes Source
Substrate/ 
amino acid
Effect o f the 
reaction
Eucaryotes:
Sir2p Yeast Histone/Sir2p/
acetyl-lysine
involved in histone 
deacetylation
Sirtuin2 Human Albumin/
acetyl-lysine
involved in histone 
deacetylation
Piersinl, 2 Cabbage butterfly DNA Cytotoxic
Arginine-specific Hamster, human Gp/Argl29 inhibits substrate 
activity
Cysteine-specific Human GDH/Cys inhibits substrate 
activity
Table 1.5. Intracellular mono-ADP-ribosylation in eukaryotes. Modified from Corda 
and Di Girolamo, 2003.
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more extensive modification of these residues remains to be clarified. The function of 
pierisin-1  in the butterfly as well as the mechanism underlying pierisin-induced apoptosis 
in cancer cells clearly require further analysis.
As an alternative to unidentified ADP-ribosyltransferases that are unrelated to the 
ARTs, secretory ecto-ARTs, such as ART5 or ART2, shed from activated T cells might 
conceivably translocate to the cytoplasm. This could be achieved in a way similar to that of 
the bacterial toxins, which have their own specific receptors on the plasma membrane 
(Lencer et al., 1999). However, the sorting mechanism reported for GPI-anchored proteins, 
which involves endocytic vesicles, would result in a lumenal localization o f the catalytic 
domain, separating it from cellular substrates, including the G proteins (Muniz and 
Riezman, 2000). Our laboratory is now actively working to identify and define potential 
new intracellular ART isoforms.
The intracellular mono-ADP-ribosylation reaction has been associated with cell 
metabolism in intact cells, and thus far, it has been demonstrated for three substrate 
proteins: the ER-resident chaperone protein GRP78/BiP (Laitusis et al., 1999; Leno and 
Ledford, 1989), the heterotrimeric G protein py subunit (Lupi et al., 2000; Lupi et al., 
2002), and mitochondrial glutamate dehydrogenase (GDH; Herrero-Yraola et al., 2001).
1.23.3.1 GRP78/BiP
GRP78/BiP is a molecular chaperone that resides in the lumen of the ER and that 
functions in the folding and assembly o f proteins entering the secretory pathway. Specific 
mono-ADP-ribosylation o f GRP78/BiP leads to its inactivation. The modified protein has 
been detected in response to nutritional stress, a condition that depletes the ER of 
processible proteins. Laitusis and co-workers (Laitusis et al., 1999) have hypothesized that 
in intact Swiss 3T3 and GH3 pituitary cells this ADP-ribosylation is related to the rate of 
protein synthesis and processing. According to this idea, in cells with high rates o f protein 
synthesis, unmodified GRP78 is complexed with protein-folding intermediates. A slowing
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of protein synthesis would result in the accumulation of the free, active form of GRP78, 
which is subject to subsequent inactivation by ADP-ribosylation. The ADP-ribosylated 
form of the chaperone thus provides a buffering system that allows the rates o f protein 
processing to be balanced with those of protein synthesis. It should be noted that while this 
mono-ADP-ribosylation occurs intracellularly, from a topological point of view, the 
enzyme involved (that has not yet been characterized) should be an ectoenzyme, due to the 
luminal localization of GRP78.
1.2.3.3.2 G protein Py dimer
An ADP-ribosylation reaction may also occur on the p subunit o f heterotrimeric G 
proteins. Indeed our group has provided direct evidence o f a functional, enzymatic 
modification o f the p subunit both in isolated plasma membranes from different cell lines 
(including Swiss 3T3, CHO and HL60 cells) and in intact cells (Lupi et al., 2000). 
Modification of the py subunit occurs on Argl29, a residue critically located in the P 
common-effector-binding surface (Chen et al., 1997; Weng et al., 1996; Yan and Gautam, 
1997; Yan et al., 1996). It is catalyzed by a plasma membrane-associated, non-GPI- 
anchored intracellular mono-ADP-ribosyltransferase that has yet to be characterised. 
Interestingly, the modified p subunit can be de-ADP-ribosylated by a cytosolic ADP- 
ribosylhydrolase, which regenerates native py by releasing the bound ADP-ribose (Figure 
1.15). In intact cells under resting condition, ca. 0.2% of the total py heterodimer is 
modified, an amount that could correspond to a cellular pool of free Py dimer heterodimer 
that remains inactive. This hypothesis is supported by the demonstration that ADP- 
ribosylation occurs only on the activated Py heterodimer, and that this inactivates the p 
subunit by impairing its interactions with its effectors enzymes. This has been shown 
directly in the case of type 1 AC and PLCp and PI3K (Lupi et al., 2000; Lupi et al., 2002). 
Thus, the ADP-ribosylation/de-ribosylation cycle might correspond to a functional 
activation/inactivation cycle of the py dimer for the modulation o f its functions. The
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Figure 1.15. The ADP-ribosylation/de-ribosylation cycle o f the heterotrimeric G 
protein p subunit. Modification o f the Gpy subunit occurs on A rgl29 and is catalyzed by 
a plasma-membrane-associated, intracellular mono-ADP-ribosyltransferase. The modified 
GPy subunit then serves as a substrate for a cytosolic ADP-ribosylhydrolase, which 
regenerates the native Gpy by releasing the bound ADP-ribose.
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demonstration that the P subunit is subject to covalent modification is o f particular interest 
because of the central role that the py dimer plays in the regulation o f signal transduction 
pathways downstream of GPCRs. This was the first in vivo demonstration of a post- 
translational modification for the G protein p subunit (Lupi et al., 2000; Lupi et al., 2002).
1.2.3.3.3 Mitochondrial GDH
An ADP-ribosylation/de-ADP-ribosylation cycle has also been proposed to occur 
in mitochondria, which involves the cysteine-specific ADP-ribosylation of liver 
mitochondrial GDH. ADP-ribosylation of GDH causes substantial inhibition o f its 
enzymatic activity in intact Hep-G2 cells (Herrero-Yraola et al., 2001). The ADP- 
ribosylation cycle could then be completed by an ADP-ribosylcysteine hydrolase present in 
mitochondria, which restores the active form of GDH. Given the central position o f GDH 
in metabolism where it lies at the crossroads o f several important pathways, a tight control 
of its catalytic activity is essential. In line with this suggestion, it has been demonstrated 
that enhanced ADP-ribosylation of GDH occurs if  glutamate is added to the cell culture 
medium. Inhibition o f excessive glutamate use by GDH would prevent the concomitant 
accumulation of ammonia that is toxic for the cells. This enzyme is also central to cellular 
nitrogen metabolism, and thus ADP-ribosylation of GDH may be part o f the complex 
regulatory system controlling the cellular nitrogen balance. As for GRP78/BiP and for the 
G protein p subunit, the nature o f this ADP-ribosyltransferase activity remains 
uncharacterised.
Further substrates of mono-ADP-ribosylation have also been identified, including 
the membrane-fissioning proteins CtBPl-s/BARS (De Matteis et al., 1994; Di Girolamo et 
al., 2005; Di Girolamo et al., 1995) and the cytoskeletal proteins actin, tubulin and desmin 
(Huang et al., 1993; Zhou et al., 1996). However, to date there has been no direct evidence 
for their in vivo modification.
86
1.2.3.4 The ADP-ribosylhydrolase
Besides mADPRTs, the other class of enzymes involved in the ADP- 
ribosylation reaction are the ADP-ribosylhydrolases. These are soluble proteins that 
release ADP-ribose from proteins that are modified on an arginine or on other amino 
acid residues (Herrero-Yraola et al., 2001; Moss et al., 1992). Specific hydrolase 
activities have been detected in mammalian, avian and bacterial systems. However, the 
functional interplay of the constituents of these postulated ADP-ribosylation cycles 
remain to be demonstrated. The ADP-ribose moiety is critical for substrate recognition; 
indeed, the ADP-ribosylhydrolase enzyme hydrolyzes ADP-ribosylarginine and (2- 
phospho-ADP-ribosyl)arginine, but is inactive with phosphoribosylarginine or 
ribosylarginine.
ADP-ribosylation of integrin catalysed by the extracellular GPI-anchored ART is 
reversed by a phosphodiesterase. As a result, 5’-AMP is released from the protein while 
phosphoribose remains attached to the modified arginine residue (Zolkiewska and 
Moss, 1995). The ADP-ribosylhydrolases have been cloned from rat (Takada et al., 
1994), mouse and human brain (Takada et al., 1993). Hydrolase activities of rat and 
mouse brain are sensitive to Mg2+ and dithiothreitol (DTT), whereas the human 
hydrolase appears to be DTT independent (Moss et al., 1992). The nucleotide and 
deduced amino acid sequences o f the mouse hydrolase shows 92% and 94% identity 
with rat; the human and rat hydrolases show 82% and 83% identity in their nucleotide 
and deduced amino-acid sequences.
1.3 The ADP-ribosvlating factors (ARFs)
During the 1980s, several cellular factors that enhance CTX-catalysed ADP- 
ribosylation o f G as were described. Kahn and Gilman (Kahn and Gilman, 1984) reported 
the purification of a ~20-kDa membrane-associated protein that is able to stimulate CTX
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activity in vitro, which they called ADP-Ribosylation Factor (ARF). Later, the purified 
soluble ARF proteins were found to stimulate both toxin-catalysed ADP-ribosylation of 
G as as well as toxin auto-ADP-ribosylation (Tsai et al., 1988). These reactions require the 
presence o f GTP, which suggests that the ARFs belong to the monomeric small G protein 
family. Kinetic studies revealed that only ARF-GTP acts as an allosteric activator o f the 
toxin, interacting with the catalytic subunit to lower the apparent Km for both NAD+ and 
acceptor substrates (Noda et al., 1990). Later, the ARF proteins were documented as being 
involved in several other cellular functions, including PLD activation, membrane traffic 
regulation, and actin cytoskeleton remodelling (Randazzo et al., 2000).
We now know that the ARFs constitute a ubiquitous family o f small G proteins that shares 
structural elements with both the monomeric G proteins of the Ras family and the a  
subunit of the heterotrimeric G proteins in the region involved in guanine-nucleotide 
binding and hydrolysis (Bobak et al., 1989; Sewell and Kahn, 1988). The ARFs are present 
in all eukaryotic cells, from Giardia lamblia to human, with high levels o f conservation 
across phylogenetic lines. To date, six ARFs (ARF1-6) have been identified in mammals, 
and through sequence homology, additional members have been identified, including the 
ARF-domain proteins (ARDs) (Mishima et al., 1993; Vitale et al., 1996), ARF-like 
proteins (ARLs) (Clark et al., 1993; Moss and Vaughan, 1998) and ARF-related proteins 
(ARPs). The functions of these extended family members remain to be clearly defined. All 
members of the ARF family are modified post-translationally by myristoylation at the N- 
terminus, which is necessary for membrane association, and is clearly important for ARF 
functions.
The ARF proteins are divided into three classes based on their amino acid 
sequences, genetic structure and phylogeny. ARF1, 2 and 3 belong to class I, ARF4 and 5 
are in class II, and ARF6  is the only member of class III (Moss and Vaughan, 1998; 
Tsuchiya et al., 1991). In Table 1.6, a comparison between the coding region nucleotides 
and the amino acid sequences of all o f the mammalian ARFs is given, and it emerges that
ARFs differ in their sequences mainly at the N- and C-terminal. Indeed, ARF6  has a gap 
corresponding to amino acids 8-11 in the other ARFs. The members within each group 
have high levels of protein sequence identity (96% amongst the class I ARFs, and 90% 
among class II ARFs). The single class III ARF is the least conserved among the ARF 
family members being only 65-70% homologous to the others members o f the family 
(Moss et al., 1993; Tsuchiya et al., 1991). The low level o f similarity between the class III 
and class I-II proteins correlates to differences in localization and function. When bound to 
GDP, mammalian ARF1-ARF5 appear to be predominantly cytosolic but upon exchange 
of GDP for GTP, they become bound to a variety of intracellular membranes. ARF1, 
ARF3 and ARF5 are recruited to isolated Golgi membranes and endosomes both in in vitro 
and in in vivo assays (Honda et al., 1999; Hosaka et al., 1996; Takatsu et al., 2002; Tsai et 
al., 1992; Whitney et al., 1995). Conversely, activated ARF4 is recruited to the plasma 
membrane following binding of epidermal growth factor (EGF) to its receptor (Kim et al., 
2003).
ARF6 , on the other hand, and again depending on its nucleotide status, cycles 
between intracellular vesicles such as the endosomes and secretory vesicles and the plasma 
membrane (Cavenagh et al., 1996; Galas et al., 1997), where it regulates endocytosis, actin 
cytoskeleton remodelling, cell shape and cell migration (reviewed by Donaldson, 2003). In 
addition to these well-described activities, a new and previously unknown function of 
ARF6  has arisen from the present study in which I found that ARF6  acts as a modulator of 
the endogenous mono-ADP-ribosylation reaction that occurs on the G protein Py subunit. 
For this reason, the second part of this section focuses mainly on ARF6 -mediated cellular 
functions.
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hARFl hARF2 hARF3 hARF4 hARF5 hARF6
hARFl s ^ 9 6 96 80 80 68
hARF2 79 95 80 80 69
hARF3 84 80 79 79 68
hARF4 67 68 71 90 64
hARF5 75 71 73 77 64
hARF6 68 64 66 60 6 5 ^
Amino
acid
sequences
Nucleotide sequences
Table 1.6. Comparison of nucleotide and deduced amino-acid sequences o f the ARFs.
Percent identity o f the indicate A rf deduced amino acid sequences is indicated above the 
diagonal and percent identity o f nucleotide sequences (coding regions) is below the 
diagonal. Abbreviations: h, human; b; bovine. Modified from Moss and Vaughan 1993; 
Tsuchiya 1991.
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1.3.1 The GDP-GTP cycle o f the ARF proteins
The ARF proteins cycle between their GDP-bound inactive, and GTP-bound active 
forms. The spontaneous release of GDP from ARF is slow and it needs to be catalysed by a 
guanine-nucleotide exchange factor (GEF). In parallel, the hydrolysis o f bound GTP to 
yield ARF-GDP is also very slow in the absence of specific GTPase-activating proteins 
(GAPs) (reviewed in Donaldson and Jackson, 2000).
For most ARFs, the GDP-bound form is primarily cytosolic, whereas ARF-GTP is 
membrane bound. Early thinking proposed that once GTP substitutes for GDP, ARF 
undergoes a conformational change that allows its myristoylated N-terminal helix to 
interact with phospholipid bilayers (Amor et al., 1994). However, further studies have 
indicated that ARF can expose its myristoylated tail even in its GDP-bound form allowing 
weak, but measurable, membrane association. This is stabilised by the loading o f GTP onto 
ARF, whereas it is completely abolished when the myristate is removed (Antonny et al., 
1997a). It is likely that membrane association has an essential role in ARF activation, by 
allowing its interaction with GEF proteins. Thus the ARFs first undergo a lipid-mediated 
conformational switch, and then they form a productive complex with a membrane- 
associated GEF (Franco et al., 1996). Hence, ARF activation takes place after both the 
GEF and its target, ARF, have been localised to membranes.
13.1.1 T heA R F G E F s
Many GEFs for ARF have been identified in both yeast and mammals, and all 
possess a conserved region of approximately 200 amino acids that is known as the Sec7 
domain, with a strong similarity with the yeast sec7 secretory protein (Jackson and 
Casanova, 2000). The guanine-nucleotide-exchange activity resides within the Sec7 
domain that is sufficient by itself for the exchange activity (Chardin et al., 1996). The 
crystal structure of the Sec7 domain of the exchange factor ARNO (ARF nucleotide 
binding site opener) has been determined at ~2 A resolution (Cherfils et al., 1998). This
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consists o f ten a-helices (A-J) arranged as an elongated cylinder having a deep 
hydrophobic groove in the central region (comprising helices F, G and H) that forms the 
binding site for nucleotide-free ARF (Figure 1.16). A second highly conserved motif 
comprises most o f helix H and contains a large number o f solvent-exposed hydrophobic 
residues. Point mutations within these conserved motifs reduce exchange factor activity, 
demonstrating that this region constitutes the active site of the Sec7 domain. In addition, 
there is an invariant glutamate residue at the C-terminus o f the F-G loop that forms a 
“glutamic finger” that inserts into the nucleotide-binding site of ARF, displacing the 
coordinating Mg2+ ion and possibly the P-phosphate of bound GDP (Beraud-Dufour et al.,
1999). Further analysis of the crystal structure of the Sec7 domain of Gea2p, another ARF 
exchange factor, in complex with nucleotide-free ARF1 support this scheme (Goldberg, 
1998) indicating that the glutamate side chain comes within 3 A of the P-phosphate site, 
and it is therefore likely to exert both steric and electrostatic repulsive forces on the bound 
nucleotide. The structure of nucleotide-free ARF1 in a complex with the Sec7 domain is 
very similar to that o f the GTP-bound form (Goldberg, 1998).
The ARF GEF family can be subdivided into two groups based on sequence 
similarities and functional differences (Figure 1.17). The first class comprises the large 
GEFs (>100 kDa) that have been found in all eukaryotes examined to date, while the 
second contains the small GEFs (<100 kDa) that are peculiar to the higher eukaryotes 
(Jackson and Casanova, 2000). The high molecular weight ARF-GEF subfamily includes 
yeast Sec7, Geal and Gea2, and mammalian BIGl/p200, BIG2 and GBF1. A feature o f 
this family of ARF GEFs (with the exception of GBF1) is their sensitivity to the fungal 
metabolite brefeldin A, which inhibits their ARF-GEF activity thus stabilising the ARF- 
GDP-Sec7 domain complex (Peyroche et al., 1999). The low-molecular-weight GEFs 
include mammalian ARNO, cytohesin-1, GRP1 and cytohesin 4, all o f which are 
insensitive to brefeldin A. EFA6 , a GEF specific for ARF6 , can also be included in this 
subfamily because it is brefeldin A-insensitive and shows the structural Sec7 domain
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Figure 1.16. S tructure of the ARNO-Sec7 domain. A, Overall view. The Sec7 domain 
consists of ten a  helices, from A to J, arranged to form an elongated cylinder. The 
hydrophobic groove in the central region that forms the binding site for nucleotide-free 
ARP is indicated by the blue arrow. B, Alignment o f the ARNO-Sec7 sequence with 
sequences of homologous Sec7 domains. The helices are shown by the red lines. Identical 
amino acids are boxed in black. The two conserved motifs that form the putative ARF- 
binding site are boxed in blue. The invariable glutamate residue, which is involved in 
nucleotide exchange on ARF, is indicated with a black arrowhead. Taken from Cherfils, 
1998.
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Figure 1.17. The ARF-GEF family. Representative members of different subfamilies of 
the Sec7-domain-exchange factors for ARFs. The grey boxes represent the Sec7 domain, 
which catalyses the GDP/GTP exchange on the ARFs. For the high-molecular-weight 
proteins, the coloured boxes represent regions showing significant levels o f sequence 
similarity; the functions of these domains have not yet been determined. The PH domain 
(PH, green boxes) and coiled-coiled regions (CC, red boxes) of the lower molecular weight 
GEFs are indicated. The proline-rich regions o f EFA6  are designed by “pr” (yellow boxes).
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despite having a slightly larger size. As shown in Figure 1.17, the ARF family members 
are outnumbered by the ARF-GEFs. Thus, an individual ARF protein may be activated by 
more than one GEF. A key question is the physiological specificity o f the different GEFs 
for the different ARFs. For example, in several in vitro systems, ARNO, cytohesin-1 and 
GRP1 catalyse GDP/GTP exchange more efficiently on the class I ARFs than on the 
members of the other classes (Jackson and Casanova, 2000). However, in vivo, ARNO, and 
GRP1 partially co-localise with ARF6  and have key roles in ARF6  activation (Frank et al., 
1998). Moreover, the overexpression of cytohesin-1 and GRP1 lead to a greater increase in 
ARF6 -GTP in cells than in ARF1-GTP, thus supporting the concept that cytohesin-1 and 
GRP1 can act as GEFs for ARF6  in vivo (Langille et al., 1999). Cytohesin-4 efficiently 
catalyses exchange on ARF1, and to a lesser extend on ARF5 in vitro, but it is inactive 
towards ARF6  (Ogasawara et al., 2000). Overall, these observations suggest that 
ARNO/cytohesins are able to localise at, and probably to act on, both Golgi and plasma 
membranes, although their ARF substrates remain to be clearly assigned. The situation is 
much clearer for the GEF EFA6 , which activates ARF6  more efficiently than ARF1 both 
in vitro (Macia et al., 2001) and in vivo. Studies on the over-expression of the wild-type or 
a dominant-negative form of EFA6  have revealed effects on membrane traffic and 
cytoskeletal organization that are consistent with its function as an ARF6 -specific GEF in 
vivo (Luton et al., 2004).
13.1.2 The A R F  GAPs
The hydrolysis of GTP is equally critical to its binding in the regulation o f ARF 
functions. GTP hydrolysis is stimulated by ARF GAPs, the functions o f which are 
regulated by ARF itself and by phospholipids and DAG (Antonny et al., 1997b; Ding et 
al., 1996). Over the past few years, 16 ARF GAPs have been identified (Figure 1.18); 
however, their substrate specificities have not yet been systematically characterised. All 
these proteins share a common GAP domain of 70 amino acids that includes a zinc finger
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m otif o f CXXCX(16-17)CXXC (where C is cysteine and X is any amino acid) that is 
essential for their GAP activity. In addition to the zinc finger, all o f the ARF GAPs have a 
conserved arginine within the GAP domain. In the GAPs ASAP1 and PAPp, mutation of 
this arginine results in a strong decrease in GTPase activity (Mandiyan et al., 1999; 
Randazzo et al., 2000), suggesting an arginine finger mechanism for GTP hydrolysis. The 
crystal structure of the GAP reveals that this arginine is positioned on the surface o f the 
molecule, near to several hydrophobic residues. Mutation o f these adjacent hydrophobic 
residues also impairs GAP activity, suggesting that this region may represent the ARF 
interaction site (Mandiyan et al., 1999). The first GAP for the ARFs that was cloned was 
ARF GAP1. This protein is cytosolic and is recruited to the Golgi complex in mammalian 
cells where it acts on ARF1 (Makler et al., 1995). This is mediated by the seven-pass 
transmembrane KDEL receptor Erd2 (Aoe et al., 1997), which recognises a Lys-Asp-Glu- 
Leu carboxy-terminal motif on certain proteins destined for Golgi-to-ER transport. This 
suggests a role for ARF GAPs in retrograde transport to the ER (Lanoix et al., 1999). A 
remarkable parallel to the observation that Erd2 recruits ARF GAP1 to the Golgi is that a 
peripheral ARF GAP, G itl, is recruited to the GPCRs at the plasma membrane level. Gitl 
is a PIP3-stimulated GAP for all ARFs. It was isolated as a binding partner o f the GRKs, 
which are implicated in the down-regulation of receptor signalling by mediating receptor 
internalisation via clathrin-dependent endocytosis (Vitale et al., 2000). In other studies, 
dioleylglycerol increased the activity of recombinant GAP. Because monosaturated 
diacylglycerols are produced chiefly by the action of PLD, it has been suggested that PLD 
activity could be the major regulator o f ARF-GAP (Antonny et al., 1997b).
Finally, A rf GAPs also appear to function independently of the ARFs. For example, they 
are incorporated into transport intermediates that lack ARFs, leading to speculation o f a 
structural role in vesicle coat formation (Yang et al., 2002). Moreover, the multidomain 
nature of the GAPs suggests that they can interact with signalling proteins and adaptor 
proteins. Consequently, A rf GAPs could form a scaffold for large protein complexes.
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Figure 1.18. The ARF-GAP family. Gcs 1 and Glo 3 are from S. cerevisiae; the others are 
all mammalian proteins. All o f the proteins share homology in their GAP domains 
(orange), which contain a critical zinc finger motif. A number o f the GAPs shown also 
have a PH domain (green); these GAPs are known as the centaurins. The ankyrin repeats 
(AR, blue) and Src homology 3 (SH3) domains (pink) are indicated.
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1.3.2 The structures o f ARF 1 and ARF6
Recently, it has been noted that the ARFs have a unique structural feature that 
allows propagation o f the structural modification occurring at the nucleotide-binding site to 
the N-terminus of the proteins. Indeed, as previously described, the ARFs require both a 
lipid-mediated conformational switch and productive complex with a membrane to be 
activated. The interaction with the membrane is mediated by a myristoylated N-terminal 
helix, which flips open upon binding GTP and inserts into the lipid bilayer. 
Communication between the N-terminal helix and the nucleotide-binding site, which are 
located on opposite sides o f the protein, is mediated by two P-strands and a P-hairpin loop 
that connect the switch I and II regions (called the interswitch region). Switch I, and to a 
lesser extent switch II, form the major sites for the interactions of ARF proteins with their 
cellular partners. Surprisingly, these sequences are almost identical among the ARFs, 
suggesting that they may have the same three-dimensional structure. Upon nucleotide 
exchange, the interswitch region passes from a retracted conformation in which it hosts the 
N-terminal a  helix, to an open conformation in which the N-terminal hasp protrudes out of 
the protein and is free to insert into the lipid bilayer (Pasqualato et al., 2002). This 
conformational shift does not take place in other small GTP-binding proteins.
The finding that ARF6  localises primarily to membranes even when bound to GDP, unlike 
ARF1 which is mostly cytosolic in this state, and that the ARF6  N-terminus is shorter than 
that of ARF1, raises the possibility that its membrane/nucleotide cycle may differ from that 
of the other ARFs (Yang et al., 1998). Biochemical and crystallographic studies on both 
ARF6  and ARF1 bound with GDP or GTP support this idea (Goldberg, 1998; Goldberg, 
1999; Menetrey et al., 2000: Pasqualato et al, 2001). The crystal structure o f the full- 
length, non-myristoylated ARF6 -GDP differs in conformation with respect to ARF 1-GDP 
(Figure 1.19). The N-terminus is folded into an a-helix that is positioned in the 
hydrophobic pocket opposite the nucleotide binding site, similar to that o f ARF 1-GDP.
The missing residues do not shorten the helix as expected, but instead shorten the linker 
that connects the helix to the protein core. As in ARP 1-GDP, the interswitch region is 
buried in the protein core and interacts with the switch I region, which forms an ordered P- 
strand. Thus, it is likely that the structural principles for the activation of ARF6  closely 
mimic those for the activation of ARF1, even including the rearrangements o f the N- 
terminus and the interswitch region. Therefore, the localization of ARF6 -GDP to 
membranes in cells cannot be due to the inability of its N-terminal helix to bind in a pocket 
in the protein core. Moreover, the structure o f ARF6 -GDP reveals that the switch 
components are also the regions where ARF1 and ARF6  diverge most, while other regions 
have essentially the same main-chain conformations. In particular, switch II prominently 
differs between ARF6  and ARF1. This region is flexible in ARF1-GDP and undergoes a 
disorder-to-order transition upon the binding of GTP (Goldberg, 1998). In contrast, it is 
well organised in ARF6 -GDP, where it rotates as a rigid body to adopt the GTP-bound 
conformation (Pasqualato et al., 2001; Figure 1.20). These disparities result in different 
conformations, and thus in distinctive nucleotide-binding properties that are large enough 
to affect protein-protein interactions. This could explain how ARF-GEF discriminates 
between ARF1 and ARF6 , and suggests a model for the peculiar GDP/GTP cycle o f ARF6 . 
The ARF proteins are recognized by their specific ARF-GEFs at the initial GDP- 
containing complex stage, rather than at the nucleotide-free stage, due to the different 
conformations and flexibility of their switch regions. Unlike their GDP-bound forms, the 
active forms (with bound GTPyS) o f ARF6  and ARF1 are very similar (Pasqualato et al., 
2001). Thus, the switch regions are discriminatory elements between ARF isoforms in their 
inactive, and not in their active forms. This suggests that the GTP-bound ARFs may 
establish specific interactions outside the switch regions and/or might be recognized in 
their cellular context, possibly in complexes with other proteins, rather than as isolated 
proteins.
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Figure 1.19. Superposition of ARF1-GDP and ARF6-GDP. Superposition is not seen 
for the N-terminal helix and linker, the switch regions and the interswitch loop. 
Superimposable regions and the GDP nucleotide are in grey, and are shown only for ARF6  
for clarity. GDP is shown as a ball-and-stick model. Diverging regions are shown for both 
ARF1 and ARF6 , with ARF6  in bright colours and a continuous outline, and ARF1 in 
pastel shades and a dotted outline. The N-terminal helix is yellow, the linker is green, 
switch I is purple, switch II is blue and the interswitch loop is red. Taken from Menetrey, 
2000.
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Figure 1.20. The interswitch toggle of hum an ARF6 . ARF6 -GDP (Menetrey et al.,
2000) (left) and ARF6 -GTPyS (Pasqualato et al., 2001) (right) are shown in the same 
orientation. Residues with disordered electron density are indicated by a dashed line and 
are expected to interact with membranes in activated ARF. Invariant residues of the 
signature are shown.
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1.3.3 The sub-cellular localisation o f ARF6 and its physiological functions
The sub-cellular localisation of ARF6  is quite different from that o f the other ARF 
proteins. The class I and class II ARFs reversibly associate with Golgi complex 
membranes during their GTP cycle with ARF 1-GDP being cytosolic and ARF1-GTP 
bound to the membranes. ARF6 , on the other hand does not localise to the Golgi complex 
(Peters 1995) although it is present at the plasma membrane and to some extent on 
endosomal membranes (Donaldson, 2003). Two mutants of ARF6 , Q67L and T27N, that 
are considered to mimic the GTP- and the GDP-bound forms respectively, have been used 
to reveal the localisation and the function o f the protein. Both immunoelectron microscopy 
and immunofluorescence analysis have revealed that the ARF6(Q67L) mutant is restricted 
to the plasma membrane, while the ARF6(T27N) mutant is on internal structures 
resembling endosomes (D'Souza-Schorey et al., 1998; Radhakrishna et al., 1996). Thus, 
based on the localisation of these two mutants, it has been proposed that ARF6  cycles 
between the plasma membrane (ARF6 -GTP) and a recycling endosomal compartment 
(ARF6 -GDP). In this way, ARF6 -GDP would encounter its exchange factor at the surface 
of an internal compartment to promote the formation of vesicles destined for the plasma 
membrane. However this hypothesis has been challenged by other observations. Firstly, 
EFA6 , a specific ARF6 -GEF, is present only at the plasma membrane, implying that 
ARF6 -GDP should also be located here (Franco et al., 1999). Secondly, by using ffee-flow 
electrophoresis, ARF6  was found to be a stable component o f the plasma membrane in 
CHO cells (Cavenagh et al., 1996). It now appear that the ARF6(T27N) mutant may not 
exactly reflect the phenotype o f ARF6 -GDP, as it has a tendency to lose its nucleotide in 
vitro, and to denature or to aggregate in the cytosol in vivo (Macia et al., 2004). A 
resolution of this question has come from the use of a mutant T44N that has a reduced 
affinity for GTP and thus remains in the GDP-state (Menetrey et al., 2000; Pasqualato et 
al., 2001). In transfected cells, ARF6(T44N) is present only at the plasma membrane
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where it co-localises with the exchange factor EFA6 , thus demonstrating that the GTP- 
GDP cycle of ARF6  takes place at the plasma membrane. This peculiarity implies that 
ARF6  is essentially involved in the regulation o f plasma membrane-related processes, 
such as membrane ruffling, endocytosis, exocytosis and membrane recycling, as well as 
the reorganization of the cortical actin cytoskeleton, activation o f phospholipase D, and 
phagocytosis. In addition, several recent studies have linked ARF6  either to the regulation 
o f GPCR signalling, desensitization and internalization, or to the regulation o f cell 
adhesion, migration and cancer cell invasion (Claing, 2004; Hunzicker-Dunn et al., 2002; 
Sabe, 2003).
These functions possibly take place through: (1) the recruitment o f cytosolic coat 
proteins onto membranes to facilitate sorting and vesicle formation; (2 ) the activation of 
lipid modifying enzymes; and (3) the reorganization of the actin structure.
1.3.3.1 Recruitment o f  cytosolic coat proteins and vesicle form ation
Vesicle formation in cells is driven by coat complexes that are recruited from the 
cytosol to generate the forces necessary to bend a relatively flat membrane into a vesicle. 
Several families o f coat proteins exist, including COPI, COPII and clathrin, which 
assemble selectively on different intracellular compartments (Nickel et al., 2002; 
Rothman, 2002). Clathrin coats function in receptor-mediated endocytosis at the plasma 
membrane when they are associated with AP-2 adaptors, and in transport from the trans- 
Golgi network (TGN) to endosomes when they are associated with AP-1 adaptors 
(McMahon and Mills, 2004). The adaptor proteins recognize and bind motifs in cargo 
molecules. Many accessory proteins take part in a network o f interactions that regulate 
clathrin-coat assembly. The ability of active ARF6  to recruit the cytosolic adaptor protein 
AP-1 and other coat proteins to membranes has been demonstrated in vitro (Austin et al., 
2002; Takatsu et al., 2002). In addition, a recent study has demonstrated that ARF6  
interacts with AP-2 in a GTP-dependent manner, but not with AP-1 both in vitro and in
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vivo (Paleotti et al., 2005). These results suggest that ARF6  is involved in the early stage 
of clathrin-mediated receptor endocytosis, probably by directly controlling AP-2 assembly 
on the plasma membrane.
1.3.3.2 Activation o f  lipid modifying enzymes
ARF6 -GTP acts also through the activation of lipid-modifying enzymes, such as 
PLD and phosphoinositide 4-phosphate 5-kinase (PIP5K). All o f the ARFs can activate 
PIP5K in vitro, but only ARF6  is able to co-localise with PIP5K and thus to activate it in 
vivo (Honda et al., 1999). PIP5K is responsible for generating PI4 ,5 P2 from 
phosphatidylinositol4-phosphate (De Matteis et al., 2002). Synthesis and turnover of 
PI4 ,5 P2 have been implicated in a variety of cellular events including membrane 
trafficking, control o f actin polymerisation and signal transduction, where it serves as a 
substrate for enzymes such as PLC and PI3K (De Matteis et al., 2002; Martin, 1997; 
Yamamoto et al., 2001). This pleiotropic role of PI4 ,5 P2 illustrates the importance of 
ARF6 -mediated regulation o f PIP5K in the correct cell functionalities. ARF6  and PI4 ,5 P2 
co-localize on the plasma membrane and on endosomal structures (Brown et al., 2001), and 
the ARF6 -regulated PI4 ,5 P2 pool at the plasma membrane is apparently involved in 
regulated secretion. In MIN6  pancreatic P-cells, a dominant-negative ARF6  reduces 
PI4 ,5 P2 levels and impairs the slow phase of insulin secretion (Lawrence and Bimbaum, 
2003). In parallel, the expression o f constitutively active ARF6  induces the trapping of 
PIP5K and PI4 ,5 P2 at endosomal membranes and the consequent depletion o f PI4 ,5 P2 from 
the plasma membrane interrupts exocytosis from dense-core vesicles in PC 12 cells 
(Aikawa and Martin, 2003; Brown et al., 2001). Direct activation of PIP5K by ARF6  has 
also been shown to stimulate clathrin-coat recruitment to synaptic membranes, thereby 
allowing synaptic vesicle recycling (Krauss et al., 2003). In cultured rat hippocampal 
neurons, ARF6  affects neuritis extension and branching, and this process apparently 
involves PIP5K (Hemandez-Deviez et al., 2004). Together, these data show that the
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regulation of PIP5K activity and organized PI4 ,5 P2 turnover is critical for ARF6 -induced 
membrane trafficking.
PLD is another important effector o f ARF6 . This enzyme mediates the hydrolysis 
o f phosphatidylcholine to generate phosphatidic acid (PA), which stimulates physiological 
responses such as endocytosis (Brown et al., 1998), exocytosis (Hughes et al., 2004) and 
the reorganisation o f actin cytoskeleton (Cross et al., 1996). Two PLD isoforms, PLD1 and 
PLD2, have been identified in mammals, each of which is expressed as two splice variants. 
These have four conserved sequences (I-IV) and PH and phox homology (PX) domains, 
which are implicated in phospholipid and protein binding (Sung et al., 1999). Both o f these 
PLDs are membrane-associated. PLD1 probably localizes to the Golgi complex or to 
perinuclear vesicular structures, whereas PLD2 probably associates with the plasma 
membrane (Exton, 2002). These enzymes may also be present in caveolae and may co- 
localize with the actin cytoskeleton. ARF6  can bind directly to and activate PLD (Brown et 
al., 1993; Toda et al., 1999), with a higher efficiency for PLD1 (up to 20-fold activation in 
vitro) than for PLD2 (2-fold activation in vitro). Under in vivo condition however, it is the 
PLD2 isoform that is susceptible to the dominant-active and the dominant-negative 
mutants o f ARF6  (Hiroyama and Exton, 2005).
PLD is currently considered as the major ARF6  effector active in exocytotic sites. 
In PCI 2 cells, over-expression of the ARF6(N48I) mutant that is unable to stimulate PLD 
activity strongly inhibits secretion, while in chromaffin cells the activation of PLD is 
blocked by addition of a myristoylated peptide corresponding to the N-terminus o f ARF6  
(Caumont et al., 1998). The conclusion is that ARF6  is associated with secretory granule 
membranes in its inactive GDP-bound conformation through a direct interaction with the 
Py subunit of heterotrimeric G proteins. Stimulation with a secretagogue triggers the 
recruitment and the docking of granules at the plasma membrane, allowing the transient 
interaction of ARF6  with an exchange factor (probably ARNO) (Caumont et al., 2000). 
The activated form of ARF6  stimulates PLD1, which is located near to the exocytotic sites,
105
to produce a local increase in PA that results in the formation of the exocytotic fusion pore. 
Beyond regulating the secretory machinery, PA can also activate PIP5K to produce 
PI4 ,5 P2, which in turn is an essential cofactor in the ARF-dependent stimulation o f PLD 
(Hammond et al., 1995). Thus, regulation of both PLD and PIP5K by ARF6  defines a 
highly integrated mechanism to change the membrane-lipid composition (Donaldson, 
2003).
1.3.3.3 Reorganization o f  actin structure
The change in lipid composition may mediate the ARF6 -induced alterations in the 
cortical actin cytoskeleton as observed in HeLa cells in which the stimulation of over­
expressed ARF6  with aluminium fluoride leads to redistribution o f actin to plasma- 
membrane protrusions and ruffle formation (Peters et al., 1995). Additional evidence for a 
role of ARF6  in regulating the actin cytoskeleton is that the expression o f ARNO and 
EFA6 , two exchange factors for ARF6 , induce the formation o f F-actin-rich ruffles and 
promotes cell-spreading (Franco et al., 1999; Frank et al., 1998). Furthermore, dominant- 
negative ARF6  blocks bombesin-induced (Boshans et al., 2000) and EGF-induced (Honda 
et al., 1999) membrane ruffling.
In many cases, it appears that ARF6  changes the actin structure at the plasma 
membrane through the activation of Rac, a member of the Rho family implicated in 
membrane ruffling. In HeLa cells, a dominant-negative mutant o f ARF6  blocks Rac- 
induced ruffling, while a dominant-negative Rac does not block ARF6 -induced actin-rich 
membrane protrusions, suggesting that ARF6  can by itself alter cortical actin, and 
moreover, that ARF6  is required for Rac-dependent ruffling (Radhakrishna et al., 1999). 
Direct evidence that ARF6 -GTP leads to activation of Rac has been obtained, although the 
mechanism has not been identified (Santy and Casanova, 2001). One protein that may 
integrate signals between Rac and ARF6  in the membrane ruffling response is PORI 
(partner o f Rac !) , the shortened form of Arfaptin 2. PORI was originally isolated as a
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protein that interacts with Racl (Van Aelst et al., 1996) and subsequently it was shown to 
bind both ARF6 -GTP as well as Racl (D'Souza-Schorey et al., 1997). A deletion mutant of 
PORI inhibits membrane ruffling in CHO cells induced by either activated Rac or 
activated ARF6 . The binding of the Rac and ARF6  proteins to PORI is mutually exclusive, 
indicating that they probably share at least part of the same binding site on PORI 
(Tarricone et al., 2001). This suggests the possible mechanism by which PORI directly 
mediates cross-talk between ARF6  and Rac GTPases. PORI, which colocalizes with Rac, 
binds to and effectively sequesters Rac (Van Aelst et al., 1996). The Rac-binding activity 
of PORI is in turn regulated by the local concentration of activated ARF6 . Activated 
ARF6  binds to PORI and displaces Rac, thus releasing it for subsequent signalling activity 
(D'Souza-Schorey et al., 1997).
The ability o f ARF6  to affect the cortical actin cytoskeleton appears to be essential 
for efficient cell adhesion and migration and for cancer cell invasion (Kondo et al., 2000). 
In contrast, the activities of other ARFs may be less closely involved in the fundamental 
aspects of cell migration (Mazaki et al., 2001). Overexpression o f ARNO, the exchange 
factor for ARF6 , in islands of MDCK epithelial cells selectively stimulates the activation 
o f ARF6  and results in the formation o f large lamellipodia. Moreover, expression of 
ARNO in peripheral cells stimulates cell motility and causes individual cells to pull away 
from their neighbours (Santy and Casanova, 2001). A constitutively active form of ARF6  
is able to induce MCDK cell motility (Palacios et al., 2001). Conversely, a dominant- 
negative form of ARF6  attenuates the motility o f these cells in a wound assay. Beyond 
affecting the actin cytoskeleton, ARF6  affects cell scattering by additional mechanisms. 
First, it has been shown that active ARF6  triggers the disassembly o f interactions between 
adjacent cells known as adherens junctions (Palacios et al., 2001). ARF6 -GDP has been 
seen to co-localise at cell junctions in polarised epithelial cells, and its activation leads to 
the inactivation of E-cadherin, a crucial component of adherens junctions. In particular, 
ARF6  regulates the spatial distribution and trafficking o f the E-cadherins, as well as the
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cadherin-based junctional components (Palacios et al., 2001). In conclusion, the activation 
o f ARF6  is necessary to disassemble adherens junctions to initiate migration in polarised 
epithelial cells. After released from the tight adhesions the cells then still require ARF6  to 
extend the plasma membrane in a forward direction.
The integrins constitute yet another group of crucial proteins that are involved in 
cell migration and that are regulated by ARF6 . The integrins exist as heterodimers, and 
they are composed of a  and p subunits that pair up in different combinations to mediate 
cellular adhesion for specific matrix components (Hynes, 2002). While adhesion occurs on 
the cell surface, the integrins also undergo endocytic recycling in a process that may have 
an important role in cell motility by mediating the redistribution o f the integrins to the 
migrating front (Bretscher, 1996). This recycling is regulated by ARF6  and requires the 
actin cytoskeleton. Indeed, over-expression of the ARF6(Q67L) dominant-positive mutant 
in HeLa cells can trap integrin p i into ARF6(Q67L)-enriched large vacuoles (Brown et al.,
2001). In line with these observations, the endocytic recycling of integrin p i , which is 
initiated by external stimuli (such as serum, EGF and PMA) is regulated by ARF6 , and 
requires a role of the actin cytoskeleton (Powelka and Buckley, 2001). Consistent with 
these observations, mutant forms of ARF6  that affect either actin rearrangements or 
recycling inhibit the motility o f a breast cancer cell line (Powelka et al., 2004). Collective 
migration of cancer cells often originates metastasis dissemination. In light o f this, the role 
o f ARF6  in tumour invasiveness was recently analysed. It appears that there is a critical 
role for ARF6  in the process of cell invasion through the regulation o f invadopodia 
formation (Tague et al., 2004). Sustained activation of ARF6  significantly enhances the 
invasive capacity of melanoma cells as well as breast tumour cell lines, whereas the 
dominant-negative ARF6(T27N) abolishes basal cell invasive capacity as well as invasion 
induced by growth factors. Moreover, the ARF6  GTPase cycle regulates enhanced 
melanoma cell invasion through the activation of the extracellular-signal-regulated kinase
r
(ERK), suggesting the existence o f a link between ARF6 -mediated signalling and ERK
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activation. Interestingly, the invasiveness of breast cancer cells requires the continued 
activation and cycling of ARF6  (Hashimoto et al., 2004). Both the hydrolysis-defective 
mutant ARF6(Q67L) and the GTP-binding-defective mutant ARF6(T27N) block the 
invasive activities o f the MDA-MB-231 human cultured breast cancer cells, while cell 
adhesion is not affected.
1.3.3.4 Receptor endocytosis
The continued cycling o f ARF6  between its GTP- and GDP-bound forms is also 
necessary for phagocytosis and endocytosis of receptors. In the case o f Fey receptor- 
mediated phagocytosis in macrophages, both types of ARF6  mutants, that defective in 
GTP hydrolysis (Q67L) and that defective in GTP binding (T27N), have been shown to 
inhibit phagocytosis of IgG-coated erythrocytes (Zhang et al., 1998). During Fey receptor- 
mediated phagocytosis in murine macrophages, endogenous ARF6  becomes activated very 
early and transiently, and it has a critical role in the delivery o f membrane from the 
recycling compartment to the forming phagosome (Niedergang et al., 2003).
The requirement o f continued activation and cycling o f ARF6  in the endocytic 
process has also been reported for the internalization o f the p2 adrenergic receptor (P2AR). 
Expression of the constitutively-active or dominant-negative ARF6  mutants significantly 
attenuates P2AR internalisation (Claing et al., 2001). A marked inhibition o f P2AR 
internalisation is also the consequence o f a reduced expression o f endogenous ARF6 , as 
obtained using an RNA interference approach (Houndolo et al., 2005). Importantly, this 
effect is not unique to the P2AR, but affects a broad variety of GPCRs, including the 
angiotensin type I and vasopressin type II receptors, the endothelin type B receptor, and 
M2 muscarinic receptors. These data clearly support an essential and broader role for 
ARF6  in the agonist-promoted internalization process o f GPCRs. The analysis o f the 
mechanisms by which ARF6  modulates P2AR internalization revealed that ARF6  and its 
guanine-exchange factor ARNO form a complex with the p-arrestin that is recruited to the
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plasma membrane following P2AR stimulation. It was thus proposed that p-arrestin 
functions as a scaffold to promote ARNO-dependent ARF6  activation, which facilitates 
P2AR endocytosis (Claing et al., 2001). When activated, ARF6  dissociates from the 
complex and may activate several signalling events and initiate receptor endocytosis.
The role o f ARF6  in receptor internalization may be linked to luteinizing 
hormone/choriogonadotropin hormone LH/CG receptor desensitization (Figure 1.21) 
(Mukheijee et al., 2001; Mukheijee et al., 2000). The activation o f ARF6  in ovarian 
follicles regulates p-arrestin binding to the active LH/CG receptor. In the GDP-bound form 
it sequesters p-arrestin in a complex that becomes inaccessible to the receptor. Upon 
LH/CG receptor stimulation, ARF6  becomes activated and p-arrestin is released, and 
becoms available to bind the activated LH/CG receptor. The activation o f ARF6  is 
mediated by ARNO; indeed addition of nanomolar concentrations of ARNO in the absence 
of an agonist promotes the desensitization of the active LH/CG receptor (Mukherjee et al.,
2000). Most importantly, this effect of ARNO is completely reversed by neutralising anti- 
arrestin antibodies that prevent interactions between the p-arrestin and the GPCRs, 
indicating that ARNO promotes the apparent release o f P-arrestin from its membrane 
docking sites.
Interestingly, the activation of ARF proteins has been shown to occur upon agonist 
stimulation of a number o f different GPCRs, including p2-adrenergic, M3 muscarinic, 
fMet-Leu-Phe, HI histamine, and B2 bradykinin receptors (Bomancin et al., 1993; Houle 
et al., 1995; Mitchell et al., 1998; Rumenapp et al., 1995; Salvador et al., 2001). This 
suggests that the ARF6 -mediated pathway constitutes widespread mechanism that 
modulates the accessibility o f P-arrestin to activated GPCRs, thus regulating their 
desensitization.
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Figure 1.21. Model of LH/CG receptor desensitization. A, Docking of arrestin 2 at a 
membrane location distinct from the inactive LH/CG receptor and in association with 
inactive ARF6-GDP. B, Activation o f the LH/CG receptor upon binding agonist promotes 
not only activation of the stimulatory heterotrimeric G protein Gs and consequent AC 
activation, but also activation of ARF6 and liberation of arrestin 2. ARNO or a similar 
ARF6 GEF promotes GDP/GTP exchange on ARF6 in response to LH/CG receptor 
activation. C, Arrestin 2 binding to the active LH/CG receptor mediates desensitization by 
interfering with the ability of agonist-activated receptor to activate Gs.
I l l
Chapter 2
Materials and Methods
2.1 Materials
DL-dithiothreitol (DTT), glucose, bovine serum albumin (BSA), 
Tris[Hydroxymethyl]aminomethane (Tris), ethylene glycolbis(beta-aminoethylether)- 
N,N,N',N'-tetraacetic acid (EGTA), ethylenediaminetetraacetic acid (EDTA), Na2HP0 4, 
Nat^PCU, Na2S2 0 3 , sucrose, aprotinin, leupeptin, pepstatin, 1 ,1 0 -phenanthroline, 
phenylmethylsulphonyl fluoride (PMSF), deoxycholic acid, Nonidet P40, ATP, UTP, GTP, 
GDP, GTPpS, a-NAD+, P-NAD+, meta-iodobenzylguanidine (MIBG),thrombin, substance 
P, clonidine and isoproterenol, were from Sigma-Aldrich (WI, USA). Mastoparan, mas7, 
mas 17 and gonadotropin releasing hormone (GnRH) were from Calbiochem (CA, USA). 
The catalytic subunit protomer A and the inactive subunit protomer B o f PTX were from 
Biomol (PA, USA). NaCl, HC1, NaOH, KOH, formaldehyde, acetic acid and methanol 
were from Carlo Erba (Italy). 4- (2-Hydroxy-ethyl)-piperazine-l-ethane-sulfonic acid 
(HEPES), glycerol, KC1, Mg(CH3COO)2, K2H P04, KH2P 0 4, Na2C 0 3, A gN 03 and MgCl2, 
were from Merck (Germany). P-mercaptoethanol were from Fluka (Switzerland). Triton X- 
100 was from Bio-Rad Laboratories (UK). [32P]-NAD (specific activity 1000 Ci/mmol) 
was from Amersham Pharmacia Biotech (NJ, USA). Pertussis toxin was a generous gift o f 
Dr. R. Rappuoli (Chiron Vaccines, Siena, Italy). Myristoylated and non-Myristoylated 
peptides of ARF6  and ARF1 were from Laboratory of Biochemistry o f Mario Negri 
Institute (Milan, Italy). Purified bovine brain py dimer was from A. Marchegiani in the 
laboratory.
Other materials will be specified for each procedure.
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2.2 Cell culture
2.2.1 Materials
Chinese Hamster Ovary (CHO) cells were from American tissue type collection 
(ATTC, USA). CHO cells stably transfected with a-Adrenergic, p-Adrenergic, 8 -Opioid 
and NK1 receptors were kindly provided by Dr. Costa (Istituto Superiore di Sanita, Rome, 
Italy). CHO cells stably transfected with the GnRH receptor were kindly provided by Dr. 
Roelle (Institute of Pharmacology and Toxicology, Marburg, Germany). Dulbecco's 
Modified Eagles Medium (DMEM), Ham F-12, penicillin, trypsin-EDTA, and L-glutamine 
were from GIBCO (UK). G418 was from Fluka. Puromycin was from Sigma-Aldrich. 
Foetal Calf Serum (FCS) was from Biochrom (Germany). All the plastic materials were 
from Coming (USA) or from Falcon (NJ, USA). Filters (0.45 and 0.2 pm) were from 
Amicon (USA).
2.2.2 Growth conditions and propasation o f  cell lines
CHO cells were grown using DMEM supplemented with 34 mg/ml proline, 2 mM 
L-glutamine, 100 U/ml penicillin and streptomycin, and 10 % FCS. CHO cells stably 
transfected with a-Adrenergic, P-Adrenergic, 8 -Opioid and NK1 receptors were grown in 
DMEM-Ham F-12 (1:1 v/v) supplemented with 34 mg/ml proline, 2 mM L-glutamine, 100 
Units/ml penicillin and streptomycin, and 10% FCS in presence of 200 pg/ml G418, for 
selection of resistance. CHO cells stably transfected with the GnRH receptor were grown 
in Ham F-12 supplemented with 2 mM L-glutamine, 100 Units/ml penicillin and 
streptomycin, and 10% FCS in presence of 6.25 pg/ml puromycin for selection of 
resistance. Complete media were prepared by diluting concentrated stock solutions with 
sterile water (Diaco, Italy) and filtering the mixture through 0.2 pm filter.
All the cell lines were grown under controlled atmosphere in the presence o f 5% 
CO2 at 37 °C. Cells were grown in 10 cm Petri dishes until 90% confluence. The medium 
was removed and 0.25% trypsin solution for wild type CHO cells and trypsin-EDTA
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solution (0.05% trypsin, 0.02% EDTA) for stably transfected CHO cells was added for 2-5 
minutes. The medium was added back to block the protease action, cells were collected 
into a plastic tube and centrifuged for 5 min at 200xg. The pellet was re-suspended in fresh 
medium and placed in a new plastic dish.
2.3 Cell fractionation
2.3.1 Materials and solutions
Dextran T-500 was from Amesham Pharmacia Biotech; polyethylene glycol 4000 
(PEG4000) was from Merk. Hanks Balance Solution without Ca2+ and Mg2+ (HBSS-) was 
from GIBCO, N-tris[hydroxymethyl]methyl-2-aminoethansulfonic acid (TES) was from 
Sigma.
Potassium phosphate buffer (PFB): 200mM PFB buffer, pH 7.4, was prepared 
dissolving 1.36 g K2HPO4 and 1.74 g KH2PO4 in 50 ml water. Protease inhibitors: 2.0 
pg/ml aprotinin, 0.5 pg/ml leupeptin, 2 pM pepstatin, 0.5 mM 1,10-phenanthroline, 1 mM • 
phenyl-methylsulphonyl fluoride (PMSF).
Hypotonic buffer: 10 mM TES, pH 7.0 and 1 mM EDTA.
Sucrose buffer: 10 mM TES, pH 7.5, containing 0.25 M sucrose.
HEPES buffer: 20 mM HEPES, pH 7.4; ImM EDTA, 250 mM sucrose.
Cytosol-buffer: 5 mM Tris-HCl, pH 8.0, 5 mM MgCl2, ImM EGTA.
Cell lysates-buffer: 20 mM Tris-HCl, pH 7.4, 0.83 mM MgCl2, ImM EDTA, 20 mM NaCl,
1 mM DTT.
2.3.2 Procedures
All the steps described were performed at 4 °C and in presence of protease 
inhibitors. The protein concentration was measured using Bio-Rad Protein assay kit (Bio- 
Rad Laboratories) according to the manufacturer's instructions.
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2.3.2.1 Preparation o f  plasma membranes
Plasma membranes were prepared following the procedure described by Gettys 
(Gettys et al., 1994), with some modification. Confluent CHO cells ( 6  x 108 cells for each 
preparation) were washed with HBSS=, detached with hypotonic buffer and then lysed with 
a Teflon/glass Potter homogeniser. Unbroken cells and nuclei were removed by a low 
speed centrifugation for 5 min at 400xg, and crude membranes were collected by the 
supernatant by a 20 min centrifugation at 48,000xg. The pelletted membranes were re­
suspended in sucrose buffer, at a final concentration o f ca. 100-150 mg/ml. 200 mg of 
membranes, and then mixed to a 14 g pre-weighted aqueous two-phase system composed 
of 5.12 g 20% dextran T-500, 2.56 g 40% PEG 4000, 0.4 ml 200 mM PFB, pH 7.4, 1.6 ml 
1M sucrose and distilled water. Separation was achieved by a centrifugation for 20 min at 
2,500xg. The upper phase was removed, and repartitioned against a fresh lower phase; 
while, to increase the yield of plasma membranes, the lower phase was extracted with a 
fresh upper phase. Finally, the two upper phases containing plasma membranes were 
combined, diluted 5 fold in sucrose buffer and collected by centrifugation (30 min at 
48,000x,g). The purified plasma membranes were re-suspended at 1 mg/ml in 25 mM 
HEPES, pH 7.4 containingl50 mM NaCl, 1 mM EDTA, and protease inhibitors and stored 
at -80 °C. Purity of plasma membrane preparation was assed by Western blotting with 
markers for cellular components (Table 2.1).
2.3.2.2 Preparation o f  total membranes
Confluent CHO cells (3 x 107 cells for each preparation) were washed with HBSS- , 
detached in 0.25% trypsin solution and then pelleted at 200xg for 5 min. Cells were re­
suspended into 1ml HEPES buffer and broken by passage (14 times) through a 25-gauge 
syringe; unbroken cells and nuclei were removed by low speed spin for 5  min at 400xg. 
Post-nuclear supernatants were centrifuged for 15 min at 16,000><g and the pellet was re-
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Marker Cellular compartment
Na+/K+ ATPase (Godi et al., 1999) 
CaBPl (Fullekrug et a l, 1994)
Rab5 and Rab7 (Chavrier et a l , 1990) 
Mannosidase II (Velasco et a l, 1993)
Plasma membranes 
Endoplasmic reticulum 
Early and late endosomes 
Golgi membranes
Table 2.1. Markers for cellular components used to assess the purity o f plasma 
membrane preparations.
suspended in 20 mM HEPES, pH 7.4, containing 1 mM EDTA and protease inhibitors and 
stored at -80 °C.
2.3.2.3 Preparation o f  cytosol
Cytosol was prepared following the procedure described by Di Girolamo et al. (Di 
Girolamo et a l, 1995) with some modification. Confluent CHO cells (3 x 107 cells for each 
preparation) were washed twice with 5 ml of HBSS=, detached in 0.25% trypsin solution 
and pelleted at 200xg for 5 min. The pellets were re-suspended in an equal volume o f 
cytosol-buffer and broken by passage (14 times) through a 25-gauge syringe. Nuclei and 
unbroken cells were removed by centrifugation at 400xg for 5 min and supernatants were 
then centrifuged at 100,000xg for 90 min. The supernatant that constitutes the cytosol 
fraction was stored at -80 °C.
2.3.2.4 Preparation o f  total cell lysates
Confluent CHO cells (3 x 107 cells for each preparation) were washed twice with 5 
ml of HBSS- , detached in 0.25% trypsin solution and pelleted at 200xg for 5 min. The 
pellets were re-suspended in 250 pl/Petri-dish of cell lysate-buffer and broken by passage 
(14 times) through a 25-gauge syringe. Nuclei and unbroken cells were removed by 
centrifugation at 400xg for 5 min and supernatant was stored at -80 °C.
2.4 SDS-PAGE and immiiRoblotting
2.4.1 Materials and solutions
Sodium dodecyl sulphate (SDS), glycine, TRIZMA base, red ponceau, 
polyoxyethylenesorbitan monolaurate (Tween-20), ammonium persulphate (APS), brilliant 
blue and N,N,N’,N’-tetramethylethylenediamine (TEMED), were from Sigma-Aldrich. 
Acrylamide stock solution: 40% (w/v) acrylamide-bisacrylamide (37.5:1) was from 
Eurobio (France). Secondary antibodies conjugated with horse-radish peroxidase (HRP)
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and directed against mouse or rabbit IgGs were from Calbiochem. Low molecular weight 
standards and ECL reagents were from Amersham Pharmacia Biotech.
Sample buffer 2X: 62.5 mM Tris-HCl, pH 6 .8 , 2% (w/v) SDS, 10% (v/v) glycerol, 
5% (v/v) P-mercaptoethanol and 0.1% (w/v) bromophenol blue. Running buffer: 25 mM 
TRIZMA base, 200 mM glycine, 0.1% (w/v) SDS. Transfer buffer: 25 mM TRIZMA base, 
200 mM glycine, 20% (v/v) methanol. TBS: 150 mM NaCl, 20 mM Tris-HCl pH 7.5. 
TTBS: 0.05% (w/v) Tween 20, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5. Blocking 
solution: 1% (w/v) BSA in TTBS.
2.4.2 Sodium dodecvlsulphate-polvacrylamide se l electrophoresis (SDS-PAGE)
2.4.2.1 Assembly o f  polyacrylamide gels
Two 16 x 18 cm glass plates were used for assembling a regular gel, while two 32 x 
18 glass plates were used for assembling a long gel. The glasses were assembled to form a 
chamber using two 1.5 mm plastic spacers aligned along the lateral edges o f the glass 
plates. The plates were then fixed using two clamps and mounted on a plastic base which 
sealed the bottom. All the materials were from Hoefer Scientific Instruments (NJ, USA). 
The ‘running’ polyacrylamide gel was prepared by mixing H2O, 40% (w/v) acrylamide- 
bisacrylamide solution, 1.5 M Tris-HCl, pH 8 .8 , 10% (w/v) SDS, in order to have the 
selected concentration of acrylamide, 375 mM Tris-HCl, 0.1% (w/v) SDS. Then, 0.06% 
(w/v) APS and 0.06% (v/v) TEMED were added; the solution was pipetted and poured in 
the gap between the plates, leaving ~ 5 cm for the stacking gel. Soon after pouring, the gel 
was covered with a layer of 375 mM Tris-HCl pH 8 .8  and left at RT for ~1 h. The Tris- 
HCl layer was removed after gel polymerisation. The ‘stacking’ polyacrylamide gel was 
prepared by mixing H2O, 40% (w/v) acrylamide-bisacrylamide solution, 0.5 M Tris-HCl, 
pH 6 .8 , 10% (w/v) SDS, in order to have 4% (w/v) acrylamide, 125 mM Tris-HCl, 0.1% 
(w/v) SDS. Then, 0.1% (w/v) APS and 0.07% (v/v) TEMED were added, and the solution
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was pipetted and poured onto the ‘running’ gel. Immediately, a 15-well comb was inserted 
between the glasses and left 1 h at RT.
2.4.2.2 Sample preparation and run
Samples were prepared by adding an equal volume o f 2X sample buffer, incubating 
for 5-15 min at 100 °C in a Multi-Block Heater (Lab-Line, IL, USA), cooled at RT, briefly 
centrifuged and loaded onto the gel. One or two wells were loaded with 5 pg of molecular 
weight standards. The gel was then transferred into the electrophoresis apparatus (Hoefer 
Scientific Instruments) and the electrophoresis was carried out under a constant current of 
8  mA (for O/N runs) or 40 mA (for ~4 hours runs).
2.4.2.3 Silver Staining and gel drying
After electrophoresis, the gels were incubated for 15 min with gentle shaking at RT 
in fixation solution (50% methanol: 5% acetic acid: 45% water v/v/v), washed with water 
(3 times rapidly) and finally placed in water for 1 h on a shaking platform. The gels were 
then incubated for 1 -2  min in sensitizing solution (0 .0 2 % Na2S2C>3), washed twice rapidly 
with water, and incubated for 30 min at 4 °C with chilled 0.1% (w/v) AgNC>3 solution. The 
gels were then developed with 0.04% formaldehyde in 2% (w/v) Na2CC>3 until bands 
became visible. The reaction was stopped by adding 12 g citric acid per 0.5 litre 
developing solution and the gels were washed with water before to be incubated for 45 min 
with 30% (v/v) methanol and 3% (v/v) glycerol. Finally, the gels were dried with a gel 
dryer (Hoefer Scientific Instruments) at 80°C under vacuum for 4 hours.
2.4.2.4 Comassie brilliant blue Staining
Gels were incubated in staining solution (50% methanol, 40% H2 O, 10% acetic 
acid and 0.1 % brilliant blue) for 2 h, washed with water and then de-stained with 30% 
methanol 10 % acetic acid. The gels were then dried as described above.
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2.4.3 Western blottins
2.4.3.1 Protein transfer onto nitrocellulose
The polyacrylamide gel was soaked for 15 min in transfer buffer, placed on a sheet 
o f 3MM paper (Whatman, NJ, USA) and covered with a nitrocellulose filter (Schleicher & 
Schuell, Germany). The filter was covered with a second sheet o f 3MM paper, to form a 
"sandwich" which was subsequently assembled into the blotting apparatus (Hoefer 
Scientific Instruments). Protein transfer occurred at 500 mA for 4 h or at 125 mA O/N. At 
the end o f the run, the sandwich was disassembled and the nitrocellulose filter was stained 
with 0.2% Red Ponceau (Sigma-Aldrich) and 5% (v/v) acetic acid for 5 min to visualize 
the protein bands, and then rinsed with 5% acetic acid to remove the excess o f unbound 
dye.
2.4.3.2 Probing the nitrocellulose with specific antibodies
The nitrocellulose filters were cut into strips with a razor blade. The strips were 
incubated in blocking solution for 60 min at RT, then with the primary antibodies directed 
against the protein o f interest, diluted at the appropriate concentration in the blocking 
solution. A list o f antibodies used in this thesis and their working dilution is provided in 
Table 2.2. After a 2-3 h incubation at RT, or an O/N incubation at 4 °C, the antibody was 
removed and the strips washed in TTBS twice, for 10 min each. The strips were next 
incubated for 1 hour with the appropriate HRP-conjugated secondary antibodies (anti­
rabbit: 1:20,000; anti-mouse: 1:5000) and washed twice in TTBS, for 10 min each, and 
once in TBS for 3 min. After washing, the strips were incubated with ECL reagents, 
according to the manufacturer instructions, for ECL-based detection.
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Specificity 
(antibody name)
Supplier Animal source Dilution
(5-common subunits 
(T20)
Santa-Cruz rabbit (polyclonal) 1 : 1 0 0 0
ARF 6 Santa-Cruz mouse (monoclonal) 1:800
c-cbl Santa-Cruz rabbit (polyclonal) 1 :1 0 0 0
His Sigma Mouse (monoclonal) 1 :1 0 0 0
Table 2.2. List of antibodies used in this study.
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2.5. ADP-ribosvlation assay
2.5.1 Procedure
The ADP-ribosyltransferase activity was measured following incorporation of 
radioactive ADP-ribose into membrane components using the procedure described by 
Lupi, with some modifications (Lupi et al., 2000). Samples (5 pg CHO plasma 
membranes) were incubated with 50 pi ADP-ribosylation buffer (50 mM PFB, pH 7.4, 5 
mM MgCl2, 4 mM DTT, 10 |xM G TPyS, 700 nM p-NAD+ and 4.5 j_iCi [32P]-NAD) for 60 
min at 37 °C. For extensive ADP-ribosylation of the p subunit, plasma membranes were 
incubated in the same buffer for 6  h at 37 °C.
For experiments with MyrARF6 , MyrARFl, MyrCoA, non-MyrARF6 , purified 
ARF6  and ARF1, these were incubated for 15 min at 37 °C with plasma membranes in 
ADP-ribosylation buffer without P-NAD+. After the incubation, 700 pM p-NAD+ and 4.5 
pCi [32P]-NAD were added, and the samples were ADP-ribosylated for 60 min at 37 °C, as 
described above.
For PTX-catalysed ADP-ribosylation of the Gi/0a  subunits, plasma membranes 
were incubated for 60 min at 37 °C with 100 nM catalytic subunit, or as a control with 100 
nM inactive protomer B o f PTX, in ADP-ribosylation buffer. When the assays were carried 
out using 25 pg total membranes or 80 pg total cell lysates from CHO cells, 250 ng 
purified bovine brain Py dimer was used to obtain better signal detection for p subunit.
The reactions were terminated by diluting the samples with 50 pi 2x sample buffer 
and analysed by 12% SDS-PAGE. Proteins were electroblotted as described above, and the 
filters were exposed to Kodak X-Omat film (Amersham). For quantitative analysis, an 
Instant Imager (Canberra Packard Instruments, CT, USA) was used. In the experiments 
where purified bovine brain Py dimers were added to samples, association o f the 
exogenous py subunit with plasma membranes was evaluated by Western blotting of
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plasma membrane pellets and supernatants (separated by centrifugation; 15 min, 1 2 ,0 0 0  x 
g), with at least 95% of the py subunit recovered in the membrane fraction.
2.5.2 Quantification o f  modified proteins
The amounts of mono-ADP-ribosylated p subunit were expressed in picomoles of 
modified protein and were calculated considering that binding between the p subunit and 
the ADP-ribose moieties is equimolar (Lupi et al., 2000). Starting from this assumption, 
and knowing the specific activity o f radiolabelled nucleotide (calculated from the 
experimental condition used and expressed as cpm [32P]-NAD/pmol P-NAD+), the amounts 
o f mono-ADP-ribosylated P subunit were calculated after separation o f the ADP- 
ribosylated samples by SDS-PAGE, through the conversion o f cpm values measured by 
Instant Imager acquisition into pmol of ADP-ribosylated proteins.
2.5.3 Kinetic analysis
2.5.3.1 Vmax and Kmfo r  Py dimer
Plasma membranes (5 pg/sample) were incubated with 50 pi ADP-ribosylation 
buffer (50 mM PFB, pH 7.4, 5 mM MgCl2, 4 mM DTT, 10 pM GTPyS, 700 pM 0-NAD+ 
and 4.5 pCi [ P]-NAD) for 60 min at 37 °C in the presence o f increasing concentrations of 
substrate (0-650 ng purified bovine brain Py dimer) and a saturating concentration o f P- 
NAD+ (1 mM). The samples were processed as described above, and the levels o f p 
subunit ADP-ribosylation were analysed with an Instant Imager. Data were transformed to 
Eadie-Hofstee analysis, and the constants (Km and Vmax) were determined using GraphPad 
PRISM software.
2.5.3.2 Vmax and Kmfo r  fi-NAD*
Plasma membranes (5 pg/sample) were incubated with 50 pi ADP-ribosylation 
buffer (50 mM PFB, pH 7.4, 5 mM MgCl2, 4 mM DTT, 10 pM GTPyS and 4.5 pCi [32P]-
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NAD) for 60 min at 37 °C in the presence o f increasing concentrations o f substrate (0-1 
mM P-NAD+) and saturating concentrations o f Py dimer (500 ng) or ARF6  (500 ng). The 
samples were processed as described above, and the levels o f p subunit ADP-ribosylation 
were analysed with an Instant Imager. Data were transformed to Eadie-Hofstee analysis, 
and the constants (Km and Vmax) were determined using GraphPad PRISM software.
2.6 De-ADP-ribosvlation assay
Following the ADP-ribosylation assay, [32P]-labelled plasma membranes were 
washed twice with 5mM Tris HC1, pH 8,0 and pelleted for 15 min at 16,000xg. The pellets 
were incubated for 30 min at 37 °C with 50 pg/sample of CHO cells cytosol in 50 pi de- 
ADP-ribosylation buffer (5mM Tris-HCl, pH 8.0, lOmM M g C y  containing protease 
inhibitors. The analysis of the samples was performed as described above for the ADP- 
ribosylation assay.
2.7 Production of I32Pl-ADP-ribose
[32P]-ADP-ribose was prepared following the procedure described by De Matteis 
(De Matteis et al., 1994), with some modification. [32P]-NAD+ (0.5 pM/sample) was 
incubated in 200 mM PFB, pH 7.4 (15 pl/sample), with 0.1 U/ml NADase from 
Neurospora crassa (Sigma), for 20 min at 37 °C. The mixture was used as source o f ADP- 
ribose. After this incubation 90% of the radioactivity was in ADP-ribose and 10% in AMP; 
NAD was undetectable, as revealed by thin-layer chromatography (TLC) analysis (Figure 
2.1; Section 2.16 for TLC protocol).
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ADP-
ribose
Figure 2.1. Production of [32P]-ADP-ribose. [32P]-NAD+ (0.5 pM/s ample) was incubated 
for 20 min at 37 °C in 200 mM PFB, pH 7.4 (15 pl/sample) and 0.1 U/ml NADase from 
Neurospora crassa. After this incubation, 90% of the radioactivity was in ADP-ribose and 
10% in AMP; NAD was not detectable.
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2.8. DNA preparation
2.8.1 Materials
Tryptone peptone and yeast extract were from Promega. RbCl, CaCl, MnCh, 
MOPS and Agar were from Sigma. QIAGEN Plasmid Maxi Kit was from Qiagen (CA, 
USA). A list o f constructs used in this thesis is shown in Table 2.3.
LB: 1% Tryptone Peptone, 0.5% Yeast extract, 1% NaCl, autoclaved 15 min at 121 
°C. LB-agar: LB plus 1.5% (w/v) agar: autoclaved 15 min at 121 °C. TE buffer: 10 mM 
Tris-HCl, 1 mM EDTA pH 7.5.
2.8.2 Preparation o f  competent cells
Competent bacteria were obtained using the rubidium chloride method (Kushner, 
1978). Bacteria were streaked and incubated overnight on a LB plate. Next day, one single 
colony was inoculated into 10 ml o f LB and grown overnight at 37°C with shaking at 225 
rpm. One ml of the overnight saturated culture was inoculated into 9 ml o f fresh LB and 
grown until the optical density at 550 nm was 0.3. The bacteria were sub-cultured 1:20 into 
100 ml pre-warmed LB and grown until the optical density at 550 nm reached 0.48. The 
cells were chilled on ice and centrifuged at lOOOxg at 4°C for 5 min, the supernatant was 
removed and the pellet gently resuspended in 40 ml 30 mM potassium acetate, 100 mM 
RbCl, 10 mM CaCl, 50 mM MnCl2 , 15% glycerol pH 5.8. The bacteria were left on ice for 
2 h, centrifuged and resuspended in 4 ml of 10 mM MOPS, pH 7, 75 mM CaCl, 10 mM 
RbCl, 15% glycerol.
2.8.3 Transformation o f  bacteria by heat shock
Competent cells were thawed on ice and -1 0  ng o f plasmid were added. After 
gentle mixing, the cells were left on ice for 30 min and then heat shocked for 90 seconds at 
42 °C. After addition o f 800 pi LB, the bacteria were grown for 45 min at 37 °C under 
constant shaking (200 rpm). The culture was then plated on LB agar containing the
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Protein Vector Resistance Expression
FLAG-ARF6 pXS Ampicillin eukaryotes
FLAG-ARF6(Q67L) pXS Ampicillin eukaryotes
FLAG-ARF 6(T27N) pXS Ampicillin eukaryotes
FLAG-EFA6 pFLAG-CMV-6 a Ampicillin eukaryotes
GFP-ARF1 pGFP-Nl Ampicillin eukaryotes
GFP-ARF1(Q71L) pGFP-Nl Ampicillin eukaryotes
GFP-ARF1 (T3 IN) pGFP-Nl Ampicillin eukaryotes
His-ARNO pRSETc Ampicillin bacteria
ARF6 pET3 Ampicillin bacteria
GST-GGA31.226 pGEX4Ti Ampicillin bacteria
NMT pBB131 Kanamycin bacteria
Table 2.3. List of constructs used in this study.
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appropriate selective antibiotic and incubated overnight at 37 °C. The next day, an isolated 
bacterial colony was picked from the plate and used to inoculate 2 ml of LB containing the 
appropriate antibiotic and the culture was incubated O/N at 37 °C. Sterile glycerol was 
added to the bacterial culture (30 % v/v) for long-term storage at -80 °C.
2.8.4 DNA purification
A small amount of bacteria transformed with the plasmid of interest, were scraped 
from the glycerol stock, and used to inoculated in 2 ml of LB containing the appropriate 
selective antibiotic. The culture was grown at 37 °C under continuous shacking (200 rpm) 
for 6 - 8  hours. This pre-culture was then used to inoculate 500 ml of LB containing 
selective antibiotic. After 15-20 hours incubation, bacteria were collected by centrifugation 
at 4000xg for 10 min at 4 °C and processed according to the QIAGEN Plasmid Maxi Kit 
protocol. The DNA obtained was resuspended in TE buffer to a final concentration o f 1 
mg/ml and stored at 4 °C, or for long-term, at -20 °C.
2.9. Cell transfection
2.9.1 Materials
Lipofectamine-Plus and OptiMEM serum free reduced culture medium, were from 
GIBCO. cDNAs for FLAG-ARF6 , FLAG-ARF6(Q67L) and FLAG-ARF6(T27N) were 
kindly provided by Dr. R. Weigert (National Institutes of Health, Bethesda, USA), cDNA 
for HA-EFA6  was kindly provided by Dr. R Buccione (Consorzio Mario Negri Sud, Italy), 
cDNAs encoding GFP-ARF1, GFP-ARF1(Q71L) and GFP-ARF1(T31N) were kindly 
provided by Dr. T. Daniele, (Consorzio Mario Negri Sud, Italy).
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2.9.2 Lipofectamine Plus-reasent-based cell transfection
CHO cells were plated on 100 mm Petri dishes or 6  well plates, in normal culture 
medium, at a concentration suitable to have 50-70% confluence for transfection The day 
after, the transfection mixture was prepared in a polypropylene tube: for each Petri dish, 4 
pg DNA and 20 pi Plus reagent were diluted in 750 pi o f OptiMEM culture medium. In 
separate tubes, 30 pi o f Lipofectamine reagent was diluted in 750 pi o f the OptiMEM. 
When CHO cells were grown in 6  well plates, for each well 1 pg DNA and 6  pi Plus 
reagent were diluted in 100 pi o f OptiMEM; while, 4 pi o f Lipofectamine reagent was 
diluted in 100 pi of the OptiMEM.
Transfection and reagent mixtures were shaken and incubated at RT for 15 min, and then 
combined and kept at RT for additional 15 min to allow DNA-Lipofectamine complex to 
form. In the meantime, cells were washed twice with OptiMEM medium. Cells were then 
incubated with the transfection mixture for 3 h at 37 °C in the presence of 5% CO2 . At the 
end of the incubation the transfection mixture was replaced by complete culture medium 
and cells incubated for additional 12-24 h prior to assay.
2.10 Expression and purification of recombinant proteins
2.10.1 Materials
✓
Ampicillin, kanamicin and chloramphenicol were from Fluka. Imidazole, 
glutathione, isopropyl-p-D-1 -thiogalactopyranoside (IPTG), and lysozyme were from 
Sigma Aldrich. Glutathione-sepharose resin was from Amersham Pharmacia Biotech. Ni- 
NTA beads were from Qiagen (CA, USA)
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2.10.2 Purification o f GST-GGA31.77*
2.10.2.1 Materials and solutions
pGEX4Tl vector containing GST-GGA31.226 fusion protein was kindly provided by 
Dr. P. Chavrier (Institute Curie, Paris).
GST-lysis buffer: 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM
DTT, 10% v/v glycerol. GST-washing buffer: 50 mM Tris-HCl, pH 8.0 containing 200
mM NaCl. GST-elution buffer: 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, and 10 mM
reduced glutathione.
2.10.2.2 Procedure
E. coli strain BL21(DE3) harbouring the GST-fusion protein o f interest, was grown 
in LB plus ampicillin (100 mg/ml) until the optical density OD(6oonm) was about 0.6. At this 
point, the fusion protein was induced for 5 h at 25 °C with 0.25 mM IPTG. The total 
bacteria culture was harvested by centrifugation at 4000xg for 10 min at 4 °C and stored at 
-80°C O/N. In parallel, one ml of the induced and non induced cultures were taken to 
confirm protein expression. The samples were collected by centrifugation, lysed with 
sample buffer, and 10-25 pi of the lysates were fractionated on a polyacrylamide gel. The 
gels were stained with Comassie blue dye, as described above.
The day after the bacterial pellet is thawed at room temperature and re-suspended (20 ml/1 
of culture) in GST-lysis buffer in the presence of protease inhibitors and 0.5 mg/ml 
lysozime. The suspension was incubated 30 min on ice and then is lysed by sonication (5-7 
pulses for 10 sec each). The lysate is centrifuged at 12,000xg for 15 min at 4 °C. The 
supernatant was recovered and added to 1 ml o f glutathione-sepharose resin previously 
equilibrated in lysis buffer. The suspension was incubated with gentle agitation O/N at 4°C 
and then pelleted at 700xg  for 10 min at 4 °C to sediment the matrix. The supernatant was 
discarded and the resin was washed twice with GST-washing buffer. Protein elution was 
started by the addition of GST-elution buffer. The purified protein was than dialysed
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against 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 10%v/v glycerol and 2 
mM p-mercaptoEtOH and stored in aliquots at -80°C.
2.10.3 Purification o f  mvristovlated A R F 6
2.10.3.1 M aterial and solutions
pBB131 vector containing N-Myristoyltransferase (NMT) was provided by Dr. 
Gordon (Washington University, St. Louis, Missouri), pET3 plasmid containing ARF6  was 
provided by Dr. P. Randazzo (National Institutes o f Health, Bethesda, USA).
ARF6 -lysis buffer: 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM MgC12, 1 mM DTT. 
Buffer A: 20 mM Tris-HCl, pH8.0, 100 mM NaCl, 1 mM MgC12, 1 mM DTT, 10%v/v 
glycerol. Buffer B l: 20 mM Tris-HCl, pH8.0, 25 mM NaCl, 1 mM MgC12, 1 mM DTT, 
10%v/v glycerol, 1% Triton X-100. Buffer B2: 20 mM Tris-HCl, pH8.0, 25 mM NaCl, 1 
mM MgC12,1 mM DTT, 10%v/v glycerol, 0.3% Triton X-100.
2.10.3.2 Procedures
The myristoylated form of ARF6  was purified following the procedure described 
by Randazzo (Randazzo and Fales, 2002), with minor modification. TurboCells 
BL21(DE3)pLysS E. coli (Gene Therapy System, CA, USA) were co-trasformed with 
pET3 vector containing ARF6  which is under ampicillin selection, and with pBB131 
vector containing yeast NMT. Positive double transformant colonies were isolated with 
ampicillin/kanamycin selection on agarose plates. A single colony o f transformed bacteria 
was used to inoculate 50 ml LB containing 100 pg/ml ampicillin and 25 pg/ml kanamycin 
and grown O/N at 37 °C under continuous shacking (200 rpm). The day after, the culture 
was diluted in 1-2 1 o f LB with the same antibiotic selection and OD(6oonm) was monitored. 
When the optical density was about reached 0.6 sodium myristate is added to the culture to 
achieve a concentration of 50 pM, and the incubation is continued for an additional 20-30 
min. Then IPTG is added to a final concentration of 1 mM and the incubation was
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continued for 3-4 h. At the end the culture was chilled on ice. The cells are harvested by 
centrifugation (4000xg) for 10 min at 4°C and stored at -80 °C O/N. One-ml samples of the 
induced and non induced cultures are taken to confirm ARF6 expression. The cells are 
collected by centrifugation and lysed in sample buffer, and 10-25 pi are fractionated on a 
15% SDS-PAGE. The gels are stained with Comassie blue dye, as described above.
The bacterial pellet is thawed at room temperature and resuspended in 10 ml of ARF6-lysis 
buffer containing the cocktail of protease inhibitors. The suspension is lysed by sonication 
on ice (5-7 pulses for 10 sec each). The lysate is centrifuged at 100,000xg for 60 min at 4 
°C, and the pellet containing the myristoylated ARF6 was stored at -80°C O/N or for few 
days. The particulate fraction is resuspended in 10 ml of the buffer A containing protease 
inhibitors and centrifuged at 100,000xg for 60 min at 4 °C. Ten ml of buffer B f were used 
to resuspend the pellet. This buffer contains Triton X-100 that extracts ARF6 from the 
particulate fraction. The suspension was sonicated on ice (5-7 pulses for 10 sec each) and 
centrifuged 100,000xg for 60 min at 4 °C. The supernatant was collected and GDP added 
to a final concentration of 10 pM. 35% of ammonium sulphate was added to precipitate 
proteins and the mixture was incubated on ice for 20 min. The precipitate proteins were 
collected by centrifugation at 16,000xg for 60 min at 4 °C and dissolved in 10 ml of buffer 
B2 containing protease inhibitors and 10 pM GDP. The solution was centrifuged at 
20,000xg for 15 min at 4°C and the pellet was resuspended in 10 ml o f fresh buffer B2 
containing protease inhibitors and GDP. The solution is dialyzed twice against 1 1 o f buffer 
B2 containing 10 pM GDP and then applied to a pre-equilibrated 5-ml HiTrap Q column 
(Amersham) in a FPLC (Fast Protein Liquid Chromatography) system (Pharmacia Bio- 
Tec, UK). The material that does not adhere to the column is collected in fraction of 2.5 ml 
each. The column was then washed with 25 ml of buffer B2 and additional fraction are 
collected. Fifty pi of each fraction were analysed by SDS-PAGE and Western Blotting to 
control purity and integrity of the proteins (Figure 2.2). The fractions containing the 
protein were pooled and stored in aliquots at -80°C.
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Figure 2 .2 . Purification of myristoylated ARF6. A, Fifty }il of the indicated fractions 
eluted from a HiTrap Q column were analysed on a 15% SDS-PAGE gel and the proteins 
revealed by silver staining. The positions of molecular weight standards are indicated on 
the left and the position of ARF6 on the right of the panel. B, The same samples as in A 
were revealed by Western blotting with an anti-A R T 6 antibody.
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2.10.4 Purification o f ARNO
2.10.4.1 Material and solutions
pRSETc vector containing His-ARNO was provided by Dr. T. Daniele (Consorzio 
Mario Negri Sud, Italy). His-lysis buffer: 20 mM Tris-HCl, pH8.0, 300 mM NaCl, 10 mM 
imidazole. His-washing buffer: 20 mM Tris-HCl, pH8.0, 300 mM NaCl, 20 mM imidazole. 
His-elution buffer: 20 mM Tris-HCl, pH8.0, 300 mM NaCl, 250 mM imidazole.
2.10.4.2 Procedures
E. coli strain BL21(DE3) harbouring the His-fusion protein o f interest, was grown 
in LB containing ampicillin (100 mg/ml) until the OD(6oo nm) was ~ 0.6. Then, the bacteria 
were induced with 2 mM IPTG for 4 hours. At the end, the culture was chilled on ice and 
centrifuged at 5000xg for 10 min at 4 °C. After discarding the supernatant, the pellet was 
resuspended in 4 ml o f His-lysis buffer containing the cocktail o f protease inhibitors and 
stored at -80°C O/N or for a few days. The suspension was thawed by transferring it to a 
4°C bath, protease inhibitors were added again and lysozyme was added to a final 
concentration of 1 mg/ml. The lysate was incubated with gentle agitation for 30 min at 4 
°C and sonicated on ice 8  times for 15 sec. Then, 10 mM MgC12 and 10 pg/ml DNAse I 
were added, and the lysate was incubated 15 min on ice and then centrifuged at 2 0 ,0 0 0 xg 
for 20 min at 4 °C. The supernatant was recovered and added to 0.5 ml o f Ni-NTA beads 
(Qiagen, CA, USA.), previously pre-equilibrated in lysis buffer. The suspension was 
incubated with gentle agitation at 4°C for 1 hour and then washed 5 times with His- 
washing buffer and the protein was eluted by adding 500 pi o f His-elution buffer and 
collecting in a clean tube. The elution and collection steps were repeated at least 3 times. 
The fractions containing high amounts (at least 0.2 mg/ml) o f protein were pooled, 
dialysed twice against 1000 x volume of PBS and stored in aliquots at -80°C. Fifty pi of
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each fraction were analysed by SDS-PAGE and the gels were stained with silver staining 
dye to control purity and integrity of the proteins (Figure 2.3).
2.11 GST-pull down assay for ARF6-GTP
Activation levels of ARF6  protein were assayed essentially as described by 
Niedergang (Niedergang et al., 2003) with minor modification. GnRH-CHO cells 
transiently transfected with the cDNA encoding FLAG-ARF6 , FLAG-ARF6(Q67L) or 
FLAG-ARF6(T27N) were stimulated with 20 nM GnRH for 15 min upon 4 h starvation. 
Each 100 mm Petri-dishes were lysed with 1 ml of lysis buffer (50 mM Tris-HCl, pH 7.4; 
137 mM NaCl; 10 mM MgCl2; 1% Triton X-100; 10% v/v glycerol) containing protease 
inhibitor. Cell lysates were clarified by centrifugation at 12,000xg- for 15 min at 4 °C, snap- 
frozen in liquid N2, and stored at -80 °C until the pull-down assay was performed. For each 
pull-down assay, 50 pg of the GST-GGA3 fusion protein (for purification see Section 
2.10.2) were incubated with 75-80% of lysate in presence of 0.5% BSA for 15 min at 4 °C 
with rocking. The suspension was incubated with glutathione sepharose beads (30 pi of 1:1 
v/v beads washed in lysis buffer) with gentle agitation for 60 min at 4 C. The beads were 
collected with centrifugation at 700xg for 5 min and washed three times with 1 ml of lysis 
buffer. Proteins that remained bound to the resin were eluted at 100 C for 5 min with 
sample buffer and subjected to SDS-PAGE and Western blotting.
2.12 Co-immunoprecipitation experiments
2.12.1. Materials and solutions
Protein-A Sepharose™ CL4B was from Amersham Pharmacia Biotech (NJ, USA). 
RIPA buffer: 100 mM Tris-HCl, pH 7.5, 1% Igepal, 0.5% Deoxycholate, 0.1% SDS, 
protease inhibitors.
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Starting Washing Eluates
His-ARNO
Figure 2.3 Purification of His-ARNO. Eluates from Ni-NTA beads were analysed on a 
10% SDS-PAGE gel and the proteins revealed by silver staining. Lane 1: 1/200 of the 
starting bacterial lysate after centrifugation; lanes 2-6: 1/200 of the washes; lanes 7-9: 50 
pi of the eluates. The positions of molecular weight standards are indicated on the left and 
the position of His-ARNO on the right.
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2.12.2. Co-inimunovrecinitation o f endosenous proteins from CHO cells
Semi-confluent CHO cells were incubated with RIP A buffer (1 ml/100 mm Petri 
dish) for 30 minutes at 4 °C with constant shaking. Cells were scraped off the plate and 
broken by passage (14 times) through a 25-gauge syringe. The lysates were collected and 
centrifuged at 12,000xg for 45 min at 4 °C. The supernatants were incubated with 2 pg o f 
anti-G p antibody or anti-c-cbl antibody O/N at 4 °C with constant shaking. The day after, 
the samples were incubated with 40 pi of a 50% slurry protein-A sepharose resin for lh  at 
4 °C with constant rotation. The resin was washed three times with RIPA buffer, boiled in 
loading buffer and resolved by Western blotting using antibodies raised against c-cbl and p 
subunit.
2.12.3 Co-immunoprecipitation assay o f  endosenous proteins from CHO cells plasma 
membranes
Twenty-five pg of CHO plasma membranes were extensively ADP-ribosylated for 
6  hours in presence o f a-NAD (1 mM) or p-NAD (1 mM). Modified and unmodified 
plasma membranes were solubilized with RIPA buffer containing protease inhibitors at 
4°C on rotating weal for 30 minutes. The mixtures were briefly sonicated and centrifuged 
at 12,000xg for 45 min at 4°C and the supernatants were collected and incubated with 2 pg 
of anti-Gp antibody overnight at 4°C with constant shaking. Then the samples were 
incubated with 40 pi o f a 50% slurry o f protein-A sepharose for lh r at 4°C with constant 
rotation. The resin was washed three times with RIPA buffer, boiled in loading buffer and 
resolved by Western blotting using antibodies raised against c-cbl and p subunit.
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2.13. Cell permeabilization with Tetanolvsin
2.13.1. Materials and Solutions
Tetanolysin and Trypan blue were from Sigma-Aldrich. PIPES was from 
Calbiochem. Potassium glutamate was from Fluka.
Tetanolysin solution: Tetanolysin was dissolved in sterile water to a final 
concentration o f 1 pg/pl. PBS: 1.5 mM KH2PO4, 8  mM Na2HPC>4, 2.7 mM KC1, 137 mM 
NaCl, pH 7.4. HGI buffer: 20 mM PIPES, 2 mM NaATP, 4.8 mM Mg(CH3COO)2, 150 mM 
potassium glutamate, 2 mM EGTA, 1 mM DTT (added just before the experiment) and 
KOH to obtain pH 7.0.
2.13.2 Procedures
The permeabilisation o f CHO cells with tetanolysin follows the procedure described 
by Riese (Riese et al., 2002) with some modifications. Semi-confluent CHO cells (6 -well 
plates) were washed with 2 ml/well of PBS and incubated in for 10 min on ice with 
1 ml/well of ice-cold HGI buffer containing 0.5 pg/well o f tetanolysin. The tetanolysin 
binds to membrane cholesterol in the cold without affecting membrane integrity and form 
pores o f 20-40 nm diameter when the temperature is raised. The cells were gently washed 
with 500 pi ice-cold HGI buffer, before 1 ml of HGI buffer containing 4.5 pCi [32P]-NAD 
and stimuli (1 U/ml thrombin, 5 nM pertussis toxin, 25 pM Mas7) were added. The plate 
was transferred to a 37 °C water bath and after 5, 10, 25, or 60 min incubation, CHO cells 
were washed twice with PBS buffer and harvested directly into 125 pi o f sample buffer IX, 
boiled and processed for SDS-PAGE. The level o f cell permeabilization was quantified by 
the penetration of trypan blue (4 mg/ml). Permeabilised CHO cells were incubated for 5 
min with 5ml HGI buffer containing trypan blue, and then washed three times with PBS 
and counted under an inverted light microscope. Non permeabilized cells incubated with 
the dye served as controls. Figure 2.4A shows that under these experimental condition 
about 90% of the cells are permeabilized. Moreover, under these permeabilization
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Figure 2.4. Permeabilization with tetanolysin. A, Levels o f CHO cell permeabilization 
quantified by dye penetration. Trypan blue (4 mg/ml) was added to permeabilised CHO 
cells. After 5 min, it was removed and the cells were washed twice with PBS and their 
permeabilisation quantified under light microscopy. B, Evaluation o f ADP- 
ribosyltransferase activity as a marker for cytosolic protein content in permeabilised cells. 
[ P]-ADP-ribosylated plasma membranes were incubated with cytosol from non- 
permeabilised and permeabilised CHO cells for 30 min at 37 °C. The levels o f ADP- 
ribosylated P subunit were quantified using an Instant Imager. The data shown represent 
means (±SD) o f five independent experiments, each performed in duplicate (n=10). * p < 
0.01, significantly different from relevant control.
139
conditions, only the 25 % of intracellular ADP-ribosylhydrolase activity (taken as a marker 
for cytosolic proteins) was lost in the supernatant (Figure 2.4B). Indeed, ADP-ribosylated 
plasma membranes were incubated with cytosol obtained from permeabilized and un- 
permeabilized CHO cells. The cytosol obtained from treated cells is able to induce a 30% 
of de-ADP-ribosylation respect the untreated cells. This result indicates that upon 
permeabilization with tetanolysin the cellular structure is not completely destroyed.
1.14. GTPyS binding assay
2.14.1 Materials
GTP-yS, triethanolammine, and 2(N-morpholino)ethansulphonic acid (MES) were 
from Sigma-Aldrich (WI, USA). [35S]GTPyS (specific activity 1250 Ci/mmol) and Filter- 
Count Solution were from PerkinElmer (NJ, USA). Cellulose nitrate membrane filters 
were from Whatman (UK), p-counter LS 6500 was from Beckam (USA). Filtration 
apparatus with vacuum pump was from Millipore (MA, USA).
2.14.2 Procedures
The assay was performed according to the procedure described by Wieland and 
Jakobs (Wieland et al., 1994). Plasma membrane of CHO cells (5 pg) were incubated for 
30 min at 30°C in a buffer containing: 50 mM triethanolammine pH 7.3, 5 mM MES, 1 
mM EDTA, 5 mM MgCl2, 143 mM NaCl, 0,16% BSA, 10 pM GTP, 4 nM [35S]GTPyS (2 
xlO5 cpm/sample); in the presence o f 200 nM GnRH in a final volume o f 100 pi. The non 
specific binding was measured adding to the sample 10 pM GTPyS. The reaction was 
stopped by adding 2.5 ml of ice cold washing buffer (50 mM TRIS-HC1 pH7.3, 1 mM 
EDTA and 5 mM MgCL). Then the samples were passed through 0.45 pM cellulose nitrate 
filters and washed 3 times with 2.5 ml o f wash buffer in vacuum apparatus. Finally the 
filters were collected, dissolved by filter count solution and counted for 4 min with P- 
scintillation counter. The results are plotted as % increase over the untreated samples.
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2.15 HPLC analysis
The contents of NAD+ and NADH in ADP-ribosylated plasma membranes were 
measured using anion exchange HPLC analysis by Cristiano Iurisci (Consorzio Mario 
Negri Sud, Italy). The samples were analysed on a Partisil 10 SAX column (4.6 mm x 25 
cm; Whatman), using water for the first 5 min, followed by a linear gradient o f 0-1 M 
ammonium phosphate, pH 3.35, (5-45 min), and of 1-0 M ammonium phosphate (45-65 
min). Radioactivity associated with the labelled compounds was analysed by an on-line 
flow detector (Packard FLO ONE A-525).
2.16 Thin-layer chromatography
Samples were chromatographed as described by Cassel (Cassel and Pfeuffer, 1978). 
After ADP-ribosylation reaction, samples (50 pi) were diluted to 500 pi with 50 mM PFB, 
pH 7.4. Three pi o f each sample were added with 1 pi of nucleotide standards (20 mM 
NAD+, ADP-ribose, ADP and AMP in water) and applied to polyethyleneimine cellulose 
sheets (PEI-cellulose F, 20 x 20 cm, 0.2 mm thick) (Merck). Prior to use, cellulose sheets 
were scraped from the lateral margin (1 cm) and samples loaded 1 cm from the bottom. As 
a standard 2 x 104 cpm of [32P]-NAD+ were used. As elution buffer a solution of 150 mM 
NH4HCO3 was prepared and left in a sealed tank for at least 2 h prior to running. TLC 
plates were placed in the tank and allowed to develop for about 1 h before being removed, 
dried and analysed by Instant Imager.
2.17 Statistical analysis
Data are expressed as means ± SD. Statistical analysis was performed using 
GraphPad PRISM software to calculate paired Student’s t test (p < 0.05 was considered 
significant).
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Chapter 3
GPCR agonists modulate mono-ADP-ribosylation of the Py subunit
3.1 Introduction
Endogenous mono-ADP-ribosylation of the p subunit o f heterotrimeric G proteins 
modifies the Argl29 situated in its common effector-binding surface, thereby the Py 
heterodimer loses its ability to modulate downstream effectors, such as type 1 AC, PI3K-y 
and PLCP2. Thus this reaction might constitute a novel cellular mechanism to modulate G- 
protein-mediated-signal transduction. To further the understanding of the physiological 
role of this reaction, it would be useful to elucidate the mechanisms by which it can be 
modulated.
We have demonstrated that mono-ADP-ribosylation of the P subunit occurs only 
when it is activated. It is well accepted that the active form o f the Py dimer originates from 
heterotrimeric G proteins when an activated GPCR causes GDP/GTP exchange on the a  
subunit (Hamm, 1998; Lambright et al., 1996). To find out whether mono-ADP- 
ribosylation o f the Py dimer is regulated by GPCR stimulation, two experimental 
approaches were taken:
i) In vitro assay of mono-ADP-ribosylation of the p subunit. Here, purified plasma 
membranes from CHO cells were stimulated with direct activators o f G proteins (i.e. 
mastoparan) and agonists for GPCRs;
ii) In vivo analysis of hormonal modulation of mono-ADP-ribosylation o f the p subunit 
using intact and permeabilized CHO cells.
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3.2 Hormonal modulation of mono-ADP-ribosvlation in vitro
3.2.1 Mastovaran induces an increase in mono-ADP-ribosvlation o f  B subunit
To address whether the activated Py dimer is a substrate for endogenous mono- 
ADP-ribosylation, the [32P]-ADP-ribose incorporation was evaluated following treatment 
of plasma membranes with mastoparan. In this system, the membranes constituted the 
source of both the p subunit and the enzymatic activity.
Mastoparan (Ile-Asn-Leu-Lya-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-amide; 
derived from wasp venom) is the prototype of a wide range of amphipatic, cationic 
peptides that can activate G proteins. As with GPCR activation, mastoparan accelerates 
guanine nucleotide exchange on the a  subunit in the presence o f Mg2+; it does not alter the 
rate o f hydrolysis o f bound GTP and its action is markedly enhanced by Py dimers and 
blocked by PTX-catalysed ADP-ribosylation of the a  subunit. Mastoparan is selective in 
its activation of different G proteins, accelerating nucleotide exchange on G0 more than 
30-fold, and it is almost as active on Gi, but less potent with Gs, Gt, Gz, Gq and p21ras. In 
parallel, synthetic analogues of mastoparan display diverse maximal activities and patterns 
o f selectivity among the different G proteins. Mastoparan has been used widely as a 
specific probe for manipulating cellular signalling pathways in which G proteins are 
involved. Thus, I used mastoparan in a previously described in vitro assay (Lupi et al., 
2000) to determine if  the activated Py dimer is a substrate of endogenous ADP- 
ribosylation. Briefly the samples (5 pg CHO plasma membrane protein) were incubated at 
37 °C for 60 min in 50 mM potassium phosphate buffer (pH 7.4) with 30 pM p-NAD+ and 
1-2 pCi [32P]-NAD (specific radioactivity, 1000 Ci/mmol) in the absence and presence o f 
mastoparan. The samples were then separated by SDS-PAGE and the [32P]-ADP- 
ribosylation of the p subunit was quantified using an Istant Imager.
As shown in Figure 3.1, mastoparan treatment resulted in a large stimulation (from 
two- to three-fold, depending on the plasma membrane preparation) of [32P]-mono-ADP-
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Figure 3.1. The G-protein 0 subunit ADP-ribosylation induced by the mastoparans.
The levels o f ADP-ribosylated P subunit induced by 25 pM mastoparan and its analogues 
mastoparan 17 and Mas7 incubated for 60 min at 37 °C with CHO plasma membranes and 
[ P]-NAD, as quantified using an Instant Imager. The data shown represent the means 
(±SD) o f five independent experiments, each performed in duplicate (n=10). *p < 0.01, 
significantly different from the control.
144
ribosylation of p was induced. To exclude any non-specific effects of mastoparan due to 
its amphipatic properties, different mastoparan derivatives were used as positive and 
negative controls. Under the same experimental conditions, mastoparan 17, an inactive 
mastoparan analogue, was inactive. On the other hand, mastoparan 7 (Mas7), known to be 
the most active o f the mastoparan derivatives, caused a more pronounced p subunit mono- 
ADP-ribosylation (190 ± 30 percent increase as compared to control).
These data support the concept that activation of the py heterodimer modulates its 
own endogenous mono-ADP-ribosylation.
3.2.2 Agonists for endosenous GPCRs modulate mono-ADP-ribosvlation o f  the B  
subunit
Once the in vitro activation of Py dimers had been shown to modulate endogenous 
mono-ADP-ribosylation, the possibility of hormonal modulation o f the reaction was 
investigated by treating plasma membranes from CHO cells with agonists for GPCRs that 
are endogenously expressed on the surface of these cells. Thus, I used agonists for the 
P2Y2 purinergic receptor, the thrombin receptor (PARI), the cholecystokinin (CCKA) 
receptor and the serotonin (5-HT IB-like) receptor.
As shown in Figure 3.2, when CHO plasma membranes were stimulated with UTP, 
CCK8  and 5-HT, there was a 50% average increase in p subunit [32P]-ADP-ribosylation. 
Under the same conditions, thrombin stimulation induced an 80% increase, while 
treatment with angiotensin II and EGF, the receptors for which are not expressed on CHO 
cells, had no effects.
This demonstrates that mono-ADP-ribosylation of the p subunit can be modulated 
by stimulation o f GPCRs with their specific agonists. Since the P2Y2 purinergic receptor, 
the thrombin receptor, and the CCKA cholecystokinin receptor are all coupled to Gq, while 
the 5-HT receptor is coupled to Gj, it can be assumed that py dimers from different classes 
of G proteins are substrates for the endogenous ADP-ribosylation reaction. Thus, there
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Figure 3.2. The G protein |3 subunit ADP-ribosylation induced by receptor activation.
The level of ADP-ribosylated P subunit induced by agonists (1 pM CCK8 , UTP, 5-HT and 
angiotensin II; 1 pg/ml EGF; 10 IU/ml thrombin) incubated for 60 min at 37 °C with CHO 
plasma membranes and [32P]-NAD, as quantified using an Instant Imager. The data shown 
represent the means (±SD) of five independent experiments, each performed in duplicate 
(n=1 0 ). * p < 0 .0 1 , significantly different from the control.
appears to be little or no specificity in the modulation of the reaction arising from specific 
classes o f G protein.
By evaluating o f the number of picomoles o f P subunit that are modified in plasma 
membrane preparations, I have also characterised the reaction in a quantitative fashion (see 
Section 2.5.2 for details of the calculation). Under basal conditions, 0.012 ± 0.004 
picomoles of the p subunit were mono-ADP-ribosylated, which corresponds to 1-2% of 
the total amount of p present in 5 pg of plasma membranes (1 picomol/ 5 pg plasma 
membrane). Under thrombin stimulation, this approximately doubled (0.024 ± 0.007 
picomoles). In both cases, the amount o f the p subunit modified was very low and this 
could represent a problem for further studies on the mechanisms that regulate this 
hormonal modulation. Therefore, the experimental conditions for the in vitro assay of 
ADP-ribosylation were modified with a view to maximising the enzyme activity. The first 
parameter was the concentration of NAD+. All ADP-ribosyltransferases, both bacterial and 
mammalian, also possess NADase activities, although these are significantly less than the 
maximal transferase activities. The balance between these two activities is influenced and 
regulated by the concentration of NAD+. Lieberman (Lieberman, 1957) first observed 
NAD-dependent inhibition of cellular NADase activity and the recovery o f the enzyme 
activity following the removal of NAD+. Further investigations have demonstrated that 
NAD+ not only decreases NADase activity o f ART5 (ADP-ribosyltransferase 5) but also 
enhances its transferase activity (Weng et al., 1999). Thus, to find out if  the activity o f the 
transferase that modifies the p subunit is similarly influenced by NAD+ concentration, 
different amounts of NAD+ (30 pM to 10 mM) were tested in an in vitro assay of mono- 
ADP-ribosylation. As shown in Figure 3.3A, there is a significant increment (about 6 -fold) 
in the amount o f modified p subunit evident at 700 pM NAD+. This indicates that the 
transferase activity can be enhanced. It is also relevant that this concentration is 
comparable with the physiological concentrations o f NAD+ in CHO cells
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Figure 3.3. The G-protein p subunit ADP-ribosylation induced by increasing 
concentrations of P-NAD+. A, picomoles o f ADP-ribosylated P subunit obtained with 
increasing concentrations of p-NAD+ incubated for 60 min at 37°C with CHO plasma 
membranes and [32P]-NAD, calculated as reported in Section 2.5.2. The data shown 
represent the means (±SD) of three independent experiments, each performed in duplicate 
(n=6 ). * p < 0.05, significantly different from the sample treated with 30 pM P-NAD+. B, 
level of ADP-ribosylated P subunit induced by 10 IU/ml thrombin in CHO plasma 
membranes incubated for 60 min at 37°C with [32P]-NAD and 30 pM or 700 pM p-NAD+, 
as quantified using Instant Imager. The data shown represent the means (±SD) o f four 
independent experiments, each performed in duplicate (n=8 ). *p < 0.05, significantly 
different from the control.
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(785 ± 1 0  pM, Lee et al., 1994; Lupi et al., 2000) and compatible with the apparent Km 
value (350 ± 20 pM) calculated for endogenous py dimer mono-ADP-ribosylation (Lupi et 
al., 2000). The transferase activity was then assayed with 700 pM NAD+ in the presence of 
thrombin stimulation. Under these conditions, the extent o f stimulation mediated by 
activation o f the PARI receptor was comparable to that obtained with 30 pM NAD+ 
(Figure 3.3B), indicating that higher amounts of NAD+ have no effect on the ability o f the 
activated receptors to modulate the reaction.
In parallel, the transferase activity was tested in the presence o f 10 pM GTPyS and
s
5 mM MgCl2, to facilitate the activation of G proteins, together with 700 pM NAD+ 
(Aoyagi et al., 1992; Cerione et al., 1986), either without or with receptor stimulation. This 
promoted the modification o f 0.135 ± 0.02 picomoles under basal condition, and 0.238 ± 
0.02 under thrombin stimulation, as shown in Figure 3.4.
Based on these findings, the following conditions were adopted (unless otherwise 
specified): samples (5 pg CHO plasma membrane protein) were incubated at 37 °C for 60 
min in 50 pi ADP-ribosylation buffer (50 mM PFB, pH 7.4, 5 mM MgCl2, 4 mM DTT, 10 
pM GTPyS, 700 pM p-NAD+, 4.5 pCi [32P]-NAD) in the presence of buffer or agonists 
for the endogenous GPCRs (for further details, see Section 2.5).
Subsequently, the range of GPCRs analysed was enlarged by using plasma 
membranes obtained from CHO cells that had been stably transfected with the (X2- 
adrenoreceptor and p2-adrenoreceptor ((X2AR and P2AR, respectively), the gonadotropin- 
releasing-hormone receptor (GnRHR) and the substance P receptor (NK1R).
Stimulation of (X2-AR and P2-AR with their agonists clonidine and isoproterenol 
induced 50% and 28% mean increases in p subunit [32P]-ADP-ribosylation, respectively 
(Figure 3.5). Interestingly, the stimulation of GnRHR with GnRH and o f NK1R with 
substance P resulted in a decrease in the amount o f modified p subunit (-31% and -42%,
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Figure 3.4. The G-protein p subunit ADP-ribosylation induced by a com bination of p-
NAD+, M gCh and GTP-yS. Picomoles o f ADP-ribosylated P subunit obtained with 700 
pM P~NAD+, 5 mM MgCb and 10 pM GTP-yS incubated for 60 min at 37°C with CHO 
plasma membranes, [32P]-NAD, in the absence and presence o f 10 IU/ml thrombin, as 
quantified using an Instant Imager. The data shown represent the means (±SD) o f three 
independent experiments, each performed in duplicate (n=6 ). *p < 0.05, significantly 
different from the control.
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Figure 3.5. The G-protein p subunit ADP-ribosylation induced by activation of over­
expressed receptors. The level of ADP-ribosylated P subunit induced by the indicated 
agonists (10 pM isoproterenol, 15 pM clonidine, 30 pM substance P, 200 nM GnRH) in 
CHO plasma membranes over-expressing the corresponding receptors, incubated for 60
T9min at 37 °C with [JZP]-NAD, as quantified using an Instant Imager. The data shown 
represent the means (±SD) of five independent experiments, each performed in duplicate 
(n=T0). *p < 0.05, significantly different from the control.
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respectively; Figure 3.5). This reveals that mono-ADP-ribosylation o f the Py subunit can 
be modulated both up and down by GPCRs.
To check whether this positive and negative modulation are both mediated by 
specific receptor stimulation, plasma membranes obtained from non-transfected CHO cells 
were stimulated with substance P, GnRH, clonidine and isoproterenol. GnRH, clonidine 
and isoproterenol failed to induce any modifications in labelling of the p subunit, thus 
indicating that these compounds modulate the endogenous mono-ADP-ribosylation 
reaction through receptor activation (Figure 3.6). However, treatment with substance P still 
led to a decrease in the modified p subunit, even though this receptor was absent. 
Substance P inhibited mono-ADP-ribosylation probably through a non-specific mechanism 
that is not related to NK1 receptor activation. The amino acid sequence o f substance P 
(Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) includes an arginine that could 
itself be ADP-ribosylated. Thus substance P might act as a competitive inhibitor o f the 
reaction, resulting in a decrease in the amount o f modified p subunit; however, to date, 
there is no experimental evidence in support of this idea. This aspect was not further 
investigated.
3.2.3 Pertussis toxin abolishes the stimulatory effects mediated by 5-H T and clonidine
To confirm that modulation of ADP-ribosylation due to agonist stimulation of 
GPCRs is mediated by G-proteins, an in vitro assay was performed using plasma 
membranes from CHO cells that had been treated with PTX. It is well accepted that upon 
prolonged incubation (at least 3 h) in a wide variety o f cell types, the catalytic subunit o f 
PTX becomes internalised and catalyses ADP-ribosylation on the a  subunit o f the Gj/0 
proteins. This disrupts their interactions with their associated receptors and leads to the 
uncoupling of their corresponding signal transduction events.
Here, semi-confluent CHO cells were incubated for 15 h with PTX (5 nM) and 
with the inactive protomer B of PTX as control. Plasma membranes from these cells were
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Figure 3.6. The G-protein P subunit ADP-ribosylation induced by agonists for over­
expressed receptors in wild-type CHO cells. The level o f ADP-ribosylated P subunit 
induced by the indicated agonists (10 pM isoproterenol, 15 pM clonidine, 30 pM substance 
P, 200 nM GnRH) in plasma membranes obtained from wild-type CHO cells, incubated for
• • T 960 min at 37 °C with [ P]-NAD, as quantified using an Instant Imager. The data shown 
represent the means (±SD) of three independent experiments, each performed in duplicate 
(n=6 ). *p < 0  .05, significantly different from the control.
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then used in the in vitro ADP-ribosylation assay. Five pg o f each membrane preparation 
were incubated with 100 nM catalytic subunit o f PTX in the presence of [32P]-NAD to 
check for a  subunit ADP-ribosylation (Figure 3.7A). Under these conditions, the plasma 
membrane preparation purified from CHO cells pre-incubated with PTX did not show any 
labelling o f the a  subunit. This indicates that the a  subunit was previously ADP 
ribosylated during the in vivo treatment with PTX, and therefore it was no longer available
• • T9 _for modification with [ P]-NAD. This confirms that under these conditions the Gi/0 
proteins are in their inactive heterotrimeric conformation.
Samples were then analysed in the in vitro assay in the presence o f Mas7 (active on 
the Gi family), serotonin and clonidine (both acting through Gj-coupled receptors). As 
anticipated, stimulation of p subunit mono-ADP-ribosylation induced by serotonin and 
clonidine was completely blocked by PTX (Figure 3.7B). By contrast, stimulation o f P 
subunit mono-ADP-ribosylation by Mas7 was only partially blocked (35 ± 5% decrease, as 
compared to control). This indicates that only part of the effect of Mas7 was due to the 
activation o f PTX-sensitive heterotrimeric G proteins. Mas7 might activate p subunit 
mono-ADP-ribosylation both by activating the heterotrimeric G proteins and through an 
indirect interaction with the ADP-ribosyltransferase.
Altogether, these data indicate that the activation o f the py heterodimer through 
GPCRs or by mastoparan allows mono-ADP-ribosylation o f the p subunit. This might be 
expected to modulate p subunit function.
3.3 In vitro hormonal modulation; mechanism of action
The results reported in the preceding Section demonstrate that the endogenous 
mono-ADP-ribosylation reaction is differently modulated by individual GPCRs. This 
suggests that it cannot be due only to the activation of the Py subunits. With respect to the 
PARI receptor, there is the additional possibility that the mechanism of thrombin-induced
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Figure 3.7. The effects of PTX treatment on P subunit ADP-ribosylation induced by 
receptor activation and Mas7. A, Mono-ADP-ribosylation o f the G-protein a  subunit 
induced by PTX. The CHO cells were incubated overnight at 37 °C with 5x1 O' 9 M  PTX. 
Purified plasma membranes (5pg/sample) from treated and untreated cells, as a control, 
were then incubated with the catalytic subunit o f PTX for an additional 60 min at 37 °C. 
Autoradiography o f plasma membranes from CHO cells pre-treated with PTX (lane 2) or 
not pre-treated (lane 1). B, The level o f the ADP-ribosylated P subunit induced by the 
agonists and by Mas7 incubated for 60 min at 37 °C with [32P]-NAD and plasma 
membranes from untreated (green columns) and PTX-treated (blue columns) CHO cells, as 
quantified using an Instant Imager. The data shown represent the means (±SD) o f four 
independent experiments, each performed in duplicate (n=8 ). *p < 0.05, significantly 
different from the control.
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ADP-ribosylation could involve activation of cellular ADP-ribosyltransferases. Recent 
reports have indicated that in addition to heterotrimeric G proteins, GPCRs can interact 
with a variety of other targets, including arrestin and the small G proteins Rho and ARF 
(Marinissen and Gutkind, 2001).
A possible cooperation between receptor and transferase might also explain the 
negative modulation mediated by the GnRH receptor, which down-regulated ADP- 
ribosylation of the p subunit, even though GnRH induced activation of Py dimers. To 
clarify this point, in vitro experiments o f mono-ADP-ribosylation were carried out in the 
presence of increasing amounts of purified bovine brain Py subunit, under resting 
conditions and under stimulation with thrombin and GnRH. In parallel, in order to 
determine the appropriate range of py concentrations, the values of Km and Vmax for py 
were estimated.
CHO plasma membranes were used as the source o f the ADP-ribosyltransferase 
together with a range of purified brain Py dimer (0-650 ng), to evaluate the ADP- 
ribosyltransferase activity. The results are shown in Figure 3.8, where the picomoles of 
modified Py subunit are shown as a function of the total amount of Py present in the 
reaction mixture. The data were fitted to Michaelis-Menten kinetics, with the V0 expressed 
as picomoles o f modified P subunit of membrane protein, while the substrate concentration 
is expressed as ng of purified py dimer. The data were then transformed according to 
Eadie-Hofstee theory and the kinetic constants were determined using SIGMA software, 
obtaining an apparent Km of 139.9 ± 28.6 nM. The Vmax was 685 ± 60 pmol/h/mg plasma 
membranes. This rate might plausibly be regulated by cytoplasmatic activators (and/or 
cofactors), and hence might be different in the natural intracellular milieu. Nevertheless, 
this kinetic analysis was necessary to further study the in vitro hormonal modulation o f the 
endogenous p subunit ADP-ribosylation mediated by the GPCRs.
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Figure 3.8. The kinetic investigation of the G-protein P subunit ADP-ribosylation. A,
Picomoles o f the ADP-ribosylated p subunit calculated in the presence o f increasing 
concentrations o f free Py dimer, incubated for 60 min at 37 °C with CHO plasma 
membranes and [32P]-NAD. The picomoles were calculated as reported in Section 2.5.2. 
The data shown represent the means (±SD) o f three independent experiments, each 
performed in duplicate (n=6 ). B, Determination o f Vmax and Km according to the Eadie- 
Hofstee theory using SIGMA software.
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3.3.1 Thrombin-mediated stimulation o f Bsubunit mono-ADP-ribosvlation results from
activation o f  By  dimers.
To clarify the mechanism by which activated GPCRs modulate the ADP- 
ribosylation reaction, increasing concentrations of purified (3y dimer (0 to 250 ng) were 
ADP-ribosylated in vitro using purified plasma membranes following their stimulation 
with thrombin (or buffer as control).
The results are shown in Figure 3.9. As expected, thrombin induces a significant 
increase in ADP-ribosylation (mean, 80%) that is counteracted when increasing 
concentrations of free py are added to the experimental mixture. It appears that the 
activation o f the PARI receptor becomes ineffective when a surplus o f free py is provided. 
This suggest that the stimulatory effect of thrombin in plasma membranes is due to the 
activation of the subset o f py associated with the PARI receptor, rather than to an 
activation of the ADP-ribosyltransferase mediated by the receptor or by other plasma- 
membrane-associated co-factors. However, this does not exclude the possibility that in 
intact cells, cytosolic factors could cooperate with receptors to regulate the transferases. To 
investigate this possibility, instead o f plasma membrane preparations, CHO cell lysates 
(prepared according to the procedure described in Section 2.3.2.4) were used in the in vitro 
assay. The samples (80 pg total cell lysate/sample containing 5 pg o f plasma membranes) 
were analysed in the presence of increasing amounts o f purified Py subunit under basal 
conditions and under thrombin stimulation. Unfortunately, the presence o f total cell lysates 
as a source o f enzyme activity prevented [ P]-labelling of the p subunit, probably due to 
the presence of cytosolic ADP-ribosylhydrolases that reverse the ADP-ribosylation 
reaction. An analysis o f the cytoplasmatic components involved in receptor-mediated 
activation o f the endogenous mono-ADP-ribosylation o f the p subunit will be possible 
when tools for inhibiting the reverse hydrolase reaction become available.
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Figure 3.9. Throm bin-induced stimulation of the G-protein p subunit ADP- 
ribosylation is mediated by activation of the Py dimer. Level of ADP-ribosylated P 
subunit induced by 10 IU/ml thrombin (green columns) incubated for 60 min at 37 °C with 
CHO plasma membranes and increasing concentrations o f free purified Py dimer in 
presence of [32P]-NAD, as quantified using an Instant Imager. The data shown represent 
the means (± SD) of three independent experiments, each performed in duplicate (n=6 ).
* p < 0.01 and **p < 0.05, significantly different from the control.
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To date, there are no data that allow us to conclude definitively that the stimulatory 
effects mediated by the thrombin receptor are due only to the activation o f Py dimers.
3.3.2 Negative modulation o f  0  subunit ADP-ribosylation by G nRH
The same experimental approach was used to find out if  GnRH-induced inhibition 
o f ADP-ribosylation of the P subunit is mediated by inhibition o f cellular transferase(s). 
Plasma membranes from CHO cells over-expressing the GnRH receptor were stimulated 
with GnRH in the presence of increasing amounts of the py subunit.
When free py subunits were added at amounts up to 100 ng, the inhibitory effect of 
GnRH was maintained, while higher concentrations antagonised this effect (Figure 3.10). 
This suggests that higher concentrations of py subunit antagonise the inhibitory influence 
of the stimulated GnRH receptor. The negative effects of GnRH are due to inhibition o f 
the cellular transferase, which is mediated by the activation o f the GnRH receptor.
3.4 Agonists modulate ADP-ribosylation of the Bv dimer in living cells
The demonstration that ADP-ribosylation in the cell-free system is regulated by 
agonists for GPCRs is of interest with regard to its potential physiological relevance. In 
this section the possibility of hormone modulation in intact cells was explored. Two 
different approaches were used:
i) Examination by Western blotting of the ~500 Da increase in the p subunit 
molecular weight due to the addition o f ADP-ribose upon stimulation of CHO 
cells with thrombin,
ii) Following the level of [32P]-ADP-ribosylated p subunit in permeabilized CHO 
cells upon stimulation with mas7 and thrombin.
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Figure 3.10. GnRH-induced negative modulation of the G-protein P subunit ADP- 
ribosylation is mediated by the inhibition of the ADP-ribosyltransferase. The level o f 
the ADP-ribosylated P subunit induced by the 200nM GnRH (pink columns) incubated for 
60 min at 37 °C with CHO plasma membranes, and increasing concentrations of purified
99free py dimers and [ PJ-NAD, as quantified using an Instant Imager. The data shown 
represent the means (±SD) of three independent experiments, performed in duplicate 
(n=6 ).* p < 0.05, significantly different from the control.
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3.4.1 Hormonal modulation in livinz cells: a shift in the apparent molecular weisht o f
the B subunit
The approach used to detect in vivo ADP-ribosylation was the identification of a 
shift in the apparent molecular weight of proteins in cells treated with the ADP- 
ribosyltransferase. This method was used to demonstrate the in vivo modification o f Ras 
by ExoS (McGuffie et al., 1998). Thus, an assay was developed to evaluate hormonal 
modulation o f endogenous ADP-ribosylation o f the p subunit in living cells by comparing 
the p subunit molecular weight under basal conditions and upon stimulation with 
thrombin.
Fifteen semi-confluent 150-mm Petri dishes o f CHO cells were stimulated for 30 min with
control buffer or thrombin (1 IU/ml). The plasma membranes were then purified according
to the procedure reported in Section 2.3.2.1, and the expected -500  Da shift in the p
subunit due to ADP-ribose addition was evaluated by SDS-PAGE. A limit in this type of
experiment is posed by the very low abundance o f the modified p subunit. Thus, to analyse
detectable amounts of ADP-ribosylated p subunit, 150 pg o f purified plasma
membrane/sample were analysed and SDS-PAGE was performed using long gels, to allow
better separation of the different p subunit species. In this way, a more precise
visualization o f the molecular weight shift was obtained. Figure 3.11 shows that in plasma
membranes from unstimulated cells (lanes 1 and 3), the antibody against the p subunit
revealed two bands, of 35 and 36 kDa, that had previously been characterised as the
unmodified pi and p2 subunits. An additional band of 36.5 kDa was revealed in the plasma
membranes purified from thrombin-stimulated cells (lane 2 ), which co-migrated with the
in vitro ADP-ribosylated p subunit (lane 4). The high amount o f protein applied to the
lanes caused some diffusion and distortion o f the samples. Nevertheless, the three bands
corresponding to the unmodified and modified p subunits could be resolved, and as
expected, the modified p subunit was present at ng levels (vs. pg levels o f the unmodified
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Figure 3.11. The G-protein P subunit ADP-ribosylation induced by receptor 
activation in living cells. Western blotting with an anti-Gp antibody o f the nitrocellulose 
filter containing 150 pg/sample plasma membranes prepared from CHO cells stimulated 
(lane 2) or not stimulated (lanes 1 and 3) with llU /m l thrombin for 30 min at 37 °C and 
separated on long gels. Lane 4 shows 150 pg o f CHO plasma membranes that have been 
pre-ADP-ribosylated in vitro for 60 min. The data shown are representative o f at least three 
independent experiments.
163
protein) and appeared less laterally diffused than the other two bands. Also, it should be 
noted that the protein o f 36.5 kDa represents only ADP-ribosylated Pi; ADP-ribosylation 
o f the p2 could not be evaluated due to its co-migration with unmodified pi.
This procedure allows the visualization of thrombin-stimulated ADP-ribosylation 
of P subunits under conditions in which the endogenous ADP-ribosylhydrolase is active, 
counteracting the action of the ADP-ribosyltransferase. Unfortunately, due to the low 
abundance of the modified p subunit under basal conditions it was not possible to use this 
shift protocol to detect the inhibitory effects mediated by the GnRH receptor.
All together, the results in this Section demonstrate the existence o f hormonal 
modulation o f endogenous p subunit mono-ADP-ribosylation also in living cells, which 
may result in the regulation of P subunit function.
3.4,2 Hormone modulation o f  permeabilised CHO cells
To further investigate hormonal modulation of mono-ADP-ribosylation of the p 
subunit in living cells, an alternative experimental approach was used. Tetanolysin was 
used to introduce pores in the plasma membranes of CHO cells and thus allow entry o f 
[32P]-NAD+. The method used followed that described by Riese et al. (Riese et al., 2002), 
with some modifications, as described in Section 2.13. This system has the advantage o f 
preserving cell structure whilst allowing entry of [32P]-NAD+.
Semi-confluent CHO cells were permeabilized with tetanolysin and then incubated
in the presence of [32P]-NAD while being treated with PTX, Mas7, thrombin and GnRH,
)
as described in Section 2.13.2. The [32P]-ADP-ribosylated p subunit was then analysed by 
autoradiography.
In intact (non-permeabilised) cells, PTX failed to incorporate radiolabelled ribose 
into intracellular proteins (Figure 3.12A, lane 7). After tetanolysin treatment, PTX 
catalysed the incorporation o f radiolabelled ADP-ribose into a protein with the predicted 
molecular mass of the G a subunit (Figure 3.12A, lane 6 ). This indicates that tetanolysin
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Figure 3.12, The G-proteiu p subunit ADP-ribosylatioe induced by Mas7 in living
cells. A, Mono-ADP-ribosylation of the G-protein P subunit revealed by autoradiography
'Xlin CHO cells permeabilized with tetanolysin and incubated at 37°C in presence of [ ~P]- 
NAD1 for the indicated times. B, Western blotting of the same samples as in A, with an 
anti-Gp antibody. The data shown are from single experiments performed in duplicate, 
which are representative of at least six independent experiments.
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had produced pores in the CHO cell membranes that allowed the entry o f [32P]-NAD+. 
This system could, therefore, be used to evaluate hormonal modulation of endogenous 
mono-ADP-ribosylation of the p subunit.
Analysis o f permeabilized wild-type CHO cells incubated with [32P]-NAD+ under 
basal conditions reveals a radiolabelled band (Figure 3.12, lane 2) that co-migrates with 
the in vitro ADP-ribosylated p subunit (Figure 3.12, lane 1). Upon stimulation with Mas7, 
the amount of modified p subunit significantly increased in a time-dependent manner 
(lanes 3, 4, 5). In parallel experiments, Mas 17, the inactive analogue o f Mas7, failed to 
induce any labelling of the P subunit (Figure 3.13).
The same procedures were used to assess hormone modulation of endogenous 
mono-ADP-ribosylation mediated by activation o f the PARI and GnRH receptors. 
Thrombin (1 IU/ml) induced an increase in the labelling of the p subunit, with respect to 
unstimulated cells (Figure 3.14). This further confirms that in living cells, mono-ADP- 
ribosylation o f the Py dimer is modulated by GPCRs. By contrast, incubation of 
permeabilized GnRH-CHO cells with [32P]-NAD+ under basal conditions revealed only a 
very weak labelling of the p subunit. This was insufficient for detection of any inhibitory 
effects that might have been due to stimulation of the GnRH receptor. So far, it has not 
been possible to follow the inhibitory effect of the GnRH receptor in living cells.
3.5 Discussion
The py complex is essential for a wide range of cellular functions, including
apoptosis, chemotaxis, secretion and cell proliferation and differentiation. All o f these
processes are mediated by interactions between Py and various target molecules, including
the ACs, PI3K, PLC-P and ion channels. We have reported that the modification of its Arg
129 inactivates the p subunit, potentially by impairing the interactions o f this subunit with
its effector molecules. This thus suggests that this modification is crucial in the regulation
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Figure 3.13. The G-protein (3 subunit ADP-ribosylation induced by M asl?  in living 
cells. Mono-ADP-ribosylation of the G-protein |3 subunit revealed by autoradiography in 
CHO cells permeabilized with tetanolysin and incubated at 37°C in presence o f [ P]-NAD 
for the indicated times. The data shown are from single experiments performed in 
duplicate, which are representative of at least six independent experiments.
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Figure 3.14. The G-protein p subunit ADP-ribosylation induced by throm bin in living 
cells. A, Mono-ADP-ribosylation of the G-protein P subunit revealed by autoradiography 
in CHO cells permeabilized with tetanolysin and incubated at 37°C in presence o f [ l2P]- 
NAD for the indicated times. Lane 1, in vitro ADP-ribosylated plasma membranes; lane 2, 
permeabilized CHO cells, 60 min; lanes 3,4 and 5, permeabilized CHO cells stimulated 
with 1 IU/ml thrombin for 5, 15, and 30 min. B, Western blotting of the same samples as in 
A, with an anti-GP antibody. The data shown are from a single experiment performed in 
duplicate, which is representative of at least four independent experiments.
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of Py activity in general. The purpose of this part of my study was to determine if  
endogenous mono-ADP-ribosyltransferase can be regulated by agonist stimulation of 
GPCRs, which would indicate that this is a physiologically relevant response. Some of the 
agonists tested (UTP, thrombin, CCK8 , 5-HT, clonidine and isoproterenol) induced 
significant increases in p subunit [32P]-ADP-ribosylation, indicating that the Py subunit is 
linked to different classes o f G-proteins, including Gq and Gi, which are thus substrates for 
the endogenous mono-ADP-ribosyltransferase. The actual increases in p subunit [32P]- 
ADP-ribosylation might appear low (ranging from 30 to 80%), but this is not surprising 
since only a subset of G-proteins specifically coupled with the activated receptors are 
involved in the reaction. Indeed, non-specific activation of G proteins by mastoparan and 
Mas7 resulted in a remarkable stimulation o f p subunit [32P]-ADP-ribosylation. Pre­
treatment of CHO cells with PTX decreased the effect o f Mas7 by about 40%. The PTX- 
insensitive component may be due to a direct action o f Mas7 on the ADP- 
ribosyltransferase (or other plasma membrane, PTX-insensitive factors that affect the 
ADP-ribosyltransferase activity).
These results are o f particular interest since they demonstrate that the rate o f Py 
ADP-ribosylation can be increased upon activation o f certain GPCRs. Therefore, while 
activation of these receptors leads to the activation o f G protein a  and Py subunits, there is 
a parallel inactivation of Py function that could potentially regulate the duration o f py 
signalling, independently o f GTPase activity o f the a  subunit.
This hypothesis cannot be considered as a general paradigm for all GPCRs. Indeed, 
in plasma membranes from CHO cells over-expressing the GnRH receptor, GnRH causes 
a negative modulation of the endogenous p subunit mono-ADP-ribosylation reaction. This 
demonstrates specificity in the modulation of the reaction, depending on the receptor type, 
rather than the existence of a general paradigm valid for all GPCRs. Moreover, the 
opposing effects mediated by hormonal modulation suggest that the mechanism involved
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cannot only be ascribed to activation of py dimers upon receptor stimulation. Other 
cellular components could have roles in the regulation o f this process. This aspect was 
investigated by analysis of the mechanisms by which activated receptors modulate 
endogenous mono-ADP-ribosylation. Beyond the dogma o f signalling mediated by 
“GPCR/G-protein-associated effectors”, it has become evident that activation of GPCRs 
can also lead to responses that are not mediated by G proteins. Indeed, a wide variety of 
intracellular molecules are now recognised as interacting with activated GPCRs, and this 
broadens the range o f mechanisms by which these receptors can transduce environmental 
signals (Marinissen and Gutkind, 2001).
In the context of the present study, this suggests that the increase in ADP- 
ribosylation due to thrombin can be ascribed not only to activation o f the subset o f Py 
dimers associated with the PARI receptor, but also to activation (direct or indirect) of the 
ADP-ribosyltransferase.
My data (Figure 3.9) indicate that at the plasma membrane level, the thrombin- 
mediated stimulatory effect is blocked by addition of increasing amounts o f free substrate. 
This suggests that the increase in [32P]-ADP-ribosylated p subunit is due to activation of 
py dimers as consequence of PARI stimulation, and it rules out the possibility that it is a 
consequence o f activation of the ADP-ribosyltransferase. At the same time, these results 
do not exclude the possibility that in intact cells, other cellular component(s) could 
cooperate to regulate the transferases. For the moment, however, no data are available to 
substantiate this hypothesis.
In contrast, the GnRH receptor appears to affect the ADP-ribosyltransferase 
reaction directly, or at least without the intervention of G protein activation. Indeed, it 
leads to activation of Py dimers, but it has a negative effect on the endogenous mono- 
ADP-ribosylation reaction. This aspect will be better elucidated and discussed in Chapter 
4.
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The in vitro receptor modulation of p subunit ADP-ribosylation set the basis for an 
analysis o f the potential modulation of this reaction in living cells. The electrophoretic 
mobility shift of ADP-ribosylated p subunit, equivalent to 500 Da, provide a means of 
detecting p modification in vivo under basal and hormone-stimulated conditions. The shift 
in molecular weight is only just detectable under basal conditions and also only in some 
plasma membrane preparations. This is due to the low proportion of the P subunit that is 
modified under basal conditions (about 0 .2 %, as detected by metabolic labelling of the 
NAD pool with [ H]-adenine). This is itself due to the balance between the transferase and 
the “reverse” ADP-ribosylhydrolase activities. O f course, the hormone-stimulated reaction 
is also affected by the ADP-ribosylhydrolase, and so it is not possible to assess its maximal 
extent without having a good inhibitor. Thus, my data must be considered as basically 
qualitative, but supporting the idea of a basal and hormone-stimulated ADP-ribosylating 
machinery acting on the p subunit. The best estimate of endogenously ADP-ribosylated P 
subunit, determined by comparing the intensities of the P subunit under in vitro and in vivo 
conditions (Figure 3.11), indicates that thrombin treatment o f intact cells induces the 
modification of 1% to 5% of the p subunit. It is possible that this fraction corresponds to 
the Py pool that is coupled to the thrombin receptor.
In conclusion, using the shift approach, I have demonstrated that endogenous 
mono-ADP-ribosylation of the P subunit is modulated by agonists for GPCRs also under 
physiological conditions in living cells. This supports the hypothesis that this reaction 
represents a novel mechanism for the control o f signalling pathways mediated by the py 
dimer.
To establish a more routine method to monitor the extent of hormone modulation 
o f the p subunit ADP-ribosylation reaction, I used a tetanolysin-based cell 
permeabilisation procedure to allow the entry o f [32P]-NAD+. Tetanolysin is a 55-kDa 
member of the streptolysin O family o f cholesterol-dependent pore-forming toxins. These
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pores allow the diffusion of small proteins and molecules and have been used in studies on 
cAMP- and Ca2+-induced effects in T-cell signal transduction (Conti et al., 1993). This 
method has some advantages with respect to the more commonly used streptolysin O, 
since it allows control of the intracellular ionic concentration, it is protease free, and it 
allows the size of the pores to be controlled by varying toxin doses and times of 
incubation.
To establish proof-of-principle for the detection of intracellular ADP-ribosylation, I 
applied PTX. This specifically ADP-ribosylates only Gaj subunits, and resulted in 
selective labelling of aj with [32P]-ADP-ribose. Importantly, in permeabilised cells, there 
was a loss o f about 25% of the endogenous hydrolase (see Section 2.13.2, Figure 2.3B). 
This should have the effect o f partially shifting the equilibrium of the cycle o f ADP- 
ribosylation/de-ribosylation towards the ADP-ribosylated form of the p subunit, making 
analysis o f endogenous mono-ADP-ribosylation in living cells easier. Thus the 
tetanolysin-based approach is not only a useful tool to investigate the existence of 
hormone modulation o f P subunit ADP-ribosylation in living cells, but also for an analysis 
of the role o f this hormone modulation in vivo.
In conclusion, in this Chapter, I have demonstrated that in an in vitro system, 
endogenous mono-ADP-ribosylation is under hormone modulation. More importantly, this 
regulation occurs also in living cells under physiological conditions. This observation 
supports the hypothesis o f a physiological role for this reaction.
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Chapter 4
ADP-ribosylating factor 6 (ARF6) inhibits mono-ADP-ribosylation of the p subunit
4.1 Introduction
ADP-ribosylation o f the p subunit is either enhanced or inhibited by activation of 
GPCRs (Chapter 3) and this suggests that cellular component(s) other than receptors are 
involved in the regulation o f the reaction. This Chapter focuses on the identification o f this 
(these) unknown component(s), starting from what is known about the regulation of ADP- 
ribosylation catalysed by bacterial toxins. As reported in Section 1.3, the ADP- 
ribosyltransferase activity o f CTX requires the presence of cellular proteins, namely ARFs. 
In this light, the relationship between ARFs and endogenous ADP-ribosylation of the p 
subunit was explored. Particular attention was paid to ARF6  because:
• The sub-cellular localization of ARF6  differs from the other ARFs, being mostly 
associated with the plasma membrane;
• ARF6  can interact with GPy subunits, as shown by chemical cross-linking and 
immunoprecipitation (Galas et al., 1997);
• ARF6 -mediated signalling pathways can be activated in response to stimulation of 
several GPCRs (Claing et al., 2001: Mukheijee et al., 2001).
Different approaches were used to investigate the potential involvement o f ARF6 :
i) In vitro assay of ADP-ribosylation in the presence of recombinant ARF6 ;
ii) In vitro assay o f ADP-ribosylation using plasma membranes depleted in 
endogenous ARF6 ;
iii) In vitro assay of ADP-ribosylation in the presence o f peptides that specifically 
inhibit endogenous ARF6 ;
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iv) In vivo assay with permeabilised CHO cells over-expressing ARF6 .
4.2 Recombinant ARF6 inhibits ADP-ribosvIation of the B subunit in vitro
To address whether ADP-ribosylation of p subunit can be modulated by ARF6 , 
plasma membranes were pre-incubated with recombinant ARF6  for 15 min at 37 °C (to 
facilitate the interaction of the protein with the lipid bilayer). ADP-ribosylation was then 
carried out as described in Section 2.5. The presence of ARF6  in the reaction mixture 
caused a marked decrease in [32P]-ADP-ribose-labelling o f the p subunit, as compared to 
the control (Figure 4.1 A, lanes 1 and 2). Under the same experimental conditions, the 
addition of ARF1, or other small G proteins, including Rho, Rac and Cdc42, showed no 
effects (Figure 4.1 A). This result represents the first indication that ARF6  negatively 
regulates ADP-ribosylation of the p subunit. This aspect was further analysed using total 
membrane preparations (25 pg protein/sample) obtained from CHO cells that had been 
transiently transfected with cDNA for ARF6 , or for the dominant-positive ARF6(Q67L) 
and the dominant-negative ARF6(T27N) mutants that mimic the GTP- and GDP-bound 
states, respectively. In parallel, CHO cells were transfected with cDNA for the ARF6 - 
specific exchange factor EFA6  (which is exclusively localised at the plasma membrane 
(Franco et al., 1999), or co-transfected with ARF6  and EFA6 .
The transfection o f ARF6(Q67L) or EFA6  decreased [32P]-labelling o f p (Figure 
4 .IB). A greater inhibition was seen with co-transfection o f ARF6  and EFA6 . This 
indicates that the activated form of ARF6  negatively modulates endogenous mono-ADP- 
ribosylation o f the p subunit. By contrast, the level of ADP-ribosylated p subunit was 
unaffected by transfection o f dominant-negative ARF6(T27N), even though this mutant 
should inhibit activation of endogenous ARF6  by trapping the exchange factors. The 
absence o f effects is probably because the over-expressed mutant is unstable and has a 
tendency to self-aggregate (Macia et al., 2004). As a consequence, only a small proportion
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Figure 4.1. ARF6  inhibits the G protein {3 subunit ADP-ribosylatioe in vitro. A, The 
level of ADP-ribosylated (3 subunit obtained in the presence o f 1 pg of the indicated 
purified proteins, incubated for 60 min at 37 °C with 5 jag CHO plasma membranes and 
[j2P]NAD, as revealed by autoradiography. The data shown are from a single experiment 
that was performed in duplicate, which is representative of at least four independent 
experiments. B, The level of ADP-ribosylated (3 subunit in 25 jag/sample total membranes
T9that over-express the indicated proteins, incubated for 60 min at 37 °C with [ P]-NAD, as 
quantified using an Instant Imager. 250 ng of purified bovine brain were added to the 
experimental mixture to obtain a better signal detection for [3 subunit. The data shown 
represent the means (±SD) of three independent experiments, each performed in duplicate 
(n=6). *p< 0.05, significantly different from the control.
175
of ARF6(T27N) is able to form a stable complex with exchange factors at the plasma 
membrane, and thus to block endogenous ARF6 .
4.3 Depletion of ARF6 from plasma membranes and the effects on ADP-ribosvlation
To substantiate a role o f ARF6  as a negative modulator of ADP-ribosylation of the 
p subunit, conditions that release ARF6  from plasma membranes were sought. Plasma 
membranes from CHO cells were incubated under conditions designed to strip ARF6  from 
the membrane described by Cavenagh (30 min at 4 °C with 500 mM Tris-HCl, pH 7, or 
100 mM sodium carbonate, pH 11, or 1 M NaCl) (Cavenagh et ah, 1996). As an 
alternative, samples were treated to modulate the distribution o f ARF6  between 
membranes and cytosol in CHO cell extracts (30 min at 4 °C with 2.5 mM MgCk) 
(Gaschet and Hsu, 1999), or to destabilise ARF6  binding to membranes (100 pM GDPpS 
for 15 min at 37 °C) (Gaschet and Hsu, 1999). Finally, plasma membranes were treated for 
30 min at 4 °C with Triton X-100 or Nonidet P40 at concentrations (0.1%) that do not 
solubilise the lipid bilayer. After these treatments, the samples were pelletted, washed 
twice in PBS, and the proteins were resolved by SDS-PAGE. The presence of ARF6  was 
revealed by Western blotting using an anti-ARF6  antibody. Upon all these treatments, only 
Triton X-100 caused substantial (~90 %) depletion of endogenous ARF6  from plasma 
membranes (Figure 4.2A). Importantly, under the same conditions, the p subunit was 
retained (Figure 4.2B).
Plasma membranes depleted in ARF6  were then used in assays o f ADP- 
ribosylation. Here, a significant increase in the level of ADP-ribosylated p subunit was 
seen (Figure 4.3). This further confirms that ARF6  interferes with ADP-ribosylation o f the 
p subunit. However, the treatment o f membranes with Triton X-100 might remove 
important component(s) of the endogenous ADP-ribosylation machinery, or in parallel, it
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Figure 4.2. Depletion of ARF6  from  plasma membranes. A, Immunoblotting o f plasma 
membranes treated as indicated, and revealed with an anti-ARF6  antibody. Plasma 
membranes were incubated as indicated, and then pelleted at 13,000xg and washed twice 
in PBS. The samples were resuspended directly in 50 pi PBS and resolved by SDS-PAGE. 
B, Immunoblot o f the same samples as in A, revealed with anti Gp-antibody. The data 
shown are from a single experiment, which is representative o f at least three independent 
experiments.
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Figure 4.3. G protein P subunit ADP-ribosylation in plasma membranes depleted of 
ARF6. The level of ADP-ribosylated p subunit induced by 0.1% Triton X-100 treatment. 
Plasma membranes were treated with the detergent for 30 min at 4 °C, pelletted at 
13,000xg for 15 min at 4 °C, resuspended in ADP-ribosylation buffer, and incubated for an 
additional 60 min at 37 °C with [32P]-NAD in the presence o f control buffer or purified 
ARF6 . The levels of modified p subunit were quantified using an Instant Imager. The data 
shown represent the means (±SD) o f four independent experiments, each performed in 
duplicate (n=8 ). *p< 0.05, significantly different from untreated control (orange column), 
and from samples that were treated with 0.1% Triton X-100 and incubated with 10 and 20 
ng ARF6 .
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might affect the three-dimensional structure of the phospholipid bilayer, thus influencing 
the activity o f the ADP-ribosyltransferase. To test these possibilities, ARF6 -depleted 
plasma membranes were ADP-ribosylated in the presence o f recombinant ARF6  protein. 
This restored the inhibitory effect that was removed by Triton X-100 treatment (Figure 
4.3) so demonstrating that the increase in the amount of modified p subunit is a 
consequence o f the removal of ARF6  from the plasma membranes, and not a non-specific 
effect o f the detergent treatment.
4.4 Mvristovlated peptides block ARF6-mediated inhibition
The involvement o f ARF6  in ADP-ribosylation o f the p subunit was further 
supported by using a myristoylated peptide that corresponds to the amino terminus (N- 
terminus) of ARF6  (MyrARF6 ). Taking advantage of its ability to prevent ARF6 -mediated 
effects, MyrARF6  has been previously used to probe the interaction o f ARF6  in the 
activation of PLD and PIP5K (Honda et al., 1999; Le Stunff et al., 2000) and Ca2+- 
dependent exocytosis (Caumont et al., 1998; Galas et al., 1997).
MyrARF6  was pre-incubated with plasma membranes for 15 min at 37 °C to 
facilitate its interaction with the lipid bilayer and the samples were then used in an in vitro 
assay of ADP-ribosylation. Treatment with MyrARF6  induced a dose-dependent increase 
in labelling of the p subunit (Figure 4.4), confirming that ARF6  acts as a negative 
regulator o f the ADP-ribosylation reaction. By contrast, under the same conditions the 
corresponding non myristoylated peptide (non-MyrARF6 ; Galas et al., 1997) was 
ineffective. This rules out the possibility that the stimulatory effects o f MyrARF6  seen 
here are due to membrane perturbations caused by the amphipathic properties o f the 
amino-acid sequence. However, some studies have shown that defects in membrane 
architecture can be induced by interactions between the acyl chain o f MyrARF6  and PIP2 
(Ge et al., 2001). Thus, to exclude such non-specific effects, myristoylated coenzyme A
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Figure 4.4. G protein (3 subunit ADP-ribosylation in plasma membranes incubated 
with the myristoylated peptide of ARF6. The level of the ADP-ribosylated (3 subunit 
induced by increasing concentrations (5, 25, 50 jiM) of MyrARF6  (green columns) and 
non-MyrARF6  (orange columns). Plasma membranes were incubated with the peptides for 
15 min at 37 °C, and then for an additional 60 min at 37 °C with [32P]-NAD. The level of 
the modified (3 subunit was measured using an Instant Imager. The data shown represent 
the means (±SD) of four independent experiments, each performed in duplicate (n=8 ). *p< 
0.05, significantly different from the control (C).
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Figure 4.5. G-protein p subunit ADP-ribosylation in plasma membranes incubated 
with MyrCoA and MyrARFl. A, The level of the ADP-ribosylated p subunit induced by 
100 jiM MyrCoA, as quantified using an Instant Imager. Plasma membranes were 
incubated with MyrCoA for 15 min at 37 °C, and then for an additional 60 min at 37 °C 
with [32P]-NAD. B, The level of ADP-ribosylated p subunit induced by increasing 
concentrations (5, 25, 50 pM) o f MyrARFl, as quantified using an Instant Imager. Plasma 
membranes were incubated with MyrARFl for 15 min at 37 °C, and then for an additional 
60 min at 37 °C with [32P]NAD. The data shown represent the means (±SD) o f five 
independent experiments, each performed in duplicate (n=1 0 ).
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(MyrCoA) and a myristoylated peptide of ARF1 that specifically blocks the functionality 
of ARF1 (MyrARFl) were tested and MyrCoA was found to be without effect (Figure 
4.5A). By contrast, and unexpectedly, MyrARFl (from 5 to 50 pM) induced an increase in 
P subunit ADP-ribosylation that was comparable to that obtained with MyrARF6  (Figure 
4.5B). This result conflicts with my previous observation that ARF1 is not involved in the 
regulation of ADP-ribosylation of p subunit (Section 4.2.1) and suggests that MyrARF6  
can affect ADP-ribosylation o f the P subunit through a non-specific mechanism. To 
exclude this possibility, plasma membranes depleted of ARF6  were incubated with 
MyrARF6  and MyrARFl. The stimulation induced by the incubation with MyrARF6  was 
completely blocked by Triton X-100 treatment, while the effect o f MyrARFl was only 
partially inhibited (Figure 4.6). This indicates that the effect o f MyrARFl is non-specific, 
while MyrARF6  causes an actual block of endogenous ARF6 .
4.5 ARF6 down regulates ADP-ribosvlation of p suhunit in living cells
To investigate whether ARF6  can also inhibit ADP-ribosylation in living cells, 
experiments were carried out with tetanolysin-permeabilised cells. CHO cells were 
transiently transfected with cDNAs encoding ARF6 , ARF6(Q67L) or ARF6(T27N), or co­
transfected with ARF6  plus its exchange factor EFA6 . After 24 h o f transfection, the cells 
were permeabilised with tetanolysin, incubated with [32P]-NAD+, and analysed for the 
labelling o f p subunit, according to the procedures described in Section 2.13. In cells 
transfected with ARF6  and ARF6(Q67L) or co-transfected with ARF6  and EFA6 , a strong 
inhibition of ADP-ribosylation o f the p subunit (ranging between 50-90%) was seen 
(Figure 4.7A). By contrast, ARF6(T27N) was without effect. In control experiments, 
where CHO cells were transiently transfected with cDNAs for GFP-ARF1 or the 
constitutively-active and inactive forms of ARF1 (GFP-ARF1(Q71L) and GFP-
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Figure 4.6. G-protein P subunit ADP-ribosylation in plasma m em branes treated with 
Triton X-100 and incubated with M yrA R Fl and M yrA RF6 . Plasma membranes, 
untreated (pink columns), or treated with 0.1% Triton X-100 (green columns), were 
incubated for 15 min at 37 °C with 50 pM MyrARFl or MyrARF6 , and then for an 
additional 60 min at 37 °C with [32P]-NAD. The levels of ADP-ribosylated p subunit were 
quantified using an Instant Imager. The data shown represent the means (±SD) of four 
independent experiments, each performed in duplicate (n=8 ).
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ARF1(T31N), respectively), no differences in labelling of the p subunit were seen (Figure 
4.7B). This confirms that ARF6  can also cause negative modulation o f the reaction in 
living cells, and moreover, that this regulation is specifically mediated by the activated 
form of ARF6 .
4,6 ARF6 is involved in GnRH-R-mediated inhibition of ADP-ribosvlation of the B 
subunit
The finding that the activated form of ARF6  can inhibit ADP-ribosylation of the p 
subunit and previous account of the activation of ARF6  by certain GPCRs (Claing et al., 
2001; Mukheijee et al., 2001) led me to evaluate whether ARF6  is involved in the 
inhibition of ADP-ribosylation mediated by the GnRH receptor. Plasma membranes from 
GnRH-CHO cells were depleted of endogenous ARF6  and then ADP-ribosylated in the 
presence of 200 nM GnRH. Under these conditions, the inhibitory effects mediated by 
receptor stimulation were completely blocked (Figure 4.8). Importantly, re-addition of 
purified ARF6  protein restored the inhibition mediated by GnRH. This confirms that 
ARF6  is directly involved in the negative modulation of mono-ADP-ribosylation o f p 
subunit mediated by the GnRH receptor. This was further confirmed using the MyrARF6  
peptide (Figure 4.9). Under resting conditions, incubation with MyrARF6  induced an 
increase in the amount o f modified p subunit that is comparable to that reached in plasma 
membranes o f wild-type CHO cells. This indicates that stable transfection o f the receptor 
did not influence the ability o f MyrARF6  to block endogenous ARF6 . More importantly, 
the incubation o f plasma membranes with MyrARF6  completely blocked the inhibitory 
effect o f GnRH (Figure 4.9). This confirms that negative modulation driven by the GnRH 
receptor involves ARF6 .
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Figure 4.8. Triton X-100-treatment blocks GnRH-mediated inhibition of G protein p 
subunit ADP-ribosylation. The level of ADP-ribosylated p subunit induced by GnRH in 
plasma membranes previously treated with Triton X-100. The samples were treated with 
0.1 % Triton X-100 for 30 min at 4 °C, pelletted at 13,000xg for 15 min at 4 °C, re­
suspended in ADP-ribosylation buffer, and incubated for an additional 60 min at 37 °C 
with [32P]-NAD, in the presence of 200 nM GnRH, and purified ARF6  or control buffer, as 
indicated. The levels of modified P subunit were quantified using an Instant Imager. The 
data shown represent the means (±SD) of three independent experiments, each performed 
in duplicate (n=6 ). *p< 0.05, significantly different from the sample treated with 0.1% 
Triton X-100 and from sample treated with 0.1% Triton X-100, 200 nM GnRH and 20 ng 
ARF6  .
186
250-
200“
1 0 0 -
50“
Myr Arf6 “ +  - +
50 pM v-----------
+ GnRH
Figure 4.9. Myr-ARF6 blocks GnRH-mediated inhibition of the G protein p subunit 
ADP-ribosylation. The level o f the ADP-ribosylated p subunit induced by 200 nM GnRH 
incubated for 60 min at 37 °C with [32P]-NAD, and with CHO plasma membranes 
previously treated with 50 pM MyrARF6  for 15 min at 37 °C. The levels o f modified p 
subunit were quantified using an Instant Imager. The data shown represent the means 
(±SD) o f four independent experiments, each performed in duplicate (n=8 ). *p< 0.05, 
significantly different from the respective untreated controls.
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4.7 ARF6 is activated by the GnRH receptor
The process by which ARF6  and the GnRH receptor regulate ADP-ribosylation of 
the p subunit is not clear. It is reasonable to believe that the pathway initiated upon 
receptor stimulation passes through the activation of ARF6 , which in its GTP-bound form 
leads to a decrease in p subunit labelling. I investigated whether the GnRH receptor 
activates ARF6 . This was carried out using a recently described pull-down assay for 
ARF6 -GTP (Niedergang et al., 2003) that takes advantage of the GTP-dependent 
interaction o f ARF with GGAs (Golgi-localized, y adaptin-ear-containing ARF-binding 
proteins, a family of ARF effector proteins) (Boman et al., 2000; Dell'Angelica et al., 
2000; Hirst et al., 2000). To precipitate GTP-bound ARF6 , a recombinant GST-fusion 
protein containing the ARF binding domains of GGA3 (GST-GGA3) was purified from 
bacteria (Section 2.10.2). The specificity o f this assay was tested using cell extracts 
obtained from GnRH-CHO cells that were previously transfected with the ARF6(Q67L) 
and ARF6(T27N) mutants. Twenty-four h after transfection, cell lysates were prepared and 
incubated with GST-GGA3 and the protein complexes were then pulled-down with a 
glutathione resin (Section 2.11) and analysed using an ARF6 -specific antibody. 
ARF6(Q67L) was recognised and bound by GST-GGA3, whereas the GDP-bound mutant, 
ARF6(T27N), was not (Figure 4.10A).
The same procedure was then used to evaluate the activation o f ARF6  upon 
stimulation of GnRH-CHO cells with GnRH. The cells were transfected with cDNA 
encoding for ARF6  and 24 h after transfection the cells were stimulated with GnRH or 
control buffer. Stimulation with GnRH caused a significant increase in the amounts of 
ARF6 -GTP compared with the control (Figure 4.10B). This result reveals a previously 
unknown pathway o f activation of ARF6  that is mediated by the GnRH receptor that will 
contribute to a better definition of the regulatory mechanisms by which ARF6  controls 
mono-ADP-ribosylation o f the p subunit.
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Figure 4.10. ARF6  is activated by GnRH receptor stimulation. A, GST-GGA3 
recognises the activated form of ARF6 . CHO cells were transfected with ARF6(Q67L) 
(lanes 1, 3 and 4) and ARF6(T27N) (lanes 2, 5 and 6 ). Lysates (lanes 1 and 2) were 
prepared and incubated with GST-GGA3 (lanes 4 and 6 ) or GST alone (lanes 3 and 5). The 
bottom panel shows the immunoblot performed with an anti-ARF6  antibody, the upper 
panel shows the total protein pattern, as revealed by Ponceau Red staining. B, CHO cells 
were transfected with ARF6  and incubated with 20 nM GnRH or control buffer for 15 min 
at 37 °C. Lysates from unstimulated (lane 1) and stimulated (lane 2 ) cells were prepared 
and incubated with GST-GGA3. The immunoblot analysis was performed with an anti- 
ARF6  antibody. The bottom panel shows aliquots o f total lysates. The data are from a 
single experiment carried out in duplicate, and are representative o f three independent 
experiments.
The activation of ARF6  mediated by GPCRs like LH/CG and FSH receptors 
involves exchange factors for ARF6 , such as ARNO (Mukheijee et al., 2000). To 
determine whether activation of ARF6  resulting from GnRH receptor stimulation also 
involves an exchange factor, GTP-binding assays were performed. Recombinant ARF6  
and ARNO were incubated with GnRH-CHO plasma membranes and stimulated with 
GnRH. The rate o f GTPyS binding was evaluated as described in Section 1.14, and the 
results are shown in Figure 4.11. Simultaneous incubation o f plasma membranes with 
ARF6  and ARNO caused an increase in binding of GTPyS with respect to ARF6  alone, 
indicating that the GnRH receptor probably activates ARF6  through activation of an 
exchange factor. This is in line with my previous observations with membranes from 
transfected cells where the strongest inhibitory effect on ADP-ribosylation was achieved 
by co-transfection with ARF6  and EFA6  (Section 4.2.1).
4.8 Discussion
The experiments described show that endogenous mono-ADP-ribosylation o f the p 
subunit can directly regulate signal transduction mediated by Py dimer. To validate this 
hypothesis, particular attention was given to the mechanisms by which the reaction is 
modulated. As shown in Chapter 3, the ADP-ribosylation reaction can be differently 
modulated by activation of GPCRs, revealing that the regulatory mechanisms controlling 
the ADP-ribosyltransferase activity might involve unknown cellular component(s), other 
than G proteins and GPCRs. Putative candidates here are the members o f the ARF family, 
due to their ability to modulate the ADP-ribosyltransferase activities o f certain bacterial 
toxins (Kahn and Gilman, 1986; Lee et al., 1991). Its localisation at the plasma membrane 
and its ability to interact with Py dimers make ARF6  the most plausible modulator from 
among the various ARFs. On this basis, the role of ARF6  on endogenous ADP- 
ribosylation of the p subunit was analysed using approaches aimed at enhancing or
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Figure 4.11. The activation of ARF6  induced by G nRH  receptor is m ediated by 
ARNO. A, Level o f [35S]GTP-yS binding in plasma membrane o f GnRH-cells incubated 
with the indicated purified proteins and stimulated with 200 nM GnRH, as measured using 
an p-counter. The data shown represent the means (±SD) o f five independent experiments, 
performed in duplicate (n=10). *p< 0.05, significantly different from the sample incubated 
with ARF 6 .
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inhibiting ARF6  activity. The activated form of ARF6  was found to modulate ADP- 
ribosylation of the p subunit negatively. In particular, an almost total inhibition of the 
reaction was obtained in vivo with co-overexpression of ARF6  and its exchange factor 
EFA6 , while there was a weaker effect with the constitutively activated ARF6(Q67L) 
mutant. This is in line with several observations that demonstrate that many functions 
mediated by ARF6  require its continued cycling between its GTP- and GDP-bound forms, 
instead o f the permanently activated state (Claing et al., 2001; Hashimoto et al., 2004; 
Zhang et al., 1998)and Section 1.3.3).
In the second part of this Chapter, I demonstrated that activated-ARF6  has a pivotal 
role in the negative modulation of ADP-ribosylation o f the p subunit induced by GnRH. In 
an attempt to elucidate this point further, I found that ARF6  becomes activated as a 
consequence of GnRH receptor stimulation and that this pathway probably involves an 
exchange factor for ARF6 . This is in agreement with the observation that guanine 
nucleotide exchange activity o f ARNO is obligatory for the activation o f ARF6  mediated 
by other receptors such as the LH/CG receptor or the FSH receptor (Salvador et al., 2001).
In conclusion, the results reported in this Chapter provide direct evidence that 
ARF6  is a crucial modulator o f endogenous mono-ADP-ribosylation o f the p subunit, and 
they contribute to a better definition o f how this regulation is achieved. As shown in 
Figure 4.12, stimulation of the GnRH receptor leads to activation o f ARF6  through 
involvement of an exchange factor. Upon activation, ARF6  can negatively modulate 
mono-ADP-ribosylation. As the data reported provide only a qualitative picture o f the 
inhibitory effects mediated by ARF6 , without explaining the mechanisms by which ARF6  
controls ADP-ribosylation, this aspect will be further explored and discussed in Chapter 5.
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Figure 4.12. Model of ARF6 -mediated inhibition of endogenous mono-ADP- 
ribosylation of the P subunit. Stimulation of the GnRH receptor with its specific agonist 
leads to activation of ARF6 through the involvement of an exchange factor (ARF-GEF). 
Upon activation, ARF6 can negatively modulate mono-ADP-ribosylation.
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Chapter 5
Regulation of ARF6-mediated inhibition of mono-ADP-ribosylation of the p subunit
5.1 Introduction
The experiments described in Chapters 3 and 4 have demonstrated that ADP- 
ribosylation o f the p subunit in living cells is regulated by a multifaceted and integrated 
pathway involving GPCRs and ARF6 . The mechanism by which ARF6  exerts its inhibitory 
effect on the reaction will now be addressed. Different potential mechanisms need to be 
taken in consideration (see also Figure 5.1) since ARF6  might:
(i) reduce the P-NAD+ available for the reaction;
(ii) sequester the Py dimer, making it inaccessible to the ADP-ribosyltransferase;
(iii) interact (directly or indirectly) with the ADP-ribosyltransferase, acting as an 
inhibitor o f its activity.
In the next Sections these possibilities will be explored.
5.2 ARF6 does not alter availability of B-NAD+ or sequester the By dimers
ARF6  might induce a decrease in the amounts o f p-NAD+ available to the ADP- 
ribosyltransferase in the following ways:
(i) enhancement of p-NAD+ degradation;
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Figure 5.1. Possible mechanisms by which ARF6 modulates ADP-ribosylation of the p 
subunit. See text for more details.
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(ii) consumption o f p-NAD+ through an auto-ADP-ribosylation process;
(iii) alteration in the redox equilibrium between NAD+ and NADH.
To determine whether ARF6  alters the degradation pathway o f p-NAD+, plasma
3 9membranes were [ P]-ADP-ribosylated in the presence of recombinant ARF6  or control 
buffer. After incubation, 3 pi of each sample were analysed by TLC for p-NAD+ 
metabolites (Section 2.16), with the remaining sample analysed by SDS-PAGE and 
electroblotting (Section 2.4). Under these conditions, ARF6  induced a significant inhibition 
of labelling of the P subunit (Figure 5.2A), while it did not affect the pattern of P-NAD+ 
metabolites (Figure 5.2B). This demonstrates that the ARF6 -mediated inhibitory effect on 
mono-ADP-ribosylation is not due to alterations o f p-NAD+ metabolism. This is supported 
by the direct incubation of recombinant ARF6  with p-NAD+, where ARF6  caused no 
depletion o f NAD+ (Figure 5.3A). In addition, under the same conditions, any significant
39[ P]-labelling of ARF6  would be revealed by the autoradiography, indicating that ARF6  
does not consume P-NAD+ via an auto-ADP-ribosylation reaction (Figure 5.3B).
ARF6  might also inhibit ADP-ribosylation of the p subunit by altering the redox 
ratio, enhancing NADH at the expense o f NAD+. To test this, plasma membranes were 
incubated with recombinant ARF6  (or control buffer) and the nucleotide content profiles 
analysed by HPLC (Section 2.15). The presence o f ARF6  had no effect on the 
concentration o f NADH (Figure 5.4) so ruling out the possibility that a shift from p-NAD+ 
to NADH could be responsible for the ARF6 -mediated inhibition o f the ADP-ribosylation 
reaction.
Finally, ARF6  might form a complex with the Py dimer, thus reducing its 
accessibility to the ADP-ribosyltransferase. A physical interaction between ARFs and py
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Figure 5.2. ARF6  does not alter the metabolism of p-NAB+ in m em branes from CHO
cells. A, The level of ADP-ribosylated p subunit in the absence and presence of 2.5 jag 
ARF6, incubated for 60 min at 37 °C with 5 pg/sample CHO plasma membranes and [32P]- 
NADf, as revealed by autoradiography. B, The degradation pattern o f p-NAD+ incubated 
in the presence of 5 pg/sample plasma membranes without or with 2.5 pg ARF6, for 60 
min at 37 °C, as revealed by autoradiography of a TLC plate. Data shown are from a single 
experiment that was performed in duplicate, and which is representative of at least three 
independent experiments.
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Figure 5.3. ARF6  does not degrade P-NAO+ and it does not catalyse auto-ADP- 
ribosylation. A, The degradation pattern of (3-NAD+ incubated without and with 2.5 pg 
ARF6, for 60 min at 37 °C in ADP-ribosylation buffer, as revealed by autoradiography o f a 
TLC plate. B, The level of ADP-ribosylated ARF6 obtained incubating 2.5 pg ARF6 in the 
presence of [ ,2P]-NAD+ and ADP-ribosylation buffer without or with 5 pg/sample plasma 
membranes, as revealed by autoradiography. The data shown are from a single experiment 
that was performed in duplicate, and which is representative of at least three independent 
experiments.
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Figure 5.4. ARF6 does not change the equilibrium between NAD+ and NADH. The
contents o f NAD+ and NADH in 5 jig/sample plasma membranes incubated in control 
buffer or with lpg  purified ARF6 , as determined by HPLC analysis. The nucleotide elution 
profile was checked by co-elution with commercially available standards. This experiment 
was done in collaboration with Cristiano Iurisci (Laboratory o f Cell Regulation, 
Department o f Cell Biology and Oncology, Consorzio Mario Negri Sud). The data shown 
are from a single experiment that was performed in duplicate, and which is representative 
o f at least three independent experiments.
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dimers has previously been demonstrated both in vivo and in vitro, and shown to be 
mediated by the GDP-bound form of ARF6  (Colombo et al., 1995; Franco et al., 1995; 
Galas et al., 1997) Section 1.1.3.6 . These observations are not in line with my own in which 
the inhibition o f ADP-ribosyltransferase activity is mediated by the activated form of ARF6  
(Section 4.2.1). Therefore, it is unlikely that the mechanism by which ARF6  negatively 
modulates ADP-ribosylation of the p subunit arises from depletion o f Py dimer available for 
the enzyme.
5.3 ARF6 acts as a classical inhibitor for ADP-ribosvlation of the B subunit
It remains to be considered whether ARF6  can modulate the activity o f the ADP- 
ribosyltransferase by acting as a classical inhibitor. Here ARF6  might:
(i) bind the ADP-ribosyltransferase in its active site, competing with the binding of 
Py (competitive inhibition);
(ii) bind the ADP-ribosyltransferase away from the active site (non-competitive 
inhibition);
(iii) bind the Py-ADP-ribosyltransferase complex to produce an inactive 
conformation (uncompetitive inhibition);
(iv) activate another cellular component that, in turn, inactivates the ADP- 
ribosyltransferase.
To discriminate between these hypotheses, a kinetic analysis was carried out. As a 
first step, the inhibitor binding constant (Kj) that quantifies the strength o f the complex 
formed between the ADP-ribosyltransferase and ARF6  was evaluated. In vitro assays o f 
ADP-ribosylation were carried out in the presence o f increasing amounts o f recombinant 
ARF6  (0 to 1,000 ng), and plasma membranes as the source o f the py dimer and the
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enzymatic activity. The result is shown in Figure 5.5, where the percentage inhibition of p 
subunit labelling is given as a function of the increasing concentrations o f ARF6 . The Kj 
for ARF6  (84 ± 20 nM) was obtained from an analysis using Graph Pad PRISMA 
software. Under these conditions, the maximum inhibitory effect only reaches a 35-40% 
decrease in labelling o f the p subunit. This is lower than the inhibition that occurred in 
CHO cells co-transfected with cDNA for ARF6  and EFA6  or transfected with 
ARF6(Q67L) (Sections 4.2.1 and 4.2.4). Since the ARF6  used in the present experiments 
was purified in its GDP-bound form (Section 2.10.3), it is possible that it lost some o f its 
activity on the ADP-ribosyltransferase. Probably the endogenous exchange factor present 
in the plasma membrane samples was insufficient to activate all the exogenous ARF6 . To 
obtain a real estimate o f IQ, it will be useful to carry out similar experiments using both 
recombinant ARF6  and recombinant exchange factor. This point is currently under 
investigation.
5.3.1 A R F 6 acts as a competitive inhibitor
Measurements o f the rates o f catalysis at different concentrations o f substrate and 
inhibitor serve to distinguish between competitive and non-competitive mechanisms. Thus, 
different concentrations of ARF6  were tested in an in vitro assay o f ADP-ribosylation in the 
presence of increasing amounts of the py dimer. Inhibition mediated by ARF6  was 
counteracted by addition of py subunit (Figure 5.6), revealing a competitive mechanism, 
where the inhibitor can block the enzyme or can act as an alternative substrate. In my 
system, this latter possibility is supported by evidence that in ADP-ribosylated plasma 
membranes there is a significant [ P]-labelling of a ~20-kDa protein corresponding to 
ARF6 , as revealed by Western blotting with a specific anti-ARF6  antibody. Interestingly, 
when 1 pg purified ARF6  or ARF1 are ADP-ribosylated under the same conditions, strong 
labelling is observed only for ARF6  (Figure 5.7A). The selectivity between these
eis
■ fisce
CQ. /-*>> fl
J5 2
O fl 
p f i  —
50
40
30
20
10
0
0 250 500 750 12501000
Arf6  concentration (ng)
Figure 5.5. Kinetics of inhibition m ediated by ARF6  on the P subunit ADP- 
ribosylation. The level o f inhibition o f p subunit ADP-ribosylation induced by increasing 
concentrations o f purified ARF6 , as quantified using an Instant Imager. Plasma membranes 
(5 pg/sample) were incubated for 15 min at 37 °C with ARF6 , and then for an additional 
60 min at 37 °C with [32P]-NAD+. The data shown represent the means (±SD) o f six 
independent experiments, each performed in duplicate (n=1 2 ).
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Figure 5.6. Inhibitory effect of ARF6 is blocked by increasing concentrations of the py 
dimer. The level of inhibition o f P subunit ADP-ribosylation induced by ARF6  in the 
presence of increasing concentrations of purified bovine brain Py dimer. Plasma 
membranes (5 pg/sample) were incubated for 15 min at 37 °C with 20 ng, 100 ng or 2 0 0  
ng ARF6 , and then for an additional 60 min at 37 °C in the presence o f [32P]-NAD+ and the 
Py dimer (ranging from 100 to 500 ng). The levels of p subunit ADP-ribosylation were 
quantified using an Instant Imager. The data shown represent the means (±SD) o f three 
independent experiments, each performed in duplicate (n=6 ) *p< 0.05, significantly 
different from the respective controls.
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ARFs parallels the selective ability of ARF6 to inhibit the mono-ADP-ribosylation reaction. 
[32P]-labelling also occurred in permeabilized cells over-expressing ARF6 (Figure 5.7B). 
Notably, only the activated form of ARF6 is labelled, while ARF6(T27N) was not. This 
parallels the ability o f the GTP-bound form of ARF6 to inhibit endogenous ADP- 
ribosylation of the p subunit. Together, these observations support the idea that the 
activated form of ARF6 can substitute py in the catalytic site o f the mono-ADP- 
ribosyltransferase.
5.3.2 A R F 6 is ADP-ribosvlated by an enzymatic activity
To confirm the hypothesis that ARF6 acts as an alternative substrate, it is necessary 
to verify that ADP-ribosylation of ARF6 is due to enzymatic catalysis and not due to 
formation o f adducts with the ADP-ribose generated by cellular NADases. Thus, 
recombinant ARF6 was incubated in ADP-ribosylation buffer (without p-NAD+) in the 
presence o f free [32P]-ADP-ribose (Section 2.7). The absence o f [32P]-labelling o f ARF6 
under these conditions ruled out the existence o f a non-enzymatic ADP-ribosylation 
reaction (Figure 5.8). Moreover, recombinant ARF6 is not modified by incubation with 
[32P]-NAD+ in the absence of plasma membranes (Figure 5.3B) demonstrating that 
labelling of ARF6 is not due to non-specific binding of [32P]-NAD+. Overall these results 
reveal that ARF6 is ADP-ribosylated by an enzyme-catalysed process. Possibly related to 
this is the observation (Galas et al., 1997) that in two-dimensional gel electrophoresis of 
purified chromaffin granule membranes, an anti-ARF6 antibody revealed the presence of 
two spots having different isoelectric points that are compatible with the ribosylated and 
un-ribosylated forms o f ARF6.
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Figure 5.7. ARF6 Is [32P]-labeIled both in vitro and in vivo. A, Bottom panel: labelling 
of purified ARF6 and ARFl incubated for 60 min at 37 °C with 5 pg/sample CHO plasma 
membranes and [j2P]-NAD+, as revealed by autoradiography. The upper panel shows the 
protein content of the same samples, as revealed by Ponceau Red staining. B, Labelling of 
over-expressed ARF6, dominant-positive ARF6 (ARF6DP) and dominant-negative ARF6 
(ARF6DN), and of ARF6 co-expressed with EFA6. The CHO cells were transfected with 
the indicated constructs for 24 h, permeabilised with tetanolysin, and incubated at 37 °C 
for an additional 60 min with [32P]-NAD+ and 100 pM GTPyS. The bottom panel shows 
ARF6 in the same samples, as revealed by Western blotting with an anti-ARF6 antibody. 
The data shown are from single experiments that were performed in duplicate, which are 
representative of at least three independent experiments.
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Figure 5.8, ARF6 is ADP-ribosylated by an enzymatic activity. Level o f ADP- 
ribosylated ARF6 following incubation for 60 min at 37 °C with 5 pg/sample CHO plasma 
membranes and 3 pCi/sample [j2P]-NAD+, or with 3 pCi/sample [32P]-ADP-ribose, as 
revealed by autoradiography. The top panel shows the immunoblot with an anti-ARF6 
antibody. The bottom two panels represent two different exposure times for the 
autoradiography. The data shown are from a single experiment that was performed in 
duplicate, which is representative of four independent experiments.
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5.3,3 ARF6 is mono-ADP-ribosvlated
To exclude the possibility that ARF6 is modified by attachment of a poly-ADP- 
ribose chain, an inhibitor for arginine-specific mono-ADP-ribosyltransferases, MIBG, was 
tested (Loesberg et al., 1990; Smets et al., 1990). Plasma membranes were used to ADP- 
ribosylate recombinant ARF6 in the presence of MIBG or control buffer. Under these 
conditions, ADP-ribosylation o f ARF6 was strongly inhibited (Figure 5.9A), confirming 
that the enzyme reaction occurs on arginine and is mediated by a mono-ADP- 
ribosyltransferase. This was further supported by the reversal o f the ADP-ribosylation o f 
ARF6 by cytosolic ribosylarginine hydrolase, which removes single (but not poly-) ADP- 
ribose moieties attached to proteins (Figure 5.9B; Section 2.6). This demonstrates not only 
that ARF6 undergoes mono-ADP-ribosylation on arginine, but also that the complete cycle 
of mono-ADP-ribosylation/ de-ADP-ribosylation is active on ARF6, as it is for the p 
subunit.
At this point, it is important to understand whether a unique enzyme is responsible 
for both p subunit and ARF6 ADP-ribosylation. This aspect is complicated by the lack of 
characterisation of the enzyme involved. To overcome this, I tested whether the two ADP- 
ribosylation reactions are similarly modulated by inhibition and activation o f the 
transferase activity. First, the inhibitory effects mediated by MIBG were quantified. 
Plasma membranes as a source of enzyme were used to modify purified Py dimer and 
recombinant ARF6 in the presence of MIBG, which significantly inhibited ribosylation of 
both proteins to the same extent (Figure 5.10).
In parallel, positive modulators of p subunit ADP-ribosylation were tested. As 
shown earlier (Section 3.2) Mas7 and thrombin increase the [32P]-labelling o f p subunits, 
although through different mechanisms. The stimulation of the PARI receptor leads to 
activation of Py dimers that become substrates o f the endogenous ADP-ribosyltransferase, 
while Mas7 enhances the reaction through both a direct effect on the ADP-
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Figure 5.9. ARF6 is mono-ADP-ribosylated by an enzymatic activity. A, The level of 
ADP-ribosylated ARF6 obtained in the absence and presence of 200 jiM MIBG, incubated 
for 60 min at 37 °C with 5 pg/sample CHO plasma membranes and [32P]-NAD+, as 
revealed by autoradiography. The bottom panel shows the immunblot with an anti-ARF6 
antibody of the same nitrocellulose filter. B, The level of ADP-ribosylated ART6 in the 
absence and presence of 50 pg cytosol, as revealed by autoradiography. Plasma 
membranes (5 pg/sample) were incubated for 60 min at 37 °C with [j2P]-NAD+, and then 
for an additional 60 min at 37 °C with cytosol from CHO cells. The bottom panel shows 
the immunblot with an anti-ART6 antibody of the same nitrocellulose filter. The data 
shown are from single experiments performed in duplicate, which are representative of 
four independent experiments.
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Figure 5.10. ARF6 mono-ADP-ribosylation is inhibited by treatm ent with M IBG. The
levels of ADP-ribosylated ARF6 (green columns) and p subunit (blue columns) obtained in 
the absence and presence of 200 pM MIBG, incubated for 60 min at 37 °C with 5
32 -j-pg/sample CHO plasma membranes and [ P]-NAD , as quantified using an Instant 
Imager. The data shown represent the means (±SD) of five independent experiments, each 
performed in duplicate (n=10). *p< 0.001, significantly different from the respective 
untreated samples.
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ribosyltransferase and activation o f G proteins (Section 3.2.3). Thus, Py dimer and ARF6 
were ADP-ribosylated under basal condition and in the presence o f thrombin or Mas7. A 
significant increase in mono-ADP-ribosylation o f ARF6 occurred with Mas7, but not with 
thrombin (Figure 5.11) indicating that the activation of heterotrimeric G proteins is 
ineffective for ARF6 ADP-ribosylation. The strong labelling of ART6 obtained with Mas7 
can be ascribed to its ability to activate the ADP-ribosyltransferase. From a quantitative 
point of view, the increase in ART6 labelling due to Mas7 (~85%) is comparable to the 
enhancement of labelling of p subunits insensible to PTX (Section 3.2.3; Figure 3.7). Thus 
Mas7 stimulates ADP-ribosylation of ARF6 and Gp to similar extents giving further 
support to the conclusion of a single enzymatic activity acting on both these substrates.
Overall, these findings support a model in which, once ARF6 is activated it can 
substitute for the p subunit at the catalytic site of the endogenous ADP-ribosyltransferase. 
If this is correct, then we can predict that stimulation of the GnRH receptor that activates 
ARF6 (Section 4.7) should lead to a decrease in the labelling o f the p subunit, and in 
parallel, to an increase in ADP-ribosylation o f ARF6. To test this, 15 ng purified ARF6 (a 
concentration that can be easily revealed by autoradiography, but that is insufficient to 
inhibit ADP-ribosylation of the p subunit; Figure 5.4) was ADP-ribosylated in the presence 
o f plasma membranes from GnRH-CHO cells incubated with GnRH or control buffer. The 
decrease in ADP-ribosylation o f the p subunit that occurred upon stimulation with GnRH 
corresponds to a comparable increase in labelling of ARF6 (Figure 5.12).
For final confirmation that ARF6 substitutes for the p subunit in the catalytic site of 
the endogenous transferase, all the experiments reported here need to be repeated using a 
purified preparation of the ADP-ribosyltransferase enzyme. In addition, one would predict 
that the Km values for the two ADP-ribosyltransferase activities, determined for the 
common substrate NAD+, should be the same if  a single enzyme modifies both ARF6 and
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Figure 5.11. ARF6 mono-ADP-ribosylation is modulated by Mas7, bu t not by 
throm bin. The level of ADP-ribosylated ARF6 (green columns) and P subunit (blue 
columns) obtained in the absence and presence o f 25 pM Mas7 or 10 IU/ml thrombin, 
incubated for 60 min at 37 °C with 5 pg/sample CHO plasma membranes and [32P]-NAD4, 
as quantified using an Instant Imager. The data shown represent the means (±SD) o f four 
independent experiments, performed in duplicate (n=8). *p< 0.05, significantly different 
from the respective untreated samples.
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Figure 5.12 ARF6 ADP-ribosylation is induced by stimulation of the G nRH  receptor.
The level of ADP-ribosylated ARF6 (green columns) and p subunit (blue columns) 
obtained in the absence and presence of 200 nM GnRH, incubated for 60 min at 37 °C with 
5 pg/sample GnRH-CHO plasma membranes and [32P]-NAD+, as quantified using an 
Instant Imager. The data shown represent the means (±SD) of three independent 
experiments, each performed in duplicate (n=6). *p< 0.05, significantly different from the 
respective untreated samples.
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the p subunit. Measurements of the apparent Km were therefore carried out using plasma 
membranes as the source of enzymatic activity in the presence o f increasing concentrations 
o f p-NAD+ and saturating concentrations of either ARF6 or py dimer. The results are 
shown in Figure 5.13A, the kinetic constants were determined giving apparent Km of 216.3 
±17.5 pM and 80.4 ±8.2 pM for the Py dimer and ARF6, respectively (Figure 5.13B). This 
result suggests the existence o f two different enzymes that catalyse ADP-ribosylation of 
ARF6 and the p subunit and conflicts with my previous observations that ARF6 down- 
regulates ADP-ribosylation of the p subunit by acting as a competitive inhibitor. However, 
there are alternative explanations, as discussed in next Section.
5.4 Discussion
In this Chapter, the mechanism by which ARF6 is able to inhibit endogenous 
mono-ADP-ribosylation of the p subunit has been investigated. I first excluded that ARF6 
acts via subtraction o f p-NAD+ or sequestering o f the Py dimers. Instead, the data suggest 
that ARF6 inhibits the ADP-ribosyltransferase by displacement o f the Py dimer from the 
catalytic site, acting as a competitive inhibitor. This conclusion is supported by the 
demonstration that increasing concentrations o f py overcome the ARF6-mediated 
inhibitory effect. In addition, I have shown that ARF6 is itself a substrate o f an endogenous 
mono-ADP-ribosylation reaction that is modulated by an activator (Mas7) and an inhibitor 
(MIBG) of the enzyme that ADP-ribosylates p subunit. An approximate quantification of 
the extent of labelling of the two substrates revealed that ARF6 is preferred, being ADP- 
ribosylated to a level twice that of the p subunit (Figure 5.13). This is not inconsistent with 
the idea that a single ADP-ribosyltransferase is involved. However, this conclusion was not 
supported by the finding that the Km values for P-NAD+ are different for the two activities. 
There are several possibilities that might explain these conflicting results:
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Figure 5.13 Kinetic investigation of ADP-ribosylation of ARF6 and the P subunit. A,
Picomoles o f ADP-ribosylated ARF6 (pink triangles) and P subunit (blue rectangles) 
calculated in the presence o f increasing concentrations o f p-NAD+, incubated for 60 min at 
37 °C with 5 pg/sample CHO plasma membranes and [32P]-NAD+, as quantified using an 
Instant Imager. The picomoles were calculated as reported in Section 2.5.2. The data 
shown represent the means (±SD) o f five independent experiments, each performed in 
duplicate (n=10). B, Kinetic parameters as calculated according to Eadie-Hofsee theory 
using GraphPad SIGMA software.
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• the interactions of ARF6 or the p subunit with the ADP-ribosyltransferase might 
differently affect the ternary structure o f the enzyme, thus leading to different 
three-dimensional rearrangements o f protein domains. As a consequence, the 
affinity for p-NAD+ might change. This hypothesis is supported by studies on the 
ARTs, which have demonstrated that certain amino-acid sequences outside the 
NAD+-binding site can differently modulate the affinity for the substrate and the 
catalytic activity of the entire enzyme (Bourgeois et al., 2003). Thus the activity of 
my ADP-ribosyltransferase could also be influenced by such protein domains. At 
present there are no data to substantiate this idea.
• the catalytic mechanisms that mediate ADP-ribosylation of ARF6 and the P subunit 
may actually be different. Bisubstrate kinetic analyses have indicated that many 
enzymes using p-NAD+ as a substrate (such as lactate dehydrogenase, CTX, ARTs 
and sirtuins) exhibit sequential mechanisms of catalysis in which all the substrates 
bind to the enzyme to form a ternary complex with the enzyme, prior to any 
catalytic step (Borra et al., 2004; Larew et al., 1991; Osborne et al., 1985). Since 
sequential mechanisms can be ordered (in which the substrates bind the enzyme in 
a defined sequence) or random (in which the order o f addition o f substrates is 
random), my ADP-ribosyltransferase might use different mechanisms that depend 
on the substrate (ARF6 or the p subunit) resulting in different affinity for p-NAD+.
• the method used to calculate Km constants might provide erroneous values. Indeed, 
Km values were extrapolated from the picomoles o f ARF6 and Py that were 
modified in the presence of increasing concentrations of p-NAD+. The labelling of 
P subunits was calculated on the understanding that binding o f ADP-ribose occurs 
only on a single arginine, as previously demonstrated in mutagenesis experiments 
for the p subunit (Section 2.5.2; Lupi et al., 2000). The same principle was applied 
in the estimation of ADP-ribosylation o f ARF6. However, it cannot be excluded
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that the enzyme catalyses addition of ADP-ribose on multiple arginine residues. 
This mono-ADP-ribosylation at multiple sites would certainly cause problems with 
the calculations of Km values for P-NAD+.
• plasma membranes (used as the source o f enzyme) might contain or lack specific 
components that are able to influence the affinity o f the endogenous ADP- 
ribosyltransferase for p-NAD+. In addition the simultaneous presence o f ARF6 and 
the p subunit in plasma membranes could also affect Km estimation.
To discriminate between these different possibilities, kinetic analyses must be repeated 
using purified proteins. In parallel, it will be important to achieve a better characterisation 
o f the ADP-ribosylation of ARF6, in order to specify the arginine residue(s) that is/are 
modified. For the present, the Km values reported here must be taken as only indicative. By 
contrast, my other results are fully consistent with a model in which once activated by the 
GnRH receptor, ARF6 interacts with the transferase and reduces the extent o f p subunit 
mono-ADP-ribosylation through a competitive mechanism (Figure 5.14). An intriguing 
aspect that also arises is the existence of a reversible ADP-ribosylation reaction that is 
active on ARF6. ARF6 is modified only when it is bound to GTP and thus in the form that 
mediates ARF6 functions. It is plausible that the ARF6 ADP-ribosylation/ de-ADP- 
ribosylation cycle modulates its functionality, as has been described for the Py dimer. 
Thus, mono-ADP-ribosylation might represent a general mechanism for regulation o f a 
variety of cellular proteins involved in signalling pathways initiated by GPCRs.
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Figure 5.14 Model for inhibition of G-protein p subunit mono-ADP-ribosylation 
mediated by ARF6. Once activated by the GnRH receptor via an exchange factor, ARF6 
interacts with the ADP-ribosyltransferase and down-regulates p subunit mono-ADP- 
ribosylation. In parallel, ADP-ribosylation takes place on ARF6. The modified ARF6 then 
serves as substrate for a cytosolic ADP-ribosylhydrolase, which regenerates native ARF6. 
The cycle of ADP-ribosylation/ de-ADP-ribosylation of ARF6 might modulate its 
functionality, as has been described for the py dimer.
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Chapter 6
In search of a physiological role for p subunit mono-ADP-ribosylation: the 
degradation pathway of the Py dimer mediated by ubiquitylation
6.1 Introduction
In previous Chapters, I have defined a multifaceted pathway that regulates 
endogenous mono-ADP-ribosylation of the p subunit. The physiological significance of 
this reaction remains to be properly defined. My data suggest that ADP-ribosylation 
influences cellular functions that are mediated by Py dimers and/or reactions or pathways 
in which py dimers act as substrates. One of these is the process o f Py degradation that 
occurs via the ubiquitin proteosome pathway (UPP) (see also Section 1.1.4.2). The UPP 
consists of a series o f reactions that are catalysed by three classes o f enzymes: ubiquitin- 
activating enzyme, ubiquitin-conjugating enzyme and ubiquitin ligase. These allow the 
attachment o f ubiquitin chains to one or more lysines in a target protein (Miller and 
Gordon, 2005). The transducin y subunit is one of the targets o f the UPP and its 
ubiquitylation coincides with degradation of the entire Py dimer. The process is inhibited 
by interaction of the Py with phosducin, which probably acts as a protective factor for Py 
upon light-dependent activation (Obin et al., 2002; Obin et al., 1994). Interestingly, a two- 
hybrid screening approach performed by Dr. M. Sallese in our Department has shown that 
a ubiquitin ligase interacts with the p subunit. These observations lead to the idea that the 
mono-ADP-ribosylation reaction can operate like phosducin to preserve the Py dimer from 
degradation. The ADP-ribosylated form of the p subunit might be unable to form a 
complex with the ubiquitin ligase enzyme and therefore prevent Py dimers from entering
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the degradation pathway (Figure 6.1).
This hypothesis was tested using:
i) Co-immunoprecipitation assays, to confirm the interaction between the py
dimer and ubiquitin ligase;
ii) Co-immunoprecipitation assays using pre-ADP-ribosylated p subunits, to
evaluate the influence o f ADP-ribosylation on the interaction between the py
dimer and ubiquitin ligase.
6.2 By interacts with the ubiquitin ligase c-cbl. and this interaction is not affected by 
ADP-ribosylation of the B subunit
To confirm the possibility o f an interaction between py dimers and c-cbl (a 
ubiquitin ligase normally expressed in CHO cells), co-immunoprecipitation assays were 
carried out using an anti-Gp subunit antibody (as described in Section 2.12). Under these 
conditions, endogenous c-cbl was found to interact with the p subunit (Figure 6.2A). 
Furthermore, the p subunits co-immunoprecipitate with the anti-c-cbl antibody (Figure 
6.2B), demonstrating that ubiquitin ligases are partners of the py dimer in living cells. If 
this interaction is affected by ADP-ribosylation as proposed, then a large proportion o f the 
p subunits would have to be modified. However, in intact cells, only a low amount o f the P 
subunit is ADP-ribosylated (Section 1.2.3.3.2) due to the presence o f ADP-ribose 
hydrolase. By contrast, a higher degree o f ADP-ribosylation (-60% ) can be achieved in 
purified plasma membranes on prolonged incubation (6 h) with ADP-ribosylation buffer 
(Figure 6.3A). Thus, interactions between c-cbl and the native or ADP-ribosylated forms 
o f the p subunit could be evaluated using plasma membranes instead o f total cell lysates
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Figure 6.1. The Py dim er as a substrate of the ubiquitin proteasome pathway (UPP).
A , The y subunit is ubiquitylated by the UPP and the entire py dimer is degraded by the 
proteosome. B, The interaction with phosducin prevents ubiquitylation by the UPP 
preserving the functionality of the py dimer. C, Model of the possible role of ADP- 
ribosylation of the p subunit in the UPP-mediated degradation pathway.
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Figure 6.2. Co-immunoprecipitation of the P subunit and c-cbl. A, Co- 
immunoprecipitation o f endogenous c-cbl from CHO cells using an anti-Gp antibody. 
Lanes 1 and 2, cell lysates; lanes 3 and 4, co-immunoprecipitation from CHO cells. B, Co- 
immunoprecipitation o f endogenous P subunit from CHO cells using an anti-c-cbl 
antibody. Lane 1, cell lysate; lanes 2 and 3, co-immunoprecipitation from CHO cells. The 
data shown are from a single experiment that was performed in duplicate, and which is 
representative o f at least three independent experiments.
221
and in this system, the modified and unmodified p subunits were both able to interact with 
c-cbl (Figure 6.3B, lanes 2 and 3). This indicates that endogenous ADP-ribosylation of the 
p subunit does not affect its interaction with ubiquitin ligase, and therefore, that the ADP- 
ribosylation reaction is not involved in the degradation pathway o f the entire py dimer.
6.3 Discussion
In this Chapter, I approached the study o f the physiological role o f endogenous p 
subunit mono-ADP-ribosylation. Recent reports have demonstrated that Py dimers are 
ubiquitylated and then targeted to the proteasome for degradation. In addition, the finding 
that p subunits interacts with the ubiquitin ligase c-cbl offers clues into a possible role for 
ADP-ribosylation in the degradation pathway of Py. Indeed, it can be postulated that the 
ADP-ribosylated py dimer might not be recognised by ubiquitin ligase, and thus will be 
protected. In this case, mono-ADP-ribosylation could act to stabilize Py dimers upon 
agonist stimulation of some GPCRs. Experimental evidence however ruled out this 
possibility, the ADP-ribosylated p subunit being able to interact with c-cbl also in its 
unmodified form. The ADP-ribosylated A rgl29 is thus probably not included in the 
interaction site with cbl. The role o f the interaction between py and c-cbl remains to be 
identified, and at present no data can be offered to elucidate these points.
However, a variety o f other possible physiological roles o f endogenous mono- 
ADP-ribosylation remain to be evaluated, and some of these will be considered in Chapter 
7.
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Figure 6.3. Effects of ADP-ribosylation on the interaction between the P subunit and 
c-cbl in plasma membranes. A, Time-dependence of P subunit ADP-ribosylation when 5 
pg o f plasma membranes were incubated for increasing times at 37 °C with P-NAD+ and 
[32P]-NAD, as quantified using an Instant Imager. The data shown represent the means 
(±SD) o f five independent experiments, each performed in duplicate (n=10). B, Co- 
immunoprecipitation of endogenous c-cbl from purified plasma membranes o f CHO cells 
using an anti-Gp antibody. Lane 1, untreated plasma membranes; lane 2, plasma 
membranes incubated with a-NAD+; lane 3, plasma membranes incubated with p-NAD+. 
Data shown are from a single experiment that was performed in duplicate, which is 
representative o f at least three independent experiments.
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Chapter 7
Final Discussion
The aim o f this investigation has been the identification o f mechanisms that 
regulate the endogenous mono-ADP-ribosylation of the p subunit o f heterotrimeric G 
proteins.
As already discussed (Chapter 1), we previously reported that p subunits are ADP- 
ribosylated in intact cells by an arginine-specific, plasma-membrane-associated enzyme 
(Lupi et al., 2000). This modification can be considered as a general mechanism since it 
occurs in several cell lines including CHO, HL60, Swiss 3T3 and FRTL5 cells (Lupi et al., 
2000). From a quantitative point of view, under resting conditions -0.2%  of the total 
complement of Py dimers is modified in intact CHO cells and it is reasonable that this 
fraction corresponds to a cellular pool o f Py dimer that remains inactive. This is supported 
by the demonstration that mono-ADP-ribosylation inactivates the Py dimers by impairing 
their interactions with effector enzymes such as AC I, PI3Ky and PLCp2 (Lupi et al., 
2002). Thus, the reaction appears to represent a cellular mechanism that modulates G- 
protein-mediated signal transduction processes through a direct regulation of py dimers. 
The possible physiological importance of this reaction is further supported by its 
reversibility; the modified p subunit is de-ADP-ribosylated by a cytosolic ADP- 
ribosylhydrolase that regenerates native Py by releasing the bound ADP-ribose. Therefore, 
in intact cells, a cycle of ADP-ribosylation/de-ADP-ribosylation operates and this can 
modulate Gp-mediated activities.
Starting from these observations, I analysed how this ADP-ribosylation is 
modulated. Previous data suggested that it preferentially occurs on the activated form of Py
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(Lupi et al., 2002). Considering that active Py originates from heterotrimeric G proteins 
upon activation of GPCRs (Hamm, 1998; Lambright et al., 1996), I demonstrated that 
ADP-ribosylation of p subunits is modulated in response to stimulation o f certain GPCRs 
in vitro, and more importantly, also in living cells. Interestingly, I demonstrated that the 
occurrence o f hormonally induced ADP-ribosylation o f the p subunit shows specificity 
with regard to receptor identity. Activation of some receptor leads to an increase in active 
Py heterodimers, which can subsequently be inactivated by ADP-ribosylation. In this case, 
ADP-ribosylation is thus a signal termination mechanism for py-mediated functions that 
are independent o f a  subunit activity. By contrast, I found that the GnRH receptor 
decreases the rate of p subunit ADP-ribosylation. This might be due to a short-lived 
inhibition o f ADP-ribosyltransferase activity, which would result in a time-extension of 
Py-mediated activities. We can speculate that the endogenous cycle of ADP-ribosylation/ 
de-ADP-ribosylation o f the p subunit represents a mechanism that transiently regulates the 
amount o f py that is available for cellular signalling. This conclusion is o f interest because 
of the role of py dimers in the control o f cell proliferation and regulation o f normal cell 
growth and development (reviewed by Schwindinger and Robishaw, 2001). Experiments 
aimed at evaluating the activities o f intracellular effectors that are regulated directly by the 
Py dimer under conditions in which the state of the ADP-ribosylation/de-ADP-ribosylation 
cycle is shifted towards the ADP-ribosylated or de-ADP-ribosylated form of p will help to 
flesh out these ideas.
A further possibility to be considered is that ADP-ribosylation o f the p subunit 
might represent a means to modulate Ga-mediated activities since inhibition o f the py 
heterodimer through its mono-ADP-ribosylation should prolong the activation state o f the 
a  subunit. This proposal however, conflicts with our observations that modified Py dimers 
retain their competence to reconstitute inactive heterotrimers with a  subunits (Di 
Girolamo, unpublished data). It is conceivable that once the modified Py re-forms the
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inactive heterotrimer with GDP-bound Ga, de-ADP-ribosylation by the cytosolic 
hydrolase takes place, hence reforming the inactive heterotrimer. This will then be ready 
for a new round of activation.
More intriguing is that mono-ADP-ribosylation represents a molecular switch for 
Py activities. One can hypothesise that the transferase serves as a scaffold protein that 
interacts with py dimers and then with other still unidentified proteins. Mono-ADP- 
ribosylation would switch off Py activity, and hence G-protein signalling. At the same time 
it could activate other signalling pathways. In this way, the transferase could act as a link 
between heterotrimeric G proteins and other signalling pathways downstream of the Py 
subunit. An example of this kind of mechanism is seen with the RGS proteins. In 
endothelial cells, pll5RhoG EF switches off thrombin-activated G a n  due to its RGS 
activity. In parallel, it activates RhoA due to its GEF activity, thus inducing downstream 
morphological changes (Fukuhara et al., 2001). The full elucidation o f the physiological 
role of P subunit mono-ADP-ribosylation must await the molecular characterisation o f the 
specific enzyme(s) involved in this modification.
Central to the present investigation is also the identification o f a new role for ARF6  
as a negative modulator of endogenous p subunit ADP-ribosylation. Although ARF6  
belongs to a family of proteins originally described as essential co-factors for ADP- 
ribosylation catalysed by CTX, I have demonstrated that the activated form o f ARF6  can 
inhibit endogenous ADP-ribosylation of the p subunit both in vitro and in vivo. In 
particular, ARF6  inhibits the p subunit ADP-ribosylation mediated by GnRH receptor 
simulation. In analysing this regulatory pathway, I also found that the stimulated GnRH 
receptor causes activation of ARF6 , probably through an ARF6 -GEF. This is in line with a 
number of studies that indicate that activation of the ARFs occurs upon agonist activation 
of certain GPCRs, including the M3 muscarinic, fMet-Leu-Phe, HI histamine and B2 
bradykinin receptors (Houle et al., 1995; Mitchell et al., 1998; Rumenapp et al., 1995;
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Salvador et al., 2001). It is further supported by the recent finding that the A2A receptor 
interacts directly with ARNO/cytohesin-2 (Gsandtner et al., 2005).
My proposal for the role of ARF6  in GnRH receptor-mediated inhibition o f P subunit 
mono-ADP-ribosylation is summarised in Figure 5.14. Upon receptor activation, ARF6  is 
activated though an exchange factor and is then able to recognise the ADP- 
ribosyltransferase. This in turn loses its ability to interact with and to modify the py dimer. 
As a consequence, the extent of p subunit modification is reduced and so its activities are 
favoured. Analysing the mechanisms by which ARF6  down-regulates the transferase, I 
found that ARF6 -GTP inhibits ADP-ribosylation of the p subunit directly by acting as a 
competitive substrate for the endogenous transferase. This is supported by the finding that 
activated ARF6  is itself a substrate for ADP-ribosylation. The ADP-ribosylated form of 
ARF6  is de-ADP-ribosylated by a cytosolic ADP-ribosylhydrolase. This means that the 
endogenous cycle o f ADP-ribosylation/ de-ADP-ribosylation should be active on different 
substrates, and thus it could modulate the functionality o f more than one membrane- 
associated protein.
Concerning the physiological role o f ADP-ribosylation o f ARF6 , it is conceivable that 
once modified, it has an altered function, as has been seen for other substrates o f the ADP- 
ribosylation reaction. The activation of ARF6  that occurs in response to receptor 
stimulation is involved in the desensitization and the internalization o f the receptors, both 
being processes that regulate the duration and strength of GPCR signals (Claing, 2004; 
Hunzicker-Dunn et al., 2002). Thus, if  ADP-ribosylation affects the functions o f ARF6 , it 
is possible that a cycle o f mono-ADP-ribosylation/ de-ADP-ribosylation will modulate the 
signalling cascade mediated by cell surface receptors. ADP-ribosylation reaction cannot be 
considered as simply a mechanism for the regulation o f Py-mediated signalling; rather, it 
represents a general mechanism that can regulate other responses to GPCR activation.
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This is of some interest because o f the loss- and gain-of-function alterations in 
GPCR-mediated signalling that have been identified as causes o f a number o f disease 
conditions, including retinal, endocrine, metabolic and developmental disorders (Maisel et 
al., 1990; Spiegel et al., 1993). So what is the molecular basis for these diseases? Stated 
most simply, receptors, G proteins and effectors function as a series o f "on-off' switches 
that are triggered by an extracellular signal. Changes that inappropriately switch on or 
switch off one of the components will cause an error in one or more cellular functions. In 
this context, it will be fascinating to determine if  the endogenous ADP-ribosylation 
reaction can regulate the correct "on-off' switching processes, thus influencing cell 
responses to external stimuli both in physiological and in pathological conditions. 
However, much further work is needed to confirm these suggestions and to provide the 
molecular foundations for the full physiological role o f ADP-ribosylation. First o f all, 
identification of the ADP-ribosyltransferase enzyme that catalyses endogenous ADP- 
ribosylation of the p subunit, and probably also of ARF6  is a number one priority. In 
parallel, understanding how the ADP-ribosylation of ARF6  is modulated will help to 
understand the impact of this reaction in ARF6 -mediated functions such as receptor 
desensitisation and internalization. The answers to these questions will further the 
understanding o f this reaction as a regulator o f GPCR-mediated signalling, and they will 
facilitate future efforts in the elucidation o f the initiation and progression o f some disease 
states.
In conclusion, the evidence provided here contributes to the definition o f the 
mechanisms that regulate endogenous ADP-ribosylation of p subunits and opens the doors 
to future studies regarding its full physiological role. Also in revealing ARF6  as a new 
substrate o f the ADP-ribosylation reaction, I have indicated the possibility o f a complex 
and multidimensional network of control for the regulation o f signal transduction 
processes.
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Abbreviations
P2-AR p2-adrenergic receptor
a 2-AR a 2-adrenergic receptor
PARK P-adrenergic receptor kinase
5-HT Serotonin
AC Adenylyl cyclase
ADP Adenosine diphosphate
AGS Activator o f G protein signalling
AP Adaptor protein
ARD ADP-ribosylation factor domain protein
ARF ADP-ribosylation factor
ARL ARF like protein
ART ADP-ribosyltransferase
ATi-R Angiotensin 1 receptor
ATP Adenosine triphosphate
B2-R Bradykinin receptor
BFA Brefeldin A
BSA Bovine serum albumin
C3 Clostridium botolinum toxin
cAMP Cyclic AMP
cAPK cAMP-dependent kinase
CCK 8  Cholecystokinin
cDNA Complementary DNA
CHO Chinese hamster hovary
COP Coat protein or coatomer
CTA Cholera toxin, monomeric A subunit
CtBPl-s/BARS BFA-ADP-ribosylated substrate
CTX Cholera toxin
DAG Diacylglycerol
DBD Double zinc-finger domain
DIC Dynein intermediate chain
DMEM Dulbecco’s modified minimal essential medium
DNA Deoxyribonucleic acid
DRAG Dinitrogenase reductase-activating glycohydrolase
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DRAT Dinitrogenase reductase/mono-ADP-ribosyltransferase
DTT Dithiothreitol
DTX Diphtheria toxin
E l  Ubiquitin-activating enzyme
E3 Ubiquitin-ligase enzyme
EC 50 50% effective concentration concentration o f substrate at
which the reaction rate is half-maximal 
ECL Enhanced chemiluminescence
EDIN Epidermal cell differentiation inhibitor
EDTA Ethylenediamine tetraacetic acid
EF-2 Elongation factor 2
EG FR Epidermal growth factor receptor
EGT A thyleneglycol-bis-(2-aminoethyllether)-N,N,N ’ ,N ’ -tetracetic
acid
ER  Endoplasmic reticulum
ERK  extracellular-signal-regulated kinase
ERM  Ezrin/radixin/moesin family
ExoS Exotoxin S
FCS Foetal calf serum
FG F Fibroblast growth factor
FGFR Fibroblast growth factor receptor
fM LP Formyl-Met-Leu-Phe
FPLC Fast protein liquid chromatography
FRET Fluorescence resonance energy transfer
g Gravity
G a  G protein a  subunit
Gp G protein P subunit
Gy G protein y subunit
G418 Geneticine
GAP GTPase-activating protein
GDI Guanine nucleotide dissociation inhibitor
GDP Guanosine 5’-diphosphate
GDPpS Guanosine 5'-0-(2-thiodiphosphate)
GEF Guanine-nucleotide exchange factor
GGA Golgi-localising gamma adaptin ear homology domain, ARF
binding proteins
G IRK  Inward rectifier G-protein-gated K+ channel
GnRH Gonadotropin releasing hormone
GPCR G-protein-coupled receptor
GPI Glycosylphosphatidylinositol
GPR G protein regulatory motif
G RK  G-protein receptor kinase
GST Glutathione S-transferase
GTP Guanosine 5 ’ -triphosphate
GTPase Guanosine triphosphatese
GTPyS Guanosine 5’-0-(3-thiotriphosphate)
h Hour
HA Hemagglutinin
HBSS Hanks balanced solution
HEPES N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
HL60 Human leukaemia
HNP-1 Human defensin
HPLC High pressure liquid chromatography
IL-8 Interleukin 8
IP3 Inositol 1,4,5-trisphosphate
IPTG  Isopropyl p-D-thiogalactopyranoside
IU International unit
K a t p  ATP-sensitive K+ channel
Kcat The catalytic rate of an enzyme
kDa kilo Dalton
Ki Inhibition constant
Km Michaelis-Menten constant, measures the affinity o f an
enzyme for its substrate 
Kon Association rate constant
Koff Dissociation rate constant
LB Luria Broth
LFA-1 Lymphocyte-function-associated antigen.
LH/CG R luteinizing hormone/choriogonadotropin hormone hormone
receptor
LT Heat-labile enterotoxin
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mADPRT Mono-ADP-ribosyltransferase
MALDI-MS Matrix assisted laser desorption/ionization mass
Spectrometry
M APK Mitogen-activated protein kinase
M IBG Meta-iodobenzylguanidine
MOPS 4-morpholinepropanesulfonic acid
M yr-ARF6 myristoylated peptide o f ARF6
NAD Nicotinamide adenine dinucleotide
NADase NAD glycohydrolase
NDPK Nucleoside diphosphate kinase
NK1-R Substance P receptor
N on-My r- ARF 6 non myristoylated peptide of ARF6
NP40 Nonylphenoxy polyethoxy ethanol
O/N Overnight
P2X7 Purinergic receptor X7
PA Phosphatidic acid
PAF Platelet activating factor
PAGE Polyacrylamide gel electrophoresis
PARI Thrombin receptor 1
PARG Poly-ADP-ribose glycohydrolase
PARP Poly-ADP-ribosylpolymerase
PBS Phosphate buffered saline
PDGF Platelet-derived growth factor
PH Pleckstrin homology domain
PhLP Phosducin-like protein
PHP Protein histidine phosphatase
PI Phosphoinositide
P L ,4,5^3 Phosphatidylinositol 3,4,5-triphosphate
PI3,4P2 Phosphatidylinositol 3,4-bisphosphate
PI3K Phosphatidylinositol 3-kinase
PI3P phosphatidylinositol 3-phosphate
PI4,5P2 Phosphatidylinositol4,5-bisphosphate
PIP5K Phosphatidylinositol 4-phosphate 5-kinase
PKA Protein kinase A
PKC Protein kinase C
PLC Phospholipase C
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PLD Phospholipase D
PM Plasma membrane
PMSF Phenylmethylsulphonyl fluoride
PORI Partner o f Rac 1
PTX Pertussis toxin
PX Phox homology domain
RGS Regulator o f G protein signalling
RNA Ribonucleic acid
rpm Revolutions per minute
RT Room temperature
RTK Receptor tyrosine kinase
SDS Sodium dodecyl sulfate
Sir2p Silent information regulator 2 protein
SIRT2 Human Sir2p homologue
TGN trans-G olgi network
TLC Thin layer chromatography
TM Transmembrane helix
TNKS Tankyrase
TRIS Tris[hydroxymethyl] aminomethane
Ubc/E2 Ubiquitin-conjugating enzyme
UPP Ubiquitin proteasome pathway
UTP Uridine 5 -triphosphate
v/v Volume/volume
V max Maximal velocity o f an enzymatic reaction at saturating 
substrate concentration
w/v Weight/volume
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